<html><head><meta content="text/html; charset=UTF-8" http-equiv="content-type"><style type="text/css">@import url('https://themes.googleusercontent.com/fonts/css?kit=fpjTOVmNbO4Lz34iLyptLcWpXo_CmM6erK5IinBZ-8N8u45WU12y72TEk3aAZtZE');.lst-kix_2qvefga6tw9t-5>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-5}.lst-kix_amnxd0o32wxe-4>li:before{content:"-  "}.lst-kix_amnxd0o32wxe-8>li:before{content:"-  "}ol.lst-kix_stodkckubncd-5.start{counter-reset:lst-ctn-kix_stodkckubncd-5 0}.lst-kix_9kz8bq8q3b2i-3>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-3}.lst-kix_5f9t9fms2d21-0>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-0,decimal) ". "}.lst-kix_amnxd0o32wxe-2>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-0.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-0 0}.lst-kix_5f9t9fms2d21-2>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-2,lower-roman) ". "}.lst-kix_km6c63ta0u1m-5>li:before{content:"\0025a0  "}ol.lst-kix_qgxhqyjzp80f-1.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-1 0}.lst-kix_5f9t9fms2d21-6>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-6,decimal) ". "}.lst-kix_6hpp8uicfxco-7>li:before{content:"-  "}.lst-kix_km6c63ta0u1m-1>li:before{content:"\0025cb  "}.lst-kix_km6c63ta0u1m-3>li:before{content:"\0025cf  "}.lst-kix_5f9t9fms2d21-4>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-4,lower-latin) ". "}ol.lst-kix_73zznxkq85l2-5.start{counter-reset:lst-ctn-kix_73zznxkq85l2-5 0}.lst-kix_amnxd0o32wxe-6>li:before{content:"-  "}ol.lst-kix_bz3wxvkk86wr-4.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-4 0}.lst-kix_6hpp8uicfxco-3>li:before{content:"-  "}.lst-kix_6hpp8uicfxco-5>li:before{content:"-  "}ol.lst-kix_bz3wxvkk86wr-6{list-style-type:none}ol.lst-kix_m0nrdnud90zq-1.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-1 0}ol.lst-kix_bz3wxvkk86wr-7{list-style-type:none}.lst-kix_6hpp8uicfxco-1>li:before{content:"-  "}ol.lst-kix_bz3wxvkk86wr-4{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-5{list-style-type:none}.lst-kix_5f9t9fms2d21-8>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-8,lower-roman) ". "}ol.lst-kix_bz3wxvkk86wr-8{list-style-type:none}ol.lst-kix_stodkckubncd-0.start{counter-reset:lst-ctn-kix_stodkckubncd-0 0}.lst-kix_km6c63ta0u1m-7>li:before{content:"\0025cb  "}ol.lst-kix_bz3wxvkk86wr-2{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-3{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-0{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-1{list-style-type:none}.lst-kix_h8i9ymdmzkx8-3>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-3}.lst-kix_stodkckubncd-2>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-2,lower-roman) ". "}.lst-kix_stodkckubncd-0>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-0,decimal) ". "}.lst-kix_stodkckubncd-4>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-4,lower-latin) ". "}ol.lst-kix_yhp6v7of3e00-5.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-5 0}ol.lst-kix_qgxhqyjzp80f-6.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-6 0}ol.lst-kix_m0nrdnud90zq-6.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-6 0}ol.lst-kix_yfnaf4f33kdr-6.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-6 0}ol.lst-kix_73zznxkq85l2-0.start{counter-reset:lst-ctn-kix_73zznxkq85l2-0 0}.lst-kix_8eggh954z6m1-6>li:before{content:"-  "}ol.lst-kix_69woh12i7ucg-8.start{counter-reset:lst-ctn-kix_69woh12i7ucg-8 0}.lst-kix_8eggh954z6m1-2>li:before{content:"-  "}.lst-kix_8eggh954z6m1-0>li:before{content:"-  "}.lst-kix_8eggh954z6m1-8>li:before{content:"-  "}.lst-kix_m09drfn41lbc-8>li:before{content:"\0025a0  "}.lst-kix_m09drfn41lbc-6>li:before{content:"\0025cf  "}.lst-kix_stodkckubncd-8>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-8,lower-roman) ". "}.lst-kix_stodkckubncd-6>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-6,decimal) ". "}.lst-kix_8eggh954z6m1-4>li:before{content:"-  "}.lst-kix_m09drfn41lbc-4>li:before{content:"\0025cb  "}ul.lst-kix_oj0ws47jaz7a-2{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-3{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-0{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-1{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-6{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-7{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-4{list-style-type:none}ol.lst-kix_fh553kxqh3vv-4.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-4 0}ul.lst-kix_oj0ws47jaz7a-5{list-style-type:none}ol.lst-kix_2qvefga6tw9t-8{list-style-type:none}ol.lst-kix_2qvefga6tw9t-7{list-style-type:none}ol.lst-kix_2qvefga6tw9t-6{list-style-type:none}ol.lst-kix_2qvefga6tw9t-5{list-style-type:none}ol.lst-kix_b0ja666m9l9x-6.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-6 0}ol.lst-kix_5f9t9fms2d21-1{list-style-type:none}ol.lst-kix_5f9t9fms2d21-2{list-style-type:none}ol.lst-kix_5f9t9fms2d21-0{list-style-type:none}ol.lst-kix_5f9t9fms2d21-5{list-style-type:none}ol.lst-kix_5f9t9fms2d21-6{list-style-type:none}ol.lst-kix_5f9t9fms2d21-3{list-style-type:none}ol.lst-kix_5f9t9fms2d21-4{list-style-type:none}ol.lst-kix_2qvefga6tw9t-0{list-style-type:none}ul.lst-kix_bh4xapke1dje-3{list-style-type:none}ul.lst-kix_bh4xapke1dje-2{list-style-type:none}ul.lst-kix_bh4xapke1dje-1{list-style-type:none}ol.lst-kix_5f9t9fms2d21-7{list-style-type:none}.lst-kix_73zznxkq85l2-3>li{counter-increment:lst-ctn-kix_73zznxkq85l2-3}ul.lst-kix_bh4xapke1dje-0{list-style-type:none}ol.lst-kix_5f9t9fms2d21-8{list-style-type:none}ol.lst-kix_2qvefga6tw9t-4{list-style-type:none}ul.lst-kix_bh4xapke1dje-7{list-style-type:none}ol.lst-kix_2qvefga6tw9t-3{list-style-type:none}ul.lst-kix_bh4xapke1dje-6{list-style-type:none}ol.lst-kix_69woh12i7ucg-3.start{counter-reset:lst-ctn-kix_69woh12i7ucg-3 0}ol.lst-kix_2qvefga6tw9t-2{list-style-type:none}ul.lst-kix_bh4xapke1dje-5{list-style-type:none}ol.lst-kix_2qvefga6tw9t-1{list-style-type:none}ul.lst-kix_bh4xapke1dje-4{list-style-type:none}.lst-kix_h8i9ymdmzkx8-0>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-0,decimal) ". "}ul.lst-kix_bh4xapke1dje-8{list-style-type:none}ol.lst-kix_seg2qxi99oen-0.start{counter-reset:lst-ctn-kix_seg2qxi99oen-0 0}.lst-kix_stodkckubncd-5>li{counter-increment:lst-ctn-kix_stodkckubncd-5}ul.lst-kix_7hpd7l1orcn5-2{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-1{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-4{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-3{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-6{list-style-type:none}ol.lst-kix_uf4umlhhckq2-7.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-7 0}ul.lst-kix_7hpd7l1orcn5-5{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-8{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-7{list-style-type:none}.lst-kix_ujrictqeu2kx-3>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-3,decimal) ". "}.lst-kix_ujrictqeu2kx-1>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-1,lower-latin) ". "}ul.lst-kix_7hpd7l1orcn5-0{list-style-type:none}ul.lst-kix_efg97u94j8hb-4{list-style-type:none}ul.lst-kix_efg97u94j8hb-3{list-style-type:none}ul.lst-kix_efg97u94j8hb-2{list-style-type:none}ul.lst-kix_efg97u94j8hb-1{list-style-type:none}ul.lst-kix_efg97u94j8hb-0{list-style-type:none}ul.lst-kix_efg97u94j8hb-8{list-style-type:none}ul.lst-kix_efg97u94j8hb-7{list-style-type:none}ul.lst-kix_efg97u94j8hb-6{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-0{list-style-type:none}.lst-kix_bh4xapke1dje-3>li:before{content:"\0025cf  "}ul.lst-kix_efg97u94j8hb-5{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-2{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-1{list-style-type:none}.lst-kix_ujrictqeu2kx-5>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-5,lower-roman) ". "}ul.lst-kix_p0rhwsmbgd7c-4{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-3{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-6{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-5{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-8{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-7{list-style-type:none}.lst-kix_seg2qxi99oen-3>li{counter-increment:lst-ctn-kix_seg2qxi99oen-3}.lst-kix_q7k3qhhwoyo7-1>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-1}.lst-kix_m0nrdnud90zq-6>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-6}.lst-kix_jrq3pc6b7fs5-8>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-8}.lst-kix_fh553kxqh3vv-1>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-1}ol.lst-kix_h8i9ymdmzkx8-4.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-4 0}.lst-kix_bh4xapke1dje-7>li:before{content:"\0025cb  "}.lst-kix_h8i9ymdmzkx8-2>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-2,lower-roman) ". "}.lst-kix_q7k3qhhwoyo7-8>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-8}.lst-kix_h8i9ymdmzkx8-6>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-6,decimal) ". "}ol.lst-kix_2qvefga6tw9t-7.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-7 0}.lst-kix_b7uuq29jz54a-0>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-0,decimal) ". "}.lst-kix_xgq4y4xln1s-4>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-4,lower-latin) ". "}ol.lst-kix_vkx5887x6ome-8.start{counter-reset:lst-ctn-kix_vkx5887x6ome-8 0}.lst-kix_xgq4y4xln1s-0>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-0,decimal) ". "}.lst-kix_fh553kxqh3vv-3>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-3}.lst-kix_jrq3pc6b7fs5-6>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-6,decimal) ". "}.lst-kix_bz3wxvkk86wr-8>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-8}.lst-kix_b0ja666m9l9x-5>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-5}.lst-kix_jrq3pc6b7fs5-3>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-3}.lst-kix_d9wep1z810b6-8>li{counter-increment:lst-ctn-kix_d9wep1z810b6-8}ol.lst-kix_xgq4y4xln1s-3.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-3 0}.lst-kix_jrq3pc6b7fs5-2>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-2,lower-roman) ". "}ul.lst-kix_33s9mn975cqx-7{list-style-type:none}ul.lst-kix_33s9mn975cqx-8{list-style-type:none}.lst-kix_73zznxkq85l2-8>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-8,lower-roman) ". "}.lst-kix_m09drfn41lbc-0>li:before{content:"\0025cf  "}.lst-kix_yhp6v7of3e00-2>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-2,lower-roman) ". "}ol.lst-kix_76cwqgc9ntcg-0.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-0 0}.lst-kix_mzqsrs9zicmn-4>li:before{content:"\0025cb  "}.lst-kix_33s9mn975cqx-6>li:before{content:"\0025cf  "}.lst-kix_yhp6v7of3e00-6>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-6,decimal) ". "}ol.lst-kix_2qvefga6tw9t-2.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-2 0}.lst-kix_yfnaf4f33kdr-6>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-6}ol.lst-kix_d9wep1z810b6-4{list-style-type:none}ol.lst-kix_d9wep1z810b6-5{list-style-type:none}ol.lst-kix_d9wep1z810b6-2{list-style-type:none}.lst-kix_73zti2swi0ua-3>li:before{content:"\0025cf  "}ol.lst-kix_d9wep1z810b6-3{list-style-type:none}ol.lst-kix_d9wep1z810b6-8{list-style-type:none}ol.lst-kix_d9wep1z810b6-6{list-style-type:none}ol.lst-kix_d9wep1z810b6-7{list-style-type:none}ol.lst-kix_b7uuq29jz54a-5.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-5 0}.lst-kix_uf4umlhhckq2-6>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-6}.lst-kix_xgq4y4xln1s-8>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-8,lower-roman) ". "}ol.lst-kix_b0ja666m9l9x-1.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-1 0}ol.lst-kix_9kz8bq8q3b2i-0.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-0 0}.lst-kix_gv17x2lsey8i-8>li:before{content:"\0025a0  "}.lst-kix_gv17x2lsey8i-0>li:before{content:"\0025cf  "}.lst-kix_1jqtmxt015qr-7>li:before{content:"-  "}ol.lst-kix_xgq4y4xln1s-8.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-8 0}.lst-kix_33s9mn975cqx-2>li:before{content:"\0025a0  "}.lst-kix_mzqsrs9zicmn-0>li:before{content:"\0025cf  "}ul.lst-kix_33s9mn975cqx-1{list-style-type:none}.lst-kix_1jqtmxt015qr-3>li:before{content:"-  "}ul.lst-kix_33s9mn975cqx-2{list-style-type:none}.lst-kix_73zti2swi0ua-7>li:before{content:"\0025cb  "}ul.lst-kix_33s9mn975cqx-0{list-style-type:none}ol.lst-kix_d9wep1z810b6-0{list-style-type:none}ul.lst-kix_33s9mn975cqx-5{list-style-type:none}ol.lst-kix_d9wep1z810b6-1{list-style-type:none}ul.lst-kix_33s9mn975cqx-6{list-style-type:none}ul.lst-kix_33s9mn975cqx-3{list-style-type:none}ul.lst-kix_33s9mn975cqx-4{list-style-type:none}.lst-kix_gv17x2lsey8i-4>li:before{content:"\0025cb  "}.lst-kix_jrq3pc6b7fs5-1>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-1}ol.lst-kix_vkx5887x6ome-7{list-style-type:none}ol.lst-kix_vkx5887x6ome-8{list-style-type:none}ol.lst-kix_vkx5887x6ome-5{list-style-type:none}ol.lst-kix_vkx5887x6ome-6{list-style-type:none}ol.lst-kix_vkx5887x6ome-3{list-style-type:none}ol.lst-kix_vkx5887x6ome-4{list-style-type:none}.lst-kix_qgxhqyjzp80f-3>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-3}ol.lst-kix_2qvefga6tw9t-4.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-4 0}.lst-kix_m0nrdnud90zq-8>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-8}.lst-kix_fh553kxqh3vv-8>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-8}.lst-kix_vfpim5mnet5b-5>li:before{content:"\0025a0  "}.lst-kix_bz3wxvkk86wr-1>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-1}ol.lst-kix_76cwqgc9ntcg-3.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-3 0}ol.lst-kix_5f9t9fms2d21-2.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-2 0}.lst-kix_mzqsrs9zicmn-8>li:before{content:"\0025a0  "}ol.lst-kix_b7uuq29jz54a-7.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-7 0}ol.lst-kix_xgq4y4xln1s-6.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-6 0}.lst-kix_amnxd0o32wxe-0>li:before{content:"-  "}ol.lst-kix_q7k3qhhwoyo7-6.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-6 0}ul.lst-kix_8eggh954z6m1-2{list-style-type:none}.lst-kix_vfpim5mnet5b-1>li:before{content:"\0025cb  "}ul.lst-kix_8eggh954z6m1-3{list-style-type:none}ul.lst-kix_8eggh954z6m1-0{list-style-type:none}ul.lst-kix_8eggh954z6m1-1{list-style-type:none}ul.lst-kix_8eggh954z6m1-6{list-style-type:none}ul.lst-kix_8eggh954z6m1-7{list-style-type:none}ul.lst-kix_8eggh954z6m1-4{list-style-type:none}ul.lst-kix_8eggh954z6m1-5{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-1{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-2{list-style-type:none}ul.lst-kix_8eggh954z6m1-8{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-0{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-5{list-style-type:none}.lst-kix_wt16kx5082x6-3>li:before{content:"\0025cf  "}ul.lst-kix_8hc53kjy1j5y-6{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-3{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-4{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-7{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-8{list-style-type:none}.lst-kix_cmax3c5l3b9l-4>li:before{content:"\0025cb  "}.lst-kix_6zkl42mjxb9i-7>li:before{content:"\0025cb  "}ol.lst-kix_puq7slv7ersb-3.start{counter-reset:lst-ctn-kix_puq7slv7ersb-3 0}.lst-kix_h8i9ymdmzkx8-5>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-5}.lst-kix_73zznxkq85l2-8>li{counter-increment:lst-ctn-kix_73zznxkq85l2-8}.lst-kix_b0ja666m9l9x-0>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-0}ul.lst-kix_kn39yucmriut-8{list-style-type:none}ul.lst-kix_kn39yucmriut-7{list-style-type:none}ul.lst-kix_kn39yucmriut-6{list-style-type:none}ul.lst-kix_kn39yucmriut-5{list-style-type:none}.lst-kix_nm3lwvrsfgs8-2>li:before{content:"\0025a0  "}.lst-kix_gnt2wo6vinpb-5>li:before{content:"-  "}ul.lst-kix_kn39yucmriut-4{list-style-type:none}ul.lst-kix_kn39yucmriut-3{list-style-type:none}.lst-kix_2qvefga6tw9t-7>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-7}ul.lst-kix_kn39yucmriut-2{list-style-type:none}ul.lst-kix_kn39yucmriut-1{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-8.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-8 0}ul.lst-kix_kn39yucmriut-0{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-1.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-1 0}.lst-kix_gvdnkwhuv0x-7>li:before{content:"\0025cb  "}.lst-kix_nm3lwvrsfgs8-4>li:before{content:"\0025cb  "}ol.lst-kix_jrq3pc6b7fs5-2.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-2 0}.lst-kix_gvdnkwhuv0x-5>li:before{content:"\0025a0  "}.lst-kix_cmax3c5l3b9l-6>li:before{content:"\0025cf  "}ol.lst-kix_q7k3qhhwoyo7-8.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-8 0}.lst-kix_6zkl42mjxb9i-1>li:before{content:"\0025cb  "}ol.lst-kix_9kz8bq8q3b2i-7.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-7 0}.lst-kix_gnt2wo6vinpb-7>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-1>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-1,lower-latin) ". "}.lst-kix_y8nzqr1vapa0-3>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-3,decimal) ". "}.lst-kix_yfnaf4f33kdr-1>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-1,lower-latin) ". "}.lst-kix_yfnaf4f33kdr-8>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-8}.lst-kix_yhp6v7of3e00-4>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-4}.lst-kix_bz3wxvkk86wr-4>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-4,lower-latin) ". "}.lst-kix_yfnaf4f33kdr-3>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-3,decimal) ". "}ol.lst-kix_puq7slv7ersb-8.start{counter-reset:lst-ctn-kix_puq7slv7ersb-8 0}.lst-kix_m0nrdnud90zq-1>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-1}.lst-kix_2qvefga6tw9t-3>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-3}.lst-kix_bz3wxvkk86wr-6>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-6,decimal) ". "}ol.lst-kix_76cwqgc9ntcg-5.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-5 0}ol.lst-kix_9kz8bq8q3b2i-2.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-2 0}.lst-kix_h8i9ymdmzkx8-1>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-1}.lst-kix_kn39yucmriut-7>li:before{content:"-  "}.lst-kix_73zznxkq85l2-1>li{counter-increment:lst-ctn-kix_73zznxkq85l2-1}ol.lst-kix_jrq3pc6b7fs5-7.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-7 0}ol.lst-kix_5f9t9fms2d21-4.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-4 0}.lst-kix_n9l39mx24y7l-7>li:before{content:"\0025cb  "}.lst-kix_73zznxkq85l2-2>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-2,lower-roman) ". "}.lst-kix_73zznxkq85l2-4>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-4,lower-latin) ". "}.lst-kix_wt16kx5082x6-5>li:before{content:"\0025a0  "}.lst-kix_n9l39mx24y7l-5>li:before{content:"\0025a0  "}.lst-kix_kn39yucmriut-1>li:before{content:"-  "}.lst-kix_uf4umlhhckq2-4>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-4}.lst-kix_9kz8bq8q3b2i-2>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-2,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-3>li:before{content:"-  "}.lst-kix_p0rhwsmbgd7c-5>li:before{content:"-  "}.lst-kix_2qvefga6tw9t-8>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-8,lower-roman) ". "}.lst-kix_vkx5887x6ome-6>li{counter-increment:lst-ctn-kix_vkx5887x6ome-6}.lst-kix_9kz8bq8q3b2i-4>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-4,lower-latin) ". "}.lst-kix_76cwqgc9ntcg-0>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-0,decimal) ". "}.lst-kix_76cwqgc9ntcg-8>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-8,lower-roman) ". "}ol.lst-kix_9kz8bq8q3b2i-5.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-5 0}.lst-kix_2qvefga6tw9t-6>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-6,decimal) ". "}ol.lst-kix_y8nzqr1vapa0-6.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-6 0}.lst-kix_nyooapufejer-0>li:before{content:"-  "}.lst-kix_b0ja666m9l9x-7>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-7}ol.lst-kix_5f9t9fms2d21-7.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-7 0}.lst-kix_y8nzqr1vapa0-7>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-7}.lst-kix_yhp6v7of3e00-8>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-8}.lst-kix_4h5ayc5t6q0q-4>li:before{content:"\0025cb  "}ol.lst-kix_76cwqgc9ntcg-8.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-8 0}.lst-kix_2qvefga6tw9t-0>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-0,decimal) ". "}.lst-kix_4h5ayc5t6q0q-6>li:before{content:"\0025cf  "}.lst-kix_b7uuq29jz54a-4>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-4,lower-latin) ". "}.lst-kix_b7uuq29jz54a-6>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-6,decimal) ". "}.lst-kix_s1e4p75lcpk8-3>li:before{content:"\0025cf  "}.lst-kix_d9wep1z810b6-1>li{counter-increment:lst-ctn-kix_d9wep1z810b6-1}.lst-kix_s1e4p75lcpk8-1>li:before{content:"\0025cb  "}.lst-kix_q7k3qhhwoyo7-6>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-6}ol.lst-kix_ks1i5lssvjkg-1.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-1 0}.lst-kix_h8i9ymdmzkx8-8>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-8}ol.lst-kix_ks1i5lssvjkg-3.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-3 0}.lst-kix_xgq4y4xln1s-4>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-4}.lst-kix_7hpd7l1orcn5-4>li:before{content:"-  "}.lst-kix_nyooapufejer-8>li:before{content:"-  "}.lst-kix_7hpd7l1orcn5-6>li:before{content:"-  "}.lst-kix_76cwqgc9ntcg-6>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-6,decimal) ". "}.lst-kix_nyooapufejer-6>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-4.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-4 0}.lst-kix_oj0ws47jaz7a-2>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-8.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-8 0}.lst-kix_r1qxtw4k9pgo-1>li:before{content:"-  "}.lst-kix_xgq4y4xln1s-8>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-8}.lst-kix_yhp6v7of3e00-1>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-1}ol.lst-kix_puq7slv7ersb-0.start{counter-reset:lst-ctn-kix_puq7slv7ersb-0 0}.lst-kix_ujrictqeu2kx-7>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-7,lower-latin) ". "}.lst-kix_m0nrdnud90zq-4>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-4}ol.lst-kix_73zznxkq85l2-8{list-style-type:none}.lst-kix_y8nzqr1vapa0-0>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-0}.lst-kix_8hc53kjy1j5y-2>li:before{content:"-  "}.lst-kix_puq7slv7ersb-0>li{counter-increment:lst-ctn-kix_puq7slv7ersb-0}.lst-kix_ujrictqeu2kx-8>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-8}.lst-kix_bh4xapke1dje-5>li:before{content:"\0025a0  "}ol.lst-kix_73zznxkq85l2-1{list-style-type:none}ol.lst-kix_73zznxkq85l2-0{list-style-type:none}.lst-kix_69woh12i7ucg-3>li{counter-increment:lst-ctn-kix_69woh12i7ucg-3}.lst-kix_b7uuq29jz54a-6>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-6}ol.lst-kix_73zznxkq85l2-3{list-style-type:none}ol.lst-kix_73zznxkq85l2-2{list-style-type:none}ol.lst-kix_73zznxkq85l2-5{list-style-type:none}ol.lst-kix_73zznxkq85l2-4{list-style-type:none}.lst-kix_seg2qxi99oen-0>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-0,decimal) ". "}.lst-kix_76cwqgc9ntcg-1>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-1}ol.lst-kix_73zznxkq85l2-7{list-style-type:none}ol.lst-kix_73zznxkq85l2-6{list-style-type:none}.lst-kix_efg97u94j8hb-4>li:before{content:"-  "}.lst-kix_uf4umlhhckq2-6>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-6,decimal) ". "}.lst-kix_6l3u48hb8och-1>li:before{content:"-  "}ol.lst-kix_y8nzqr1vapa0-4.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-4 0}.lst-kix_puq7slv7ersb-7>li{counter-increment:lst-ctn-kix_puq7slv7ersb-7}.lst-kix_jrq3pc6b7fs5-8>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-8,lower-roman) ". "}.lst-kix_h8i9ymdmzkx8-8>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-8,lower-roman) ". "}.lst-kix_seg2qxi99oen-8>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-8,lower-roman) ". "}.lst-kix_xgq4y4xln1s-2>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-2,lower-roman) ". "}.lst-kix_jrq3pc6b7fs5-0>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-0,decimal) ". "}.lst-kix_ujrictqeu2kx-1>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-1}.lst-kix_5f9t9fms2d21-8>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-8}.lst-kix_76cwqgc9ntcg-8>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-8}ol.lst-kix_ks1i5lssvjkg-6.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-6 0}ul.lst-kix_oj0ws47jaz7a-8{list-style-type:none}.lst-kix_vkx5887x6ome-4>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-4,lower-latin) ". "}ol.lst-kix_yfnaf4f33kdr-1.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-1 0}.lst-kix_1jqtmxt015qr-1>li:before{content:"-  "}.lst-kix_fh553kxqh3vv-5>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-5,lower-roman) ". "}.lst-kix_2qvefga6tw9t-0>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-0}ol.lst-kix_yfnaf4f33kdr-4.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-4 0}.lst-kix_yhp6v7of3e00-4>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-4,lower-latin) ". "}.lst-kix_rjzoughkzvzw-1>li:before{content:"\0025cb  "}.lst-kix_33s9mn975cqx-8>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-4>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-4,lower-latin) ". "}.lst-kix_gv17x2lsey8i-6>li:before{content:"\0025cf  "}.lst-kix_a6itagplhb2w-4>li:before{content:"\0025cb  "}.lst-kix_c9w8l0v8vj60-1>li:before{content:"-  "}.lst-kix_mzqsrs9zicmn-2>li:before{content:"\0025a0  "}.lst-kix_5f9t9fms2d21-1>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-1}.lst-kix_s078hly7oqfy-7>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-8.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-8 0}.lst-kix_73zti2swi0ua-5>li:before{content:"\0025a0  "}.lst-kix_33s9mn975cqx-0>li:before{content:"\0025cf  "}ul.lst-kix_vfpim5mnet5b-0{list-style-type:none}ul.lst-kix_vfpim5mnet5b-1{list-style-type:none}ol.lst-kix_puq7slv7ersb-5.start{counter-reset:lst-ctn-kix_puq7slv7ersb-5 0}ul.lst-kix_vfpim5mnet5b-2{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-3.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-3 0}.lst-kix_vfpim5mnet5b-3>li:before{content:"\0025cf  "}.lst-kix_d9wep1z810b6-4>li{counter-increment:lst-ctn-kix_d9wep1z810b6-4}.lst-kix_m0nrdnud90zq-4>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-4,lower-latin) ". "}.lst-kix_q7k3qhhwoyo7-5>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-5,lower-roman) ". "}ul.lst-kix_vfpim5mnet5b-3{list-style-type:none}ul.lst-kix_vfpim5mnet5b-4{list-style-type:none}ul.lst-kix_vfpim5mnet5b-5{list-style-type:none}.lst-kix_73zznxkq85l2-5>li{counter-increment:lst-ctn-kix_73zznxkq85l2-5}ul.lst-kix_vfpim5mnet5b-6{list-style-type:none}ul.lst-kix_vfpim5mnet5b-7{list-style-type:none}ul.lst-kix_vfpim5mnet5b-8{list-style-type:none}.lst-kix_xgq4y4xln1s-1>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-1}.lst-kix_seg2qxi99oen-7>li{counter-increment:lst-ctn-kix_seg2qxi99oen-7}ol.lst-kix_y8nzqr1vapa0-1.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-1 0}.lst-kix_ks1i5lssvjkg-5>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-5}.lst-kix_vkx5887x6ome-3>li{counter-increment:lst-ctn-kix_vkx5887x6ome-3}ol.lst-kix_jrq3pc6b7fs5-4.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-4 0}.lst-kix_puq7slv7ersb-4>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-4,lower-latin) ". "}.lst-kix_uf4umlhhckq2-2>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-2}ol.lst-kix_d9wep1z810b6-6.start{counter-reset:lst-ctn-kix_d9wep1z810b6-6 0}ol.lst-kix_y8nzqr1vapa0-2.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-2 0}.lst-kix_qgxhqyjzp80f-6>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-6}.lst-kix_m0nrdnud90zq-3>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-3}.lst-kix_yhp6v7of3e00-2>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-2}ol.lst-kix_fh553kxqh3vv-2.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-2 0}.lst-kix_73zznxkq85l2-6>li{counter-increment:lst-ctn-kix_73zznxkq85l2-6}ol.lst-kix_h8i9ymdmzkx8-7.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-7 0}.lst-kix_ks1i5lssvjkg-6>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-6,decimal) ". "}.lst-kix_ks1i5lssvjkg-2>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-2,lower-roman) ". "}.lst-kix_ks1i5lssvjkg-3>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-3,decimal) ". "}.lst-kix_b0ja666m9l9x-7>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-7,lower-latin) ". "}.lst-kix_b0ja666m9l9x-8>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-8,lower-roman) ". "}.lst-kix_d9wep1z810b6-1>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-1,lower-latin) ". "}.lst-kix_d9wep1z810b6-3>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-3,decimal) ". "}.lst-kix_d9wep1z810b6-0>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-0,decimal) ". "}.lst-kix_d9wep1z810b6-4>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-4,lower-latin) ". "}.lst-kix_ks1i5lssvjkg-0>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-0,decimal) ". "}.lst-kix_vkx5887x6ome-4>li{counter-increment:lst-ctn-kix_vkx5887x6ome-4}.lst-kix_b0ja666m9l9x-1>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-1,lower-latin) ". "}.lst-kix_69woh12i7ucg-1>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-1,lower-latin) ". "}.lst-kix_d9wep1z810b6-7>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-7,lower-latin) ". "}.lst-kix_h8i9ymdmzkx8-7>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-7}ol.lst-kix_69woh12i7ucg-1.start{counter-reset:lst-ctn-kix_69woh12i7ucg-1 0}.lst-kix_zyb4ozncdg-0>li:before{content:"\0025cf  "}ol.lst-kix_fh553kxqh3vv-7.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-7 0}.lst-kix_zyb4ozncdg-1>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-4>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-4,lower-latin) ". "}.lst-kix_69woh12i7ucg-5>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-5,lower-roman) ". "}ol.lst-kix_puq7slv7ersb-2.start{counter-reset:lst-ctn-kix_puq7slv7ersb-2 0}.lst-kix_bz3wxvkk86wr-5>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-5}.lst-kix_zyb4ozncdg-3>li:before{content:"\0025cf  "}.lst-kix_zyb4ozncdg-7>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-8>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-8,lower-roman) ". "}.lst-kix_b0ja666m9l9x-4>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-4,lower-latin) ". "}.lst-kix_zyb4ozncdg-4>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-7>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-7,lower-latin) ". "}.lst-kix_b0ja666m9l9x-5>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-5,lower-roman) ". "}.lst-kix_ujrictqeu2kx-3>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-3}.lst-kix_vkx5887x6ome-3>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-3,decimal) ". "}.lst-kix_fh553kxqh3vv-4>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-4,lower-latin) ". "}ol.lst-kix_ks1i5lssvjkg-4.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-4 0}.lst-kix_qaijc6nbpdk4-2>li:before{content:"-  "}.lst-kix_qaijc6nbpdk4-6>li:before{content:"-  "}.lst-kix_fh553kxqh3vv-5>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-5}.lst-kix_a6itagplhb2w-7>li:before{content:"\0025cb  "}ol.lst-kix_yhp6v7of3e00-8{list-style-type:none}.lst-kix_qaijc6nbpdk4-8>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-4{list-style-type:none}.lst-kix_s078hly7oqfy-2>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-5{list-style-type:none}ol.lst-kix_yhp6v7of3e00-6{list-style-type:none}ol.lst-kix_yhp6v7of3e00-7{list-style-type:none}.lst-kix_yfnaf4f33kdr-3>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-3}.lst-kix_u7vldufjcii4-6>li:before{content:"\0025cf  "}ol.lst-kix_yhp6v7of3e00-0{list-style-type:none}.lst-kix_s078hly7oqfy-4>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-1{list-style-type:none}ol.lst-kix_yhp6v7of3e00-2{list-style-type:none}ol.lst-kix_yhp6v7of3e00-3{list-style-type:none}.lst-kix_jrq3pc6b7fs5-5>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-5}.lst-kix_69woh12i7ucg-6>li{counter-increment:lst-ctn-kix_69woh12i7ucg-6}.lst-kix_a6itagplhb2w-3>li:before{content:"\0025cf  "}.lst-kix_s078hly7oqfy-8>li:before{content:"-  "}.lst-kix_u7vldufjcii4-4>li:before{content:"\0025cb  "}.lst-kix_b7uuq29jz54a-3>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-3}.lst-kix_vkx5887x6ome-7>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-7,lower-latin) ". "}.lst-kix_5f9t9fms2d21-4>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-4}ol.lst-kix_69woh12i7ucg-6.start{counter-reset:lst-ctn-kix_69woh12i7ucg-6 0}.lst-kix_ks1i5lssvjkg-1>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-1}.lst-kix_76cwqgc9ntcg-4>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-4}.lst-kix_2qvefga6tw9t-8>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-8}.lst-kix_2qvefga6tw9t-2>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-2}ol.lst-kix_d9wep1z810b6-1.start{counter-reset:lst-ctn-kix_d9wep1z810b6-1 0}.lst-kix_q7k3qhhwoyo7-8>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-8,lower-roman) ". "}ol.lst-kix_ujrictqeu2kx-0.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-0 0}.lst-kix_u7vldufjcii4-0>li:before{content:"\0025cf  "}.lst-kix_q7k3qhhwoyo7-4>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-4,lower-latin) ". "}ol.lst-kix_fh553kxqh3vv-7{list-style-type:none}ol.lst-kix_fh553kxqh3vv-8{list-style-type:none}ol.lst-kix_fh553kxqh3vv-5{list-style-type:none}ol.lst-kix_fh553kxqh3vv-6{list-style-type:none}.lst-kix_puq7slv7ersb-5>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-5,lower-roman) ". "}ol.lst-kix_fh553kxqh3vv-3{list-style-type:none}ol.lst-kix_fh553kxqh3vv-4{list-style-type:none}ol.lst-kix_fh553kxqh3vv-1{list-style-type:none}ol.lst-kix_fh553kxqh3vv-2{list-style-type:none}ol.lst-kix_fh553kxqh3vv-0{list-style-type:none}.lst-kix_puq7slv7ersb-1>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-1,lower-latin) ". "}.lst-kix_fh553kxqh3vv-8>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-8,lower-roman) ". "}ol.lst-kix_y8nzqr1vapa0-7.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-7 0}ul.lst-kix_6l3u48hb8och-2{list-style-type:none}ul.lst-kix_6l3u48hb8och-1{list-style-type:none}ul.lst-kix_6l3u48hb8och-0{list-style-type:none}ul.lst-kix_6l3u48hb8och-6{list-style-type:none}ul.lst-kix_6l3u48hb8och-5{list-style-type:none}ul.lst-kix_6l3u48hb8och-4{list-style-type:none}ul.lst-kix_6l3u48hb8och-3{list-style-type:none}.lst-kix_oj0ws47jaz7a-3>li:before{content:"-  "}ul.lst-kix_6l3u48hb8och-8{list-style-type:none}ul.lst-kix_6l3u48hb8och-7{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-7.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-7 0}ol.lst-kix_ks1i5lssvjkg-0.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-0 0}.lst-kix_b0ja666m9l9x-1>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-1}.lst-kix_8hc53kjy1j5y-8>li:before{content:"-  "}.lst-kix_b0ja666m9l9x-3>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-3}.lst-kix_8hc53kjy1j5y-4>li:before{content:"-  "}ul.lst-kix_s078hly7oqfy-0{list-style-type:none}ul.lst-kix_s078hly7oqfy-1{list-style-type:none}ul.lst-kix_s078hly7oqfy-2{list-style-type:none}.lst-kix_8hc53kjy1j5y-1>li:before{content:"-  "}.lst-kix_8hc53kjy1j5y-5>li:before{content:"-  "}ul.lst-kix_s078hly7oqfy-3{list-style-type:none}.lst-kix_bz3wxvkk86wr-6>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-6}ul.lst-kix_s078hly7oqfy-4{list-style-type:none}ul.lst-kix_s078hly7oqfy-5{list-style-type:none}ul.lst-kix_s078hly7oqfy-6{list-style-type:none}ul.lst-kix_s078hly7oqfy-7{list-style-type:none}ul.lst-kix_s078hly7oqfy-8{list-style-type:none}ol.lst-kix_5f9t9fms2d21-0.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-0 0}ol.lst-kix_2qvefga6tw9t-0.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-0 0}ol.lst-kix_2qvefga6tw9t-6.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-6 0}.lst-kix_r1qxtw4k9pgo-2>li:before{content:"-  "}ol.lst-kix_5f9t9fms2d21-6.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-6 0}ol.lst-kix_76cwqgc9ntcg-1.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-1 0}.lst-kix_uf4umlhhckq2-4>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-4,lower-latin) ". "}.lst-kix_efg97u94j8hb-2>li:before{content:"-  "}.lst-kix_efg97u94j8hb-1>li:before{content:"-  "}.lst-kix_efg97u94j8hb-5>li:before{content:"-  "}ul.lst-kix_s1e4p75lcpk8-0{list-style-type:none}.lst-kix_seg2qxi99oen-1>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-1,lower-latin) ". "}ul.lst-kix_s1e4p75lcpk8-1{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-2{list-style-type:none}ol.lst-kix_fh553kxqh3vv-6.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-6 0}ul.lst-kix_s1e4p75lcpk8-3{list-style-type:none}.lst-kix_uf4umlhhckq2-0>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-0,decimal) ". "}ul.lst-kix_s1e4p75lcpk8-4{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-5{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-6{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-7{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-8{list-style-type:none}.lst-kix_uf4umlhhckq2-1>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-1,lower-latin) ". "}ol.lst-kix_5f9t9fms2d21-5.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-5 0}.lst-kix_6l3u48hb8och-8>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-7{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-6{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-8{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-3{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-2{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-5{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-4{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-1{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-0{list-style-type:none}.lst-kix_76cwqgc9ntcg-5>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-5}ol.lst-kix_2qvefga6tw9t-1.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-1 0}ol.lst-kix_76cwqgc9ntcg-6.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-6 0}.lst-kix_qgxhqyjzp80f-5>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-5}.lst-kix_qaijc6nbpdk4-5>li:before{content:"-  "}.lst-kix_vkx5887x6ome-6>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-6,decimal) ". "}.lst-kix_69woh12i7ucg-7>li{counter-increment:lst-ctn-kix_69woh12i7ucg-7}.lst-kix_fh553kxqh3vv-7>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-7,lower-latin) ". "}.lst-kix_q7k3qhhwoyo7-5>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-5}ul.lst-kix_rjzoughkzvzw-2{list-style-type:none}ul.lst-kix_rjzoughkzvzw-3{list-style-type:none}ul.lst-kix_rjzoughkzvzw-4{list-style-type:none}.lst-kix_nyooapufejer-1>li:before{content:"-  "}ul.lst-kix_rjzoughkzvzw-5{list-style-type:none}ul.lst-kix_rjzoughkzvzw-0{list-style-type:none}.lst-kix_a6itagplhb2w-6>li:before{content:"\0025cf  "}ul.lst-kix_rjzoughkzvzw-1{list-style-type:none}.lst-kix_s078hly7oqfy-1>li:before{content:"-  "}.lst-kix_s078hly7oqfy-5>li:before{content:"-  "}.lst-kix_qgxhqyjzp80f-2>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-2,lower-roman) ". "}.lst-kix_u7vldufjcii4-7>li:before{content:"\0025cb  "}.lst-kix_c9w8l0v8vj60-3>li:before{content:"-  "}.lst-kix_2qvefga6tw9t-1>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-1,lower-latin) ". "}ul.lst-kix_mzqsrs9zicmn-4{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-3{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-2{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-1{list-style-type:none}ul.lst-kix_rjzoughkzvzw-6{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-0{list-style-type:none}ul.lst-kix_rjzoughkzvzw-7{list-style-type:none}ul.lst-kix_rjzoughkzvzw-8{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-2{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-3{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-0{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-1{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-8{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-7{list-style-type:none}.lst-kix_seg2qxi99oen-8>li{counter-increment:lst-ctn-kix_seg2qxi99oen-8}.lst-kix_u7vldufjcii4-3>li:before{content:"\0025cf  "}ul.lst-kix_mzqsrs9zicmn-6{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-5{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-8{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-6{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-7{list-style-type:none}.lst-kix_puq7slv7ersb-3>li{counter-increment:lst-ctn-kix_puq7slv7ersb-3}ul.lst-kix_qaijc6nbpdk4-4{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-5{list-style-type:none}.lst-kix_xgq4y4xln1s-0>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-0}ol.lst-kix_5f9t9fms2d21-1.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-1 0}.lst-kix_q7k3qhhwoyo7-7>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-7,lower-latin) ". "}.lst-kix_m0nrdnud90zq-2>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-2,lower-roman) ". "}ol.lst-kix_76cwqgc9ntcg-2.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-2 0}ol.lst-kix_h8i9ymdmzkx8-2.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-2 0}.lst-kix_q7k3qhhwoyo7-3>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-3}.lst-kix_b7uuq29jz54a-5>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-5}.lst-kix_9kz8bq8q3b2i-0>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-0}.lst-kix_stodkckubncd-1>li{counter-increment:lst-ctn-kix_stodkckubncd-1}ol.lst-kix_ujrictqeu2kx-2{list-style-type:none}ol.lst-kix_ujrictqeu2kx-3{list-style-type:none}ol.lst-kix_ujrictqeu2kx-0{list-style-type:none}ol.lst-kix_ujrictqeu2kx-1{list-style-type:none}ol.lst-kix_ujrictqeu2kx-6{list-style-type:none}ol.lst-kix_ujrictqeu2kx-7{list-style-type:none}ol.lst-kix_ujrictqeu2kx-4{list-style-type:none}ol.lst-kix_ujrictqeu2kx-5{list-style-type:none}ol.lst-kix_ujrictqeu2kx-8{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-5{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-4{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-3{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-3.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-3 0}ul.lst-kix_c9w8l0v8vj60-2{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-1{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-0{list-style-type:none}.lst-kix_c9w8l0v8vj60-7>li:before{content:"-  "}ol.lst-kix_2qvefga6tw9t-5.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-5 0}ol.lst-kix_qgxhqyjzp80f-8{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-7{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-4{list-style-type:none}.lst-kix_oj0ws47jaz7a-0>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-3{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-6{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-5{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-0{list-style-type:none}.lst-kix_puq7slv7ersb-2>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-2,lower-roman) ". "}ol.lst-kix_qgxhqyjzp80f-2{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-1{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-8{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-7{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-6{list-style-type:none}ol.lst-kix_69woh12i7ucg-7.start{counter-reset:lst-ctn-kix_69woh12i7ucg-7 0}.lst-kix_wt16kx5082x6-2>li:before{content:"\0025a0  "}.lst-kix_cmax3c5l3b9l-5>li:before{content:"\0025a0  "}.lst-kix_6zkl42mjxb9i-8>li:before{content:"\0025a0  "}.lst-kix_cmax3c5l3b9l-2>li:before{content:"\0025a0  "}.lst-kix_gnt2wo6vinpb-4>li:before{content:"-  "}.lst-kix_gnt2wo6vinpb-1>li:before{content:"-  "}.lst-kix_nm3lwvrsfgs8-3>li:before{content:"\0025cf  "}.lst-kix_bz3wxvkk86wr-3>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-3}.lst-kix_seg2qxi99oen-2>li{counter-increment:lst-ctn-kix_seg2qxi99oen-2}ol.lst-kix_fh553kxqh3vv-8.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-8 0}.lst-kix_gvdnkwhuv0x-6>li:before{content:"\0025cf  "}.lst-kix_6zkl42mjxb9i-5>li:before{content:"\0025a0  "}.lst-kix_yfnaf4f33kdr-5>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-5,lower-roman) ". "}.lst-kix_cmax3c5l3b9l-8>li:before{content:"\0025a0  "}.lst-kix_gvdnkwhuv0x-3>li:before{content:"\0025cf  "}.lst-kix_nm3lwvrsfgs8-0>li:before{content:"\0025cf  "}.lst-kix_6zkl42mjxb9i-2>li:before{content:"\0025a0  "}.lst-kix_bz3wxvkk86wr-2>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-2,lower-roman) ". "}.lst-kix_y8nzqr1vapa0-2>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-2,lower-roman) ". "}.lst-kix_bz3wxvkk86wr-5>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-5,lower-roman) ". "}.lst-kix_y8nzqr1vapa0-5>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-5,lower-roman) ". "}.lst-kix_yfnaf4f33kdr-2>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-2,lower-roman) ". "}.lst-kix_69woh12i7ucg-4>li{counter-increment:lst-ctn-kix_69woh12i7ucg-4}ol.lst-kix_h8i9ymdmzkx8-6.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-6 0}.lst-kix_y8nzqr1vapa0-8>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-8,lower-roman) ". "}.lst-kix_nm3lwvrsfgs8-6>li:before{content:"\0025cf  "}ol.lst-kix_ujrictqeu2kx-4.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-4 0}ol.lst-kix_69woh12i7ucg-2.start{counter-reset:lst-ctn-kix_69woh12i7ucg-2 0}.lst-kix_bz3wxvkk86wr-8>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-8,lower-roman) ". "}.lst-kix_n9l39mx24y7l-1>li:before{content:"\0025cb  "}.lst-kix_kn39yucmriut-8>li:before{content:"-  "}.lst-kix_9kz8bq8q3b2i-5>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-5}.lst-kix_76cwqgc9ntcg-2>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-2}.lst-kix_kn39yucmriut-5>li:before{content:"-  "}.lst-kix_73zznxkq85l2-3>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-3,decimal) ". "}.lst-kix_qgxhqyjzp80f-8>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-8}.lst-kix_73zznxkq85l2-6>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-6,decimal) ". "}.lst-kix_n9l39mx24y7l-4>li:before{content:"\0025cb  "}.lst-kix_kn39yucmriut-2>li:before{content:"-  "}.lst-kix_p0rhwsmbgd7c-1>li:before{content:"-  "}.lst-kix_d9wep1z810b6-5>li{counter-increment:lst-ctn-kix_d9wep1z810b6-5}.lst-kix_qgxhqyjzp80f-0>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-0}ol.lst-kix_ujrictqeu2kx-2.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-2 0}.lst-kix_76cwqgc9ntcg-2>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-2,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-7>li:before{content:"-  "}.lst-kix_uf4umlhhckq2-8>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-8}.lst-kix_rjzoughkzvzw-2>li:before{content:"\0025a0  "}.lst-kix_2qvefga6tw9t-4>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-4,lower-latin) ". "}.lst-kix_1jqtmxt015qr-8>li:before{content:"-  "}.lst-kix_73zznxkq85l2-0>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-0,decimal) ". "}.lst-kix_5f9t9fms2d21-2>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-2}ol.lst-kix_h8i9ymdmzkx8-8.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-8 0}ol.lst-kix_fh553kxqh3vv-1.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-1 0}.lst-kix_yhp6v7of3e00-5>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-5,lower-roman) ". "}.lst-kix_gv17x2lsey8i-5>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-5>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-5,lower-roman) ". "}.lst-kix_b7uuq29jz54a-2>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-2,lower-roman) ". "}.lst-kix_c9w8l0v8vj60-0>li:before{content:"-  "}.lst-kix_mzqsrs9zicmn-3>li:before{content:"\0025cf  "}.lst-kix_4h5ayc5t6q0q-0>li:before{content:"\0025cf  "}.lst-kix_9kz8bq8q3b2i-8>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-8,lower-roman) ". "}ol.lst-kix_d9wep1z810b6-2.start{counter-reset:lst-ctn-kix_d9wep1z810b6-2 0}.lst-kix_s1e4p75lcpk8-5>li:before{content:"\0025a0  "}.lst-kix_xgq4y4xln1s-3>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-3}.lst-kix_1jqtmxt015qr-2>li:before{content:"-  "}.lst-kix_b7uuq29jz54a-8>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-8,lower-roman) ". "}ol.lst-kix_69woh12i7ucg-5.start{counter-reset:lst-ctn-kix_69woh12i7ucg-5 0}.lst-kix_m0nrdnud90zq-5>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-5,lower-roman) ". "}.lst-kix_7hpd7l1orcn5-2>li:before{content:"-  "}ol.lst-kix_d9wep1z810b6-0.start{counter-reset:lst-ctn-kix_d9wep1z810b6-0 0}ol.lst-kix_fh553kxqh3vv-3.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-3 0}ol.lst-kix_69woh12i7ucg-4.start{counter-reset:lst-ctn-kix_69woh12i7ucg-4 0}.lst-kix_nyooapufejer-4>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-2>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-2}.lst-kix_7hpd7l1orcn5-8>li:before{content:"-  "}.lst-kix_rjzoughkzvzw-8>li:before{content:"\0025a0  "}.lst-kix_oj0ws47jaz7a-6>li:before{content:"-  "}.lst-kix_ks1i5lssvjkg-7>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-7}.lst-kix_b7uuq29jz54a-8>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-8}.lst-kix_vkx5887x6ome-1>li{counter-increment:lst-ctn-kix_vkx5887x6ome-1}.lst-kix_69woh12i7ucg-1>li{counter-increment:lst-ctn-kix_69woh12i7ucg-1}ol.lst-kix_d9wep1z810b6-3.start{counter-reset:lst-ctn-kix_d9wep1z810b6-3 0}.lst-kix_ujrictqeu2kx-8>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-8,lower-roman) ". "}ol.lst-kix_ujrictqeu2kx-1.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-1 0}.lst-kix_r1qxtw4k9pgo-8>li:before{content:"-  "}.lst-kix_seg2qxi99oen-5>li{counter-increment:lst-ctn-kix_seg2qxi99oen-5}.lst-kix_yfnaf4f33kdr-0>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-0}.lst-kix_stodkckubncd-7>li{counter-increment:lst-ctn-kix_stodkckubncd-7}.lst-kix_bh4xapke1dje-6>li:before{content:"\0025cf  "}.lst-kix_r1qxtw4k9pgo-5>li:before{content:"-  "}.lst-kix_xgq4y4xln1s-6>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-6}.lst-kix_uf4umlhhckq2-7>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-7,lower-latin) ". "}.lst-kix_seg2qxi99oen-4>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-4,lower-latin) ". "}.lst-kix_6l3u48hb8och-2>li:before{content:"-  "}ol.lst-kix_puq7slv7ersb-0{list-style-type:none}.lst-kix_h8i9ymdmzkx8-4>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-4,lower-latin) ". "}ol.lst-kix_puq7slv7ersb-1{list-style-type:none}.lst-kix_6l3u48hb8och-5>li:before{content:"-  "}.lst-kix_jrq3pc6b7fs5-7>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-7,lower-latin) ". "}ol.lst-kix_puq7slv7ersb-2{list-style-type:none}ol.lst-kix_puq7slv7ersb-3{list-style-type:none}ol.lst-kix_puq7slv7ersb-4{list-style-type:none}ol.lst-kix_puq7slv7ersb-5{list-style-type:none}.lst-kix_seg2qxi99oen-7>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-7,lower-latin) ". "}.lst-kix_efg97u94j8hb-8>li:before{content:"-  "}.lst-kix_xgq4y4xln1s-6>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-6,decimal) ". "}.lst-kix_xgq4y4xln1s-3>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-3,decimal) ". "}ul.lst-kix_cmax3c5l3b9l-8{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-7{list-style-type:none}.lst-kix_d9wep1z810b6-2>li{counter-increment:lst-ctn-kix_d9wep1z810b6-2}ol.lst-kix_puq7slv7ersb-6{list-style-type:none}ol.lst-kix_puq7slv7ersb-7{list-style-type:none}ol.lst-kix_puq7slv7ersb-8{list-style-type:none}.lst-kix_9kz8bq8q3b2i-8>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-8}.lst-kix_jrq3pc6b7fs5-4>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-4,lower-latin) ". "}ul.lst-kix_cmax3c5l3b9l-0{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-2{list-style-type:none}ol.lst-kix_d9wep1z810b6-4.start{counter-reset:lst-ctn-kix_d9wep1z810b6-4 0}ul.lst-kix_cmax3c5l3b9l-1{list-style-type:none}ol.lst-kix_fh553kxqh3vv-0.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-0 1}ul.lst-kix_cmax3c5l3b9l-4{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-3{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-6{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-5{list-style-type:none}ol.lst-kix_69woh12i7ucg-0.start{counter-reset:lst-ctn-kix_69woh12i7ucg-0 0}.lst-kix_fh553kxqh3vv-1>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-1,lower-latin) ". "}.lst-kix_yhp6v7of3e00-8>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-8,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-4>li:before{content:"-  "}ol.lst-kix_ujrictqeu2kx-5.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-5 0}.lst-kix_33s9mn975cqx-4>li:before{content:"\0025cb  "}.lst-kix_2qvefga6tw9t-7>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-7,lower-latin) ". "}.lst-kix_vkx5887x6ome-0>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-0,decimal) ". "}ul.lst-kix_6zkl42mjxb9i-7{list-style-type:none}ul.lst-kix_6zkl42mjxb9i-8{list-style-type:none}.lst-kix_mzqsrs9zicmn-6>li:before{content:"\0025cf  "}ul.lst-kix_6zkl42mjxb9i-0{list-style-type:none}.lst-kix_73zti2swi0ua-1>li:before{content:"\0025cb  "}ul.lst-kix_6zkl42mjxb9i-1{list-style-type:none}ol.lst-kix_d9wep1z810b6-5.start{counter-reset:lst-ctn-kix_d9wep1z810b6-5 0}ul.lst-kix_6zkl42mjxb9i-2{list-style-type:none}ol.lst-kix_ujrictqeu2kx-8.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-8 0}ul.lst-kix_6zkl42mjxb9i-3{list-style-type:none}ul.lst-kix_6zkl42mjxb9i-4{list-style-type:none}ul.lst-kix_6zkl42mjxb9i-5{list-style-type:none}.lst-kix_gv17x2lsey8i-2>li:before{content:"\0025a0  "}ul.lst-kix_6zkl42mjxb9i-6{list-style-type:none}.lst-kix_qgxhqyjzp80f-8>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-8,lower-roman) ". "}.lst-kix_bz3wxvkk86wr-0>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-0}.lst-kix_jrq3pc6b7fs5-2>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-2}.lst-kix_s1e4p75lcpk8-2>li:before{content:"\0025a0  "}.lst-kix_1jqtmxt015qr-5>li:before{content:"-  "}.lst-kix_b7uuq29jz54a-5>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-5,lower-roman) ". "}.lst-kix_h8i9ymdmzkx8-1>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-1,lower-latin) ". "}.lst-kix_73zznxkq85l2-0>li{counter-increment:lst-ctn-kix_73zznxkq85l2-0}.lst-kix_a6itagplhb2w-0>li:before{content:"\0025cf  "}.lst-kix_uf4umlhhckq2-5>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-5}.lst-kix_ujrictqeu2kx-6>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-6}ol.lst-kix_ujrictqeu2kx-7.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-7 0}.lst-kix_fh553kxqh3vv-2>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-2}.lst-kix_vfpim5mnet5b-7>li:before{content:"\0025cb  "}.lst-kix_q7k3qhhwoyo7-1>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-1,lower-latin) ". "}.lst-kix_m0nrdnud90zq-8>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-8,lower-roman) ". "}ol.lst-kix_d9wep1z810b6-8.start{counter-reset:lst-ctn-kix_d9wep1z810b6-8 0}ul.lst-kix_n9l39mx24y7l-7{list-style-type:none}ul.lst-kix_n9l39mx24y7l-8{list-style-type:none}ul.lst-kix_n9l39mx24y7l-3{list-style-type:none}ul.lst-kix_n9l39mx24y7l-4{list-style-type:none}.lst-kix_puq7slv7ersb-8>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-8,lower-roman) ". "}ul.lst-kix_n9l39mx24y7l-5{list-style-type:none}ul.lst-kix_n9l39mx24y7l-6{list-style-type:none}ul.lst-kix_n9l39mx24y7l-0{list-style-type:none}ul.lst-kix_n9l39mx24y7l-1{list-style-type:none}ul.lst-kix_n9l39mx24y7l-2{list-style-type:none}ol.lst-kix_ujrictqeu2kx-6.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-6 0}.lst-kix_7hpd7l1orcn5-5>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-5>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-5}.lst-kix_rjzoughkzvzw-5>li:before{content:"\0025a0  "}ol.lst-kix_d9wep1z810b6-7.start{counter-reset:lst-ctn-kix_d9wep1z810b6-7 0}.lst-kix_nyooapufejer-7>li:before{content:"-  "}ul.lst-kix_amnxd0o32wxe-1{list-style-type:none}ul.lst-kix_amnxd0o32wxe-2{list-style-type:none}ul.lst-kix_amnxd0o32wxe-3{list-style-type:none}.lst-kix_amnxd0o32wxe-3>li:before{content:"-  "}ul.lst-kix_amnxd0o32wxe-4{list-style-type:none}.lst-kix_amnxd0o32wxe-5>li:before{content:"-  "}ol.lst-kix_jrq3pc6b7fs5-8.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-8 0}ol.lst-kix_5f9t9fms2d21-3.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-3 0}ul.lst-kix_amnxd0o32wxe-5{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-4.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-4 0}ul.lst-kix_amnxd0o32wxe-6{list-style-type:none}ul.lst-kix_amnxd0o32wxe-7{list-style-type:none}.lst-kix_km6c63ta0u1m-0>li:before{content:"\0025cf  "}ul.lst-kix_amnxd0o32wxe-8{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-1.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-1 0}.lst-kix_amnxd0o32wxe-1>li:before{content:"-  "}ol.lst-kix_b7uuq29jz54a-6.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-6 0}.lst-kix_5f9t9fms2d21-1>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-1,lower-latin) ". "}.lst-kix_q7k3qhhwoyo7-0>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-0}.lst-kix_km6c63ta0u1m-6>li:before{content:"\0025cf  "}ul.lst-kix_amnxd0o32wxe-0{list-style-type:none}.lst-kix_d9wep1z810b6-7>li{counter-increment:lst-ctn-kix_d9wep1z810b6-7}.lst-kix_69woh12i7ucg-2>li{counter-increment:lst-ctn-kix_69woh12i7ucg-2}.lst-kix_b7uuq29jz54a-7>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-7}.lst-kix_5f9t9fms2d21-3>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-3,decimal) ". "}.lst-kix_km6c63ta0u1m-4>li:before{content:"\0025cb  "}.lst-kix_y8nzqr1vapa0-1>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-1}.lst-kix_6hpp8uicfxco-8>li:before{content:"-  "}.lst-kix_amnxd0o32wxe-7>li:before{content:"-  "}.lst-kix_6hpp8uicfxco-6>li:before{content:"-  "}.lst-kix_5f9t9fms2d21-5>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-5,lower-roman) ". "}.lst-kix_km6c63ta0u1m-2>li:before{content:"\0025a0  "}.lst-kix_6hpp8uicfxco-4>li:before{content:"-  "}ol.lst-kix_2qvefga6tw9t-3.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-3 0}.lst-kix_5f9t9fms2d21-7>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-7,lower-latin) ". "}.lst-kix_6hpp8uicfxco-2>li:before{content:"-  "}.lst-kix_km6c63ta0u1m-8>li:before{content:"\0025a0  "}.lst-kix_6hpp8uicfxco-0>li:before{content:"-  "}.lst-kix_5f9t9fms2d21-7>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-7}.lst-kix_stodkckubncd-1>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-1,lower-latin) ". "}.lst-kix_stodkckubncd-3>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-3,decimal) ". "}.lst-kix_ks1i5lssvjkg-4>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-4}.lst-kix_xgq4y4xln1s-5>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-5}ol.lst-kix_q7k3qhhwoyo7-1{list-style-type:none}.lst-kix_ujrictqeu2kx-7>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-7}ol.lst-kix_q7k3qhhwoyo7-2{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-3{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-4{list-style-type:none}.lst-kix_m0nrdnud90zq-7>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-7}ol.lst-kix_q7k3qhhwoyo7-5{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-2.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-2 0}ol.lst-kix_q7k3qhhwoyo7-6{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-7{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-8{list-style-type:none}.lst-kix_8eggh954z6m1-7>li:before{content:"-  "}ol.lst-kix_2qvefga6tw9t-8.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-8 0}ol.lst-kix_q7k3qhhwoyo7-0{list-style-type:none}.lst-kix_8eggh954z6m1-1>li:before{content:"-  "}.lst-kix_m09drfn41lbc-5>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-2>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-2}.lst-kix_m09drfn41lbc-3>li:before{content:"\0025cf  "}.lst-kix_m09drfn41lbc-7>li:before{content:"\0025cb  "}.lst-kix_8eggh954z6m1-3>li:before{content:"-  "}.lst-kix_stodkckubncd-5>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-5,lower-roman) ". "}.lst-kix_stodkckubncd-7>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-7,lower-latin) ". "}.lst-kix_8eggh954z6m1-5>li:before{content:"-  "}ol.lst-kix_ujrictqeu2kx-3.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-3 0}ul.lst-kix_73zti2swi0ua-7{list-style-type:none}ul.lst-kix_73zti2swi0ua-8{list-style-type:none}ul.lst-kix_73zti2swi0ua-3{list-style-type:none}ul.lst-kix_73zti2swi0ua-4{list-style-type:none}ul.lst-kix_73zti2swi0ua-5{list-style-type:none}ul.lst-kix_73zti2swi0ua-6{list-style-type:none}ul.lst-kix_73zti2swi0ua-0{list-style-type:none}.lst-kix_33s9mn975cqx-5>li:before{content:"\0025a0  "}ul.lst-kix_73zti2swi0ua-1{list-style-type:none}ul.lst-kix_73zti2swi0ua-2{list-style-type:none}.lst-kix_m09drfn41lbc-1>li:before{content:"\0025cb  "}.lst-kix_stodkckubncd-4>li{counter-increment:lst-ctn-kix_stodkckubncd-4}ol.lst-kix_xgq4y4xln1s-2.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-2 0}.lst-kix_73zznxkq85l2-2>li{counter-increment:lst-ctn-kix_73zznxkq85l2-2}.lst-kix_33s9mn975cqx-7>li:before{content:"\0025cb  "}.lst-kix_d9wep1z810b6-0>li{counter-increment:lst-ctn-kix_d9wep1z810b6-0}.lst-kix_73zti2swi0ua-2>li:before{content:"\0025a0  "}.lst-kix_b0ja666m9l9x-6>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-6}.lst-kix_73zti2swi0ua-0>li:before{content:"\0025cf  "}.lst-kix_73zti2swi0ua-4>li:before{content:"\0025cb  "}.lst-kix_xgq4y4xln1s-7>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-7,lower-latin) ". "}.lst-kix_m0nrdnud90zq-0>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-0}.lst-kix_33s9mn975cqx-1>li:before{content:"\0025cb  "}.lst-kix_33s9mn975cqx-3>li:before{content:"\0025cf  "}.lst-kix_73zti2swi0ua-8>li:before{content:"\0025a0  "}.lst-kix_vkx5887x6ome-7>li{counter-increment:lst-ctn-kix_vkx5887x6ome-7}.lst-kix_73zti2swi0ua-6>li:before{content:"\0025cf  "}.lst-kix_puq7slv7ersb-6>li{counter-increment:lst-ctn-kix_puq7slv7ersb-6}ol.lst-kix_5f9t9fms2d21-8.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-8 0}.lst-kix_vfpim5mnet5b-2>li:before{content:"\0025a0  "}ol.lst-kix_ks1i5lssvjkg-2.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-2 0}.lst-kix_vfpim5mnet5b-4>li:before{content:"\0025cb  "}ol.lst-kix_9kz8bq8q3b2i-6.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-6 0}.lst-kix_vfpim5mnet5b-6>li:before{content:"\0025cf  "}.lst-kix_vfpim5mnet5b-8>li:before{content:"\0025a0  "}.lst-kix_q7k3qhhwoyo7-7>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-7}ol.lst-kix_b7uuq29jz54a-1.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-1 0}ol.lst-kix_vkx5887x6ome-4.start{counter-reset:lst-ctn-kix_vkx5887x6ome-4 0}.lst-kix_vkx5887x6ome-0>li{counter-increment:lst-ctn-kix_vkx5887x6ome-0}.lst-kix_y8nzqr1vapa0-8>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-8}.lst-kix_seg2qxi99oen-4>li{counter-increment:lst-ctn-kix_seg2qxi99oen-4}.lst-kix_vfpim5mnet5b-0>li:before{content:"\0025cf  "}.lst-kix_bh4xapke1dje-0>li:before{content:"\0025cf  "}ol.lst-kix_b0ja666m9l9x-2.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-2 0}.lst-kix_bh4xapke1dje-4>li:before{content:"\0025cb  "}.lst-kix_ujrictqeu2kx-6>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-6,decimal) ". "}.lst-kix_2qvefga6tw9t-6>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-6}ol.lst-kix_fh553kxqh3vv-5.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-5 0}.lst-kix_2qvefga6tw9t-4>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-4}.lst-kix_bh4xapke1dje-8>li:before{content:"\0025a0  "}ol.lst-kix_b0ja666m9l9x-7.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-7 0}.lst-kix_h8i9ymdmzkx8-3>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-3,decimal) ". "}.lst-kix_xgq4y4xln1s-5>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-5,lower-roman) ". "}.lst-kix_h8i9ymdmzkx8-7>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-7,lower-latin) ". "}ul.lst-kix_wt16kx5082x6-8{list-style-type:none}.lst-kix_jrq3pc6b7fs5-1>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-1,lower-latin) ". "}ul.lst-kix_wt16kx5082x6-7{list-style-type:none}ul.lst-kix_wt16kx5082x6-4{list-style-type:none}ul.lst-kix_wt16kx5082x6-3{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-5.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-5 0}ul.lst-kix_wt16kx5082x6-6{list-style-type:none}ul.lst-kix_wt16kx5082x6-5{list-style-type:none}ul.lst-kix_wt16kx5082x6-0{list-style-type:none}.lst-kix_xgq4y4xln1s-1>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-1,lower-latin) ". "}ul.lst-kix_wt16kx5082x6-2{list-style-type:none}.lst-kix_h8i9ymdmzkx8-4>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-4}ol.lst-kix_m0nrdnud90zq-5.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-5 0}ul.lst-kix_wt16kx5082x6-1{list-style-type:none}.lst-kix_jrq3pc6b7fs5-5>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-5,lower-roman) ". "}.lst-kix_9kz8bq8q3b2i-2>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-2}.lst-kix_76cwqgc9ntcg-1>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-1,lower-latin) ". "}.lst-kix_76cwqgc9ntcg-7>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-7}.lst-kix_yhp6v7of3e00-7>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-7}.lst-kix_9kz8bq8q3b2i-5>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-5,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-6>li:before{content:"-  "}ol.lst-kix_h8i9ymdmzkx8-0.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-0 0}ol.lst-kix_q7k3qhhwoyo7-7.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-7 0}ol.lst-kix_b0ja666m9l9x-0{list-style-type:none}ol.lst-kix_b0ja666m9l9x-3{list-style-type:none}ol.lst-kix_b0ja666m9l9x-4{list-style-type:none}ol.lst-kix_b0ja666m9l9x-1{list-style-type:none}ol.lst-kix_b0ja666m9l9x-2{list-style-type:none}ol.lst-kix_b0ja666m9l9x-7{list-style-type:none}ol.lst-kix_b0ja666m9l9x-8{list-style-type:none}ol.lst-kix_b0ja666m9l9x-5{list-style-type:none}.lst-kix_9kz8bq8q3b2i-1>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-1,lower-latin) ". "}ol.lst-kix_b0ja666m9l9x-6{list-style-type:none}.lst-kix_yhp6v7of3e00-5>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-5}.lst-kix_s1e4p75lcpk8-8>li:before{content:"\0025a0  "}.lst-kix_4h5ayc5t6q0q-7>li:before{content:"\0025cb  "}.lst-kix_b7uuq29jz54a-3>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-3,decimal) ". "}.lst-kix_b7uuq29jz54a-0>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-0}ol.lst-kix_73zznxkq85l2-4.start{counter-reset:lst-ctn-kix_73zznxkq85l2-4 0}.lst-kix_s1e4p75lcpk8-0>li:before{content:"\0025cf  "}.lst-kix_s1e4p75lcpk8-4>li:before{content:"\0025cb  "}.lst-kix_4h5ayc5t6q0q-3>li:before{content:"\0025cf  "}ol.lst-kix_73zznxkq85l2-1.start{counter-reset:lst-ctn-kix_73zznxkq85l2-1 0}.lst-kix_b7uuq29jz54a-7>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-7,lower-latin) ". "}.lst-kix_ujrictqeu2kx-0>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-0}.lst-kix_5f9t9fms2d21-0>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-0}ol.lst-kix_xgq4y4xln1s-7.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-7 0}.lst-kix_puq7slv7ersb-8>li{counter-increment:lst-ctn-kix_puq7slv7ersb-8}.lst-kix_xgq4y4xln1s-7>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-7}.lst-kix_76cwqgc9ntcg-0>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-0}.lst-kix_ujrictqeu2kx-2>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-2,lower-roman) ". "}.lst-kix_yhp6v7of3e00-0>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-0}.lst-kix_76cwqgc9ntcg-5>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-5,lower-roman) ". "}.lst-kix_wt16kx5082x6-0>li:before{content:"\0025cf  "}ol.lst-kix_qgxhqyjzp80f-7.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-7 0}.lst-kix_cmax3c5l3b9l-1>li:before{content:"\0025cb  "}.lst-kix_gnt2wo6vinpb-0>li:before{content:"-  "}ol.lst-kix_ks1i5lssvjkg-6{list-style-type:none}.lst-kix_y8nzqr1vapa0-3>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-3}ol.lst-kix_ks1i5lssvjkg-7{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-4{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-5{list-style-type:none}.lst-kix_gnt2wo6vinpb-2>li:before{content:"-  "}ol.lst-kix_ks1i5lssvjkg-2{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-3{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-0{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-1{list-style-type:none}.lst-kix_gvdnkwhuv0x-8>li:before{content:"\0025a0  "}.lst-kix_uf4umlhhckq2-0>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-0}ol.lst-kix_ks1i5lssvjkg-8{list-style-type:none}.lst-kix_6zkl42mjxb9i-6>li:before{content:"\0025cf  "}.lst-kix_yfnaf4f33kdr-6>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-6,decimal) ". "}.lst-kix_yfnaf4f33kdr-8>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-8,lower-roman) ". "}ol.lst-kix_yfnaf4f33kdr-5.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-5 0}.lst-kix_cmax3c5l3b9l-7>li:before{content:"\0025cb  "}.lst-kix_6zkl42mjxb9i-4>li:before{content:"\0025cb  "}ol.lst-kix_m0nrdnud90zq-7.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-7 0}.lst-kix_gvdnkwhuv0x-2>li:before{content:"\0025a0  "}.lst-kix_gnt2wo6vinpb-8>li:before{content:"-  "}.lst-kix_nm3lwvrsfgs8-1>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-0>li{counter-increment:lst-ctn-kix_69woh12i7ucg-0}.lst-kix_yfnaf4f33kdr-0>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-0,decimal) ". "}.lst-kix_stodkckubncd-6>li{counter-increment:lst-ctn-kix_stodkckubncd-6}.lst-kix_bz3wxvkk86wr-1>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-1,lower-latin) ". "}.lst-kix_gvdnkwhuv0x-0>li:before{content:"\0025cf  "}.lst-kix_y8nzqr1vapa0-4>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-4,lower-latin) ". "}.lst-kix_y8nzqr1vapa0-6>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-6,decimal) ". "}ol.lst-kix_b0ja666m9l9x-0.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-0 0}.lst-kix_n9l39mx24y7l-8>li:before{content:"\0025a0  "}.lst-kix_nm3lwvrsfgs8-7>li:before{content:"\0025cb  "}.lst-kix_puq7slv7ersb-1>li{counter-increment:lst-ctn-kix_puq7slv7ersb-1}.lst-kix_bz3wxvkk86wr-7>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-7,lower-latin) ". "}.lst-kix_n9l39mx24y7l-0>li:before{content:"\0025cf  "}.lst-kix_n9l39mx24y7l-2>li:before{content:"\0025a0  "}.lst-kix_kn39yucmriut-6>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-0.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-0 0}.lst-kix_kn39yucmriut-4>li:before{content:"-  "}.lst-kix_5f9t9fms2d21-5>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-5}.lst-kix_fh553kxqh3vv-0>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-0}.lst-kix_wt16kx5082x6-8>li:before{content:"\0025a0  "}.lst-kix_jrq3pc6b7fs5-0>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-0}.lst-kix_q7k3qhhwoyo7-2>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-2}.lst-kix_p0rhwsmbgd7c-0>li:before{content:"-  "}.lst-kix_73zznxkq85l2-7>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-7,lower-latin) ". "}ol.lst-kix_yhp6v7of3e00-6.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-6 0}.lst-kix_73zznxkq85l2-5>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-5,lower-roman) ". "}.lst-kix_wt16kx5082x6-6>li:before{content:"\0025cf  "}.lst-kix_p0rhwsmbgd7c-2>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-0.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-0 2}.lst-kix_b7uuq29jz54a-2>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-2}.lst-kix_yhp6v7of3e00-7>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-7,lower-latin) ". "}.lst-kix_jrq3pc6b7fs5-4>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-4}.lst-kix_yfnaf4f33kdr-5>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-5}ol.lst-kix_yhp6v7of3e00-4.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-4 0}.lst-kix_ks1i5lssvjkg-2>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-2}.lst-kix_puq7slv7ersb-4>li{counter-increment:lst-ctn-kix_puq7slv7ersb-4}ol.lst-kix_m0nrdnud90zq-0.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-0 0}.lst-kix_mzqsrs9zicmn-5>li:before{content:"\0025a0  "}.lst-kix_c9w8l0v8vj60-4>li:before{content:"-  "}.lst-kix_gv17x2lsey8i-3>li:before{content:"\0025cf  "}ol.lst-kix_yhp6v7of3e00-1.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-1 0}.lst-kix_qgxhqyjzp80f-1>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-1,lower-latin) ". "}.lst-kix_qgxhqyjzp80f-7>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-7,lower-latin) ". "}.lst-kix_gv17x2lsey8i-1>li:before{content:"\0025cb  "}.lst-kix_yhp6v7of3e00-1>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-1,lower-latin) ". "}ol.lst-kix_stodkckubncd-5{list-style-type:none}ol.lst-kix_stodkckubncd-4{list-style-type:none}ol.lst-kix_stodkckubncd-3{list-style-type:none}.lst-kix_1jqtmxt015qr-6>li:before{content:"-  "}ol.lst-kix_stodkckubncd-2{list-style-type:none}ol.lst-kix_puq7slv7ersb-1.start{counter-reset:lst-ctn-kix_puq7slv7ersb-1 0}ol.lst-kix_stodkckubncd-8{list-style-type:none}ol.lst-kix_stodkckubncd-7{list-style-type:none}ol.lst-kix_stodkckubncd-6{list-style-type:none}.lst-kix_1jqtmxt015qr-4>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-5.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-5 0}.lst-kix_fh553kxqh3vv-4>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-4}ol.lst-kix_m0nrdnud90zq-2.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-2 0}ol.lst-kix_qgxhqyjzp80f-2.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-2 0}ol.lst-kix_9kz8bq8q3b2i-5{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-6{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-7{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-8{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-1{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-2{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-3{list-style-type:none}.lst-kix_h8i9ymdmzkx8-2>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-2}ol.lst-kix_9kz8bq8q3b2i-4{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-8.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-8 0}ol.lst-kix_9kz8bq8q3b2i-0{list-style-type:none}.lst-kix_m0nrdnud90zq-7>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-7,lower-latin) ". "}.lst-kix_c9w8l0v8vj60-6>li:before{content:"-  "}ul.lst-kix_gnt2wo6vinpb-0{list-style-type:none}.lst-kix_mzqsrs9zicmn-7>li:before{content:"\0025cb  "}ul.lst-kix_gnt2wo6vinpb-1{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-2{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-3{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-4{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-5{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-6{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-7{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-8{list-style-type:none}.lst-kix_rjzoughkzvzw-4>li:before{content:"\0025cb  "}ol.lst-kix_m0nrdnud90zq-6{list-style-type:none}ol.lst-kix_m0nrdnud90zq-5{list-style-type:none}ol.lst-kix_m0nrdnud90zq-8{list-style-type:none}ol.lst-kix_m0nrdnud90zq-7{list-style-type:none}ol.lst-kix_m0nrdnud90zq-2{list-style-type:none}ol.lst-kix_m0nrdnud90zq-1{list-style-type:none}ol.lst-kix_m0nrdnud90zq-4{list-style-type:none}ol.lst-kix_m0nrdnud90zq-3{list-style-type:none}.lst-kix_rjzoughkzvzw-6>li:before{content:"\0025cf  "}ol.lst-kix_m0nrdnud90zq-0{list-style-type:none}.lst-kix_bh4xapke1dje-2>li:before{content:"\0025a0  "}.lst-kix_oj0ws47jaz7a-5>li:before{content:"-  "}ol.lst-kix_jrq3pc6b7fs5-5.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-5 0}.lst-kix_8hc53kjy1j5y-7>li:before{content:"-  "}.lst-kix_7hpd7l1orcn5-1>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-2.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-2 0}ol.lst-kix_y8nzqr1vapa0-5.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-5 0}.lst-kix_uf4umlhhckq2-3>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-3}ul.lst-kix_6hpp8uicfxco-7{list-style-type:none}ul.lst-kix_6hpp8uicfxco-6{list-style-type:none}ul.lst-kix_6hpp8uicfxco-8{list-style-type:none}ul.lst-kix_6hpp8uicfxco-3{list-style-type:none}ul.lst-kix_6hpp8uicfxco-2{list-style-type:none}ul.lst-kix_6hpp8uicfxco-5{list-style-type:none}ul.lst-kix_6hpp8uicfxco-4{list-style-type:none}.lst-kix_m0nrdnud90zq-1>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-1,lower-latin) ". "}ul.lst-kix_6hpp8uicfxco-1{list-style-type:none}.lst-kix_r1qxtw4k9pgo-4>li:before{content:"-  "}ul.lst-kix_6hpp8uicfxco-0{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-7{list-style-type:none}ul.lst-kix_zyb4ozncdg-8{list-style-type:none}.lst-kix_seg2qxi99oen-3>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-3,decimal) ". "}ul.lst-kix_4h5ayc5t6q0q-6{list-style-type:none}ul.lst-kix_zyb4ozncdg-7{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-5{list-style-type:none}ul.lst-kix_zyb4ozncdg-6{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-4{list-style-type:none}ul.lst-kix_zyb4ozncdg-5{list-style-type:none}.lst-kix_uf4umlhhckq2-3>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-3,decimal) ". "}ul.lst-kix_4h5ayc5t6q0q-8{list-style-type:none}ul.lst-kix_zyb4ozncdg-0{list-style-type:none}.lst-kix_yfnaf4f33kdr-2>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-2}ol.lst-kix_stodkckubncd-1{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-3{list-style-type:none}ul.lst-kix_zyb4ozncdg-4{list-style-type:none}ol.lst-kix_stodkckubncd-0{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-2{list-style-type:none}ul.lst-kix_zyb4ozncdg-3{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-6.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-6 0}ul.lst-kix_4h5ayc5t6q0q-1{list-style-type:none}ul.lst-kix_zyb4ozncdg-2{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-0{list-style-type:none}ul.lst-kix_zyb4ozncdg-1{list-style-type:none}.lst-kix_h8i9ymdmzkx8-5>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-5,lower-roman) ". "}.lst-kix_efg97u94j8hb-7>li:before{content:"-  "}ol.lst-kix_jrq3pc6b7fs5-0.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-0 0}ol.lst-kix_ks1i5lssvjkg-5.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-5 0}.lst-kix_6l3u48hb8och-6>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-7.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-7 0}ul.lst-kix_gvdnkwhuv0x-0{list-style-type:none}.lst-kix_bz3wxvkk86wr-2>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-2}ul.lst-kix_gvdnkwhuv0x-4{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-3{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-2{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-1{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-8{list-style-type:none}.lst-kix_jrq3pc6b7fs5-3>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-3,decimal) ". "}ul.lst-kix_gvdnkwhuv0x-7{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-6{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-5{list-style-type:none}.lst-kix_uf4umlhhckq2-7>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-7}ul.lst-kix_a6itagplhb2w-1{list-style-type:none}ul.lst-kix_a6itagplhb2w-0{list-style-type:none}ul.lst-kix_a6itagplhb2w-3{list-style-type:none}ul.lst-kix_a6itagplhb2w-2{list-style-type:none}ul.lst-kix_a6itagplhb2w-5{list-style-type:none}ul.lst-kix_a6itagplhb2w-4{list-style-type:none}ul.lst-kix_a6itagplhb2w-7{list-style-type:none}ul.lst-kix_a6itagplhb2w-6{list-style-type:none}.lst-kix_p0rhwsmbgd7c-8>li:before{content:"-  "}ul.lst-kix_a6itagplhb2w-8{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-1.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-1 0}ol.lst-kix_ks1i5lssvjkg-7.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-7 0}.lst-kix_qaijc6nbpdk4-3>li:before{content:"-  "}ol.lst-kix_76cwqgc9ntcg-8{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-7{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-6{list-style-type:none}ol.lst-kix_69woh12i7ucg-0{list-style-type:none}.lst-kix_2qvefga6tw9t-3>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-3,decimal) ". "}ol.lst-kix_69woh12i7ucg-1{list-style-type:none}ol.lst-kix_69woh12i7ucg-4{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-1{list-style-type:none}ol.lst-kix_69woh12i7ucg-5{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-0{list-style-type:none}ol.lst-kix_69woh12i7ucg-2{list-style-type:none}ol.lst-kix_69woh12i7ucg-3{list-style-type:none}ol.lst-kix_69woh12i7ucg-8{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-5{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-4{list-style-type:none}ol.lst-kix_69woh12i7ucg-6{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-3{list-style-type:none}ol.lst-kix_69woh12i7ucg-7{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-2{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-3.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-3 0}.lst-kix_b7uuq29jz54a-1>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-1,lower-latin) ". "}.lst-kix_s1e4p75lcpk8-6>li:before{content:"\0025cf  "}.lst-kix_stodkckubncd-2>li{counter-increment:lst-ctn-kix_stodkckubncd-2}.lst-kix_u7vldufjcii4-1>li:before{content:"\0025cb  "}.lst-kix_fh553kxqh3vv-7>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-7}ol.lst-kix_puq7slv7ersb-7.start{counter-reset:lst-ctn-kix_puq7slv7ersb-7 0}.lst-kix_9kz8bq8q3b2i-7>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-7,lower-latin) ". "}.lst-kix_4h5ayc5t6q0q-1>li:before{content:"\0025cb  "}ol.lst-kix_puq7slv7ersb-4.start{counter-reset:lst-ctn-kix_puq7slv7ersb-4 0}.lst-kix_jrq3pc6b7fs5-7>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-7}.lst-kix_9kz8bq8q3b2i-6>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-6}ol.lst-kix_jrq3pc6b7fs5-3.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-3 0}ol.lst-kix_y8nzqr1vapa0-0.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-0 0}.lst-kix_b0ja666m9l9x-4>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-4}ol.lst-kix_h8i9ymdmzkx8-4{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-3{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-2{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-1{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-8{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-7{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-6{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-5{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-0{list-style-type:none}ol.lst-kix_puq7slv7ersb-6.start{counter-reset:lst-ctn-kix_puq7slv7ersb-6 0}.lst-kix_ujrictqeu2kx-4>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-4,lower-latin) ". "}.lst-kix_nyooapufejer-3>li:before{content:"-  "}.lst-kix_76cwqgc9ntcg-3>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-3,decimal) ". "}ul.lst-kix_gv17x2lsey8i-0{list-style-type:none}ul.lst-kix_gv17x2lsey8i-1{list-style-type:none}ul.lst-kix_gv17x2lsey8i-2{list-style-type:none}ul.lst-kix_gv17x2lsey8i-3{list-style-type:none}ul.lst-kix_gv17x2lsey8i-4{list-style-type:none}ul.lst-kix_gv17x2lsey8i-5{list-style-type:none}.lst-kix_stodkckubncd-8>li{counter-increment:lst-ctn-kix_stodkckubncd-8}ol.lst-kix_vkx5887x6ome-6.start{counter-reset:lst-ctn-kix_vkx5887x6ome-6 0}.lst-kix_ks1i5lssvjkg-8>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-8,lower-roman) ". "}ul.lst-kix_gv17x2lsey8i-6{list-style-type:none}.lst-kix_ks1i5lssvjkg-7>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-7,lower-latin) ". "}ul.lst-kix_gv17x2lsey8i-7{list-style-type:none}ul.lst-kix_gv17x2lsey8i-8{list-style-type:none}.lst-kix_ks1i5lssvjkg-5>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-5,lower-roman) ". "}.lst-kix_d9wep1z810b6-2>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-2,lower-roman) ". "}.lst-kix_ks1i5lssvjkg-4>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-4,lower-latin) ". "}.lst-kix_b0ja666m9l9x-6>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-6,decimal) ". "}ol.lst-kix_seg2qxi99oen-3.start{counter-reset:lst-ctn-kix_seg2qxi99oen-3 0}.lst-kix_seg2qxi99oen-0>li{counter-increment:lst-ctn-kix_seg2qxi99oen-0}.lst-kix_zyb4ozncdg-8>li:before{content:"\0025a0  "}.lst-kix_69woh12i7ucg-3>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-3,decimal) ". "}.lst-kix_ks1i5lssvjkg-1>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-1,lower-latin) ". "}.lst-kix_b0ja666m9l9x-0>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-0,decimal) ". "}.lst-kix_d9wep1z810b6-8>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-8,lower-roman) ". "}.lst-kix_69woh12i7ucg-2>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-2,lower-roman) ". "}.lst-kix_d9wep1z810b6-6>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-6,decimal) ". "}.lst-kix_69woh12i7ucg-0>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-0,decimal) ". "}.lst-kix_d9wep1z810b6-5>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-5,lower-roman) ". "}ol.lst-kix_vkx5887x6ome-1.start{counter-reset:lst-ctn-kix_vkx5887x6ome-1 0}.lst-kix_zyb4ozncdg-2>li:before{content:"\0025a0  "}ol.lst-kix_seg2qxi99oen-3{list-style-type:none}ol.lst-kix_seg2qxi99oen-2{list-style-type:none}ol.lst-kix_seg2qxi99oen-1{list-style-type:none}ol.lst-kix_seg2qxi99oen-0{list-style-type:none}ol.lst-kix_seg2qxi99oen-7{list-style-type:none}.lst-kix_zyb4ozncdg-6>li:before{content:"\0025cf  "}ol.lst-kix_seg2qxi99oen-6{list-style-type:none}ol.lst-kix_seg2qxi99oen-5{list-style-type:none}ol.lst-kix_seg2qxi99oen-4{list-style-type:none}.lst-kix_69woh12i7ucg-6>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-6,decimal) ". "}.lst-kix_b0ja666m9l9x-2>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-2,lower-roman) ". "}ol.lst-kix_seg2qxi99oen-8{list-style-type:none}.lst-kix_b0ja666m9l9x-3>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-3,decimal) ". "}.lst-kix_b0ja666m9l9x-2>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-2}.lst-kix_zyb4ozncdg-5>li:before{content:"\0025a0  "}.lst-kix_fh553kxqh3vv-2>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-2,lower-roman) ". "}ul.lst-kix_1jqtmxt015qr-2{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-8.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-8 0}ul.lst-kix_1jqtmxt015qr-1{list-style-type:none}.lst-kix_vkx5887x6ome-5>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-5,lower-roman) ". "}ul.lst-kix_1jqtmxt015qr-4{list-style-type:none}.lst-kix_5f9t9fms2d21-3>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-3}ul.lst-kix_1jqtmxt015qr-3{list-style-type:none}.lst-kix_fh553kxqh3vv-0>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-0,decimal) ". "}ul.lst-kix_1jqtmxt015qr-6{list-style-type:none}ul.lst-kix_1jqtmxt015qr-5{list-style-type:none}ul.lst-kix_1jqtmxt015qr-8{list-style-type:none}ul.lst-kix_1jqtmxt015qr-7{list-style-type:none}.lst-kix_fh553kxqh3vv-6>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-6,decimal) ". "}.lst-kix_qaijc6nbpdk4-4>li:before{content:"-  "}ul.lst-kix_1jqtmxt015qr-0{list-style-type:none}ol.lst-kix_uf4umlhhckq2-5.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-5 0}.lst-kix_ujrictqeu2kx-4>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-4}.lst-kix_vkx5887x6ome-1>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-1,lower-latin) ". "}.lst-kix_s078hly7oqfy-0>li:before{content:"-  "}ol.lst-kix_m0nrdnud90zq-3.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-3 0}.lst-kix_a6itagplhb2w-1>li:before{content:"\0025cb  "}.lst-kix_u7vldufjcii4-8>li:before{content:"\0025a0  "}.lst-kix_a6itagplhb2w-5>li:before{content:"\0025a0  "}.lst-kix_2qvefga6tw9t-1>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-1}ol.lst-kix_73zznxkq85l2-7.start{counter-reset:lst-ctn-kix_73zznxkq85l2-7 0}.lst-kix_u7vldufjcii4-2>li:before{content:"\0025a0  "}.lst-kix_s078hly7oqfy-6>li:before{content:"-  "}.lst-kix_qaijc6nbpdk4-0>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-2.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-2 0}ol.lst-kix_stodkckubncd-3.start{counter-reset:lst-ctn-kix_stodkckubncd-3 0}.lst-kix_q7k3qhhwoyo7-6>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-6,decimal) ". "}.lst-kix_76cwqgc9ntcg-3>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-3}.lst-kix_69woh12i7ucg-5>li{counter-increment:lst-ctn-kix_69woh12i7ucg-5}.lst-kix_q7k3qhhwoyo7-2>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-2,lower-roman) ". "}.lst-kix_puq7slv7ersb-7>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-7,lower-latin) ". "}ol.lst-kix_qgxhqyjzp80f-3.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-3 0}ol.lst-kix_b7uuq29jz54a-8{list-style-type:none}.lst-kix_q7k3qhhwoyo7-0>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-0,decimal) ". "}ol.lst-kix_xgq4y4xln1s-0.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-0 0}ol.lst-kix_q7k3qhhwoyo7-0.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-0 0}.lst-kix_ks1i5lssvjkg-8>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-8}ul.lst-kix_m09drfn41lbc-8{list-style-type:none}.lst-kix_oj0ws47jaz7a-1>li:before{content:"-  "}ul.lst-kix_m09drfn41lbc-7{list-style-type:none}ul.lst-kix_m09drfn41lbc-6{list-style-type:none}ul.lst-kix_m09drfn41lbc-5{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-6.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-6 0}.lst-kix_puq7slv7ersb-3>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-3,decimal) ". "}ul.lst-kix_m09drfn41lbc-4{list-style-type:none}ol.lst-kix_b7uuq29jz54a-5{list-style-type:none}ol.lst-kix_stodkckubncd-2.start{counter-reset:lst-ctn-kix_stodkckubncd-2 0}ol.lst-kix_yhp6v7of3e00-3.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-3 0}ul.lst-kix_m09drfn41lbc-3{list-style-type:none}ol.lst-kix_b7uuq29jz54a-4{list-style-type:none}ul.lst-kix_m09drfn41lbc-2{list-style-type:none}ol.lst-kix_b7uuq29jz54a-7{list-style-type:none}ul.lst-kix_m09drfn41lbc-1{list-style-type:none}ol.lst-kix_b7uuq29jz54a-6{list-style-type:none}ul.lst-kix_m09drfn41lbc-0{list-style-type:none}ol.lst-kix_b7uuq29jz54a-1{list-style-type:none}ol.lst-kix_b7uuq29jz54a-0{list-style-type:none}ol.lst-kix_b7uuq29jz54a-3{list-style-type:none}ol.lst-kix_b7uuq29jz54a-2{list-style-type:none}.lst-kix_oj0ws47jaz7a-7>li:before{content:"-  "}.lst-kix_oj0ws47jaz7a-4>li:before{content:"-  "}.lst-kix_oj0ws47jaz7a-8>li:before{content:"-  "}ol.lst-kix_73zznxkq85l2-8.start{counter-reset:lst-ctn-kix_73zznxkq85l2-8 0}ol.lst-kix_bz3wxvkk86wr-7.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-7 0}.lst-kix_7hpd7l1orcn5-0>li:before{content:"-  "}.lst-kix_bz3wxvkk86wr-4>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-4}ol.lst-kix_yhp6v7of3e00-8.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-8 0}ol.lst-kix_q7k3qhhwoyo7-5.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-5 0}ol.lst-kix_b7uuq29jz54a-3.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-3 0}.lst-kix_r1qxtw4k9pgo-7>li:before{content:"-  "}ol.lst-kix_9kz8bq8q3b2i-4.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-4 0}.lst-kix_r1qxtw4k9pgo-3>li:before{content:"-  "}.lst-kix_h8i9ymdmzkx8-6>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-6}ol.lst-kix_m0nrdnud90zq-4.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-4 0}.lst-kix_8hc53kjy1j5y-0>li:before{content:"-  "}.lst-kix_r1qxtw4k9pgo-6>li:before{content:"-  "}.lst-kix_seg2qxi99oen-2>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-2,lower-roman) ". "}.lst-kix_seg2qxi99oen-5>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-5,lower-roman) ". "}.lst-kix_6l3u48hb8och-0>li:before{content:"-  "}ol.lst-kix_xgq4y4xln1s-4.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-4 0}.lst-kix_uf4umlhhckq2-8>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-8,lower-roman) ". "}.lst-kix_6l3u48hb8och-3>li:before{content:"-  "}.lst-kix_6l3u48hb8och-7>li:before{content:"-  "}.lst-kix_6l3u48hb8och-4>li:before{content:"-  "}.lst-kix_seg2qxi99oen-6>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-6,decimal) ". "}.lst-kix_efg97u94j8hb-6>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-4>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-4}ol.lst-kix_9kz8bq8q3b2i-3.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-3 0}.lst-kix_uf4umlhhckq2-5>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-5,lower-roman) ". "}.lst-kix_fh553kxqh3vv-6>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-6}.lst-kix_b0ja666m9l9x-8>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-8}.lst-kix_uf4umlhhckq2-1>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-1}ol.lst-kix_b7uuq29jz54a-4.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-4 0}.lst-kix_jrq3pc6b7fs5-6>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-6}.lst-kix_fh553kxqh3vv-3>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-3,decimal) ". "}ol.lst-kix_q7k3qhhwoyo7-4.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-4 0}.lst-kix_vkx5887x6ome-2>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-2,lower-roman) ". "}.lst-kix_xgq4y4xln1s-2>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-2}.lst-kix_2qvefga6tw9t-5>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-5,lower-roman) ". "}ol.lst-kix_yhp6v7of3e00-7.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-7 0}ol.lst-kix_uf4umlhhckq2-6{list-style-type:none}ol.lst-kix_uf4umlhhckq2-5{list-style-type:none}ol.lst-kix_uf4umlhhckq2-8{list-style-type:none}.lst-kix_y8nzqr1vapa0-6>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-6}ol.lst-kix_uf4umlhhckq2-7{list-style-type:none}.lst-kix_qgxhqyjzp80f-6>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-6,decimal) ". "}.lst-kix_a6itagplhb2w-2>li:before{content:"\0025a0  "}ol.lst-kix_uf4umlhhckq2-0{list-style-type:none}ol.lst-kix_uf4umlhhckq2-2{list-style-type:none}ol.lst-kix_xgq4y4xln1s-5.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-5 0}ol.lst-kix_uf4umlhhckq2-1{list-style-type:none}ol.lst-kix_uf4umlhhckq2-4{list-style-type:none}ol.lst-kix_uf4umlhhckq2-3{list-style-type:none}ol.lst-kix_b0ja666m9l9x-4.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-4 0}.lst-kix_qaijc6nbpdk4-1>li:before{content:"-  "}.lst-kix_ujrictqeu2kx-5>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-5}ul.lst-kix_nm3lwvrsfgs8-7{list-style-type:none}.lst-kix_y8nzqr1vapa0-0>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-0,decimal) ". "}ul.lst-kix_nm3lwvrsfgs8-8{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-5{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-6{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-3{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-4{list-style-type:none}.lst-kix_q7k3qhhwoyo7-3>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-3,decimal) ". "}.lst-kix_m0nrdnud90zq-6>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-6,decimal) ". "}ol.lst-kix_73zznxkq85l2-2.start{counter-reset:lst-ctn-kix_73zznxkq85l2-2 0}.lst-kix_d9wep1z810b6-3>li{counter-increment:lst-ctn-kix_d9wep1z810b6-3}.lst-kix_9kz8bq8q3b2i-7>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-7}ol.lst-kix_b0ja666m9l9x-3.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-3 0}ol.lst-kix_b7uuq29jz54a-8.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-8 0}.lst-kix_puq7slv7ersb-6>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-6,decimal) ". "}ol.lst-kix_m0nrdnud90zq-8.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-8 0}.lst-kix_7hpd7l1orcn5-3>li:before{content:"-  "}.lst-kix_rjzoughkzvzw-3>li:before{content:"\0025cf  "}ol.lst-kix_73zznxkq85l2-3.start{counter-reset:lst-ctn-kix_73zznxkq85l2-3 0}.lst-kix_yfnaf4f33kdr-1>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-1}.lst-kix_seg2qxi99oen-1>li{counter-increment:lst-ctn-kix_seg2qxi99oen-1}.lst-kix_7hpd7l1orcn5-7>li:before{content:"-  "}.lst-kix_nyooapufejer-5>li:before{content:"-  "}.lst-kix_rjzoughkzvzw-7>li:before{content:"\0025cb  "}.lst-kix_wt16kx5082x6-1>li:before{content:"\0025cb  "}.lst-kix_m0nrdnud90zq-5>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-5}.lst-kix_wt16kx5082x6-4>li:before{content:"\0025cb  "}ol.lst-kix_uf4umlhhckq2-1.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-1 0}ul.lst-kix_nyooapufejer-7{list-style-type:none}ul.lst-kix_nyooapufejer-6{list-style-type:none}ul.lst-kix_nyooapufejer-5{list-style-type:none}ul.lst-kix_nyooapufejer-4{list-style-type:none}.lst-kix_cmax3c5l3b9l-3>li:before{content:"\0025cf  "}ul.lst-kix_nyooapufejer-8{list-style-type:none}.lst-kix_ks1i5lssvjkg-6>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-6}ol.lst-kix_vkx5887x6ome-0.start{counter-reset:lst-ctn-kix_vkx5887x6ome-0 0}.lst-kix_cmax3c5l3b9l-0>li:before{content:"\0025cf  "}ul.lst-kix_r1qxtw4k9pgo-5{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-4{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-3{list-style-type:none}.lst-kix_vkx5887x6ome-2>li{counter-increment:lst-ctn-kix_vkx5887x6ome-2}ul.lst-kix_r1qxtw4k9pgo-2{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-8{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-7{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-6{list-style-type:none}.lst-kix_6zkl42mjxb9i-0>li:before{content:"\0025cf  "}.lst-kix_qgxhqyjzp80f-4>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-4}ul.lst-kix_nyooapufejer-3{list-style-type:none}.lst-kix_nm3lwvrsfgs8-5>li:before{content:"\0025a0  "}ul.lst-kix_nyooapufejer-2{list-style-type:none}ul.lst-kix_nyooapufejer-1{list-style-type:none}ol.lst-kix_seg2qxi99oen-4.start{counter-reset:lst-ctn-kix_seg2qxi99oen-4 0}ul.lst-kix_nyooapufejer-0{list-style-type:none}.lst-kix_gnt2wo6vinpb-3>li:before{content:"-  "}ol.lst-kix_xgq4y4xln1s-1.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-1 0}.lst-kix_gvdnkwhuv0x-4>li:before{content:"\0025cb  "}ol.lst-kix_vkx5887x6ome-1{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-1{list-style-type:none}ol.lst-kix_vkx5887x6ome-2{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-2{list-style-type:none}ol.lst-kix_vkx5887x6ome-0{list-style-type:none}.lst-kix_6zkl42mjxb9i-3>li:before{content:"\0025cf  "}.lst-kix_gnt2wo6vinpb-6>li:before{content:"-  "}ul.lst-kix_nm3lwvrsfgs8-0{list-style-type:none}.lst-kix_yfnaf4f33kdr-7>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-7,lower-latin) ". "}ol.lst-kix_73zznxkq85l2-6.start{counter-reset:lst-ctn-kix_73zznxkq85l2-6 0}.lst-kix_gvdnkwhuv0x-1>li:before{content:"\0025cb  "}.lst-kix_yfnaf4f33kdr-4>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-4,lower-latin) ". "}.lst-kix_bz3wxvkk86wr-3>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-3,decimal) ". "}.lst-kix_y8nzqr1vapa0-7>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-7,lower-latin) ". "}ol.lst-kix_stodkckubncd-6.start{counter-reset:lst-ctn-kix_stodkckubncd-6 0}.lst-kix_seg2qxi99oen-6>li{counter-increment:lst-ctn-kix_seg2qxi99oen-6}.lst-kix_nm3lwvrsfgs8-8>li:before{content:"\0025a0  "}ol.lst-kix_xgq4y4xln1s-8{list-style-type:none}ol.lst-kix_xgq4y4xln1s-5{list-style-type:none}ol.lst-kix_xgq4y4xln1s-4{list-style-type:none}ol.lst-kix_xgq4y4xln1s-7{list-style-type:none}ol.lst-kix_xgq4y4xln1s-6{list-style-type:none}.lst-kix_kn39yucmriut-3>li:before{content:"-  "}.lst-kix_n9l39mx24y7l-6>li:before{content:"\0025cf  "}.lst-kix_73zznxkq85l2-1>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-1,lower-latin) ". "}.lst-kix_73zznxkq85l2-4>li{counter-increment:lst-ctn-kix_73zznxkq85l2-4}ol.lst-kix_b0ja666m9l9x-5.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-5 0}.lst-kix_wt16kx5082x6-7>li:before{content:"\0025cb  "}.lst-kix_kn39yucmriut-0>li:before{content:"-  "}ol.lst-kix_q7k3qhhwoyo7-3.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-3 0}.lst-kix_stodkckubncd-3>li{counter-increment:lst-ctn-kix_stodkckubncd-3}.lst-kix_n9l39mx24y7l-3>li:before{content:"\0025cf  "}.lst-kix_bz3wxvkk86wr-0>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-0,decimal) ". "}ol.lst-kix_bz3wxvkk86wr-3.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-3 0}ol.lst-kix_y8nzqr1vapa0-0{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-1{list-style-type:none}.lst-kix_1jqtmxt015qr-0>li:before{content:"-  "}ol.lst-kix_y8nzqr1vapa0-2{list-style-type:none}.lst-kix_9kz8bq8q3b2i-0>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-0,decimal) ". "}ol.lst-kix_y8nzqr1vapa0-3{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-4{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-5{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-6{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-7{list-style-type:none}.lst-kix_9kz8bq8q3b2i-6>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-6,decimal) ". "}ol.lst-kix_b7uuq29jz54a-2.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-2 0}ol.lst-kix_vkx5887x6ome-7.start{counter-reset:lst-ctn-kix_vkx5887x6ome-7 0}.lst-kix_nyooapufejer-2>li:before{content:"-  "}ol.lst-kix_stodkckubncd-1.start{counter-reset:lst-ctn-kix_stodkckubncd-1 0}.lst-kix_yhp6v7of3e00-3>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-3,decimal) ". "}ol.lst-kix_xgq4y4xln1s-1{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-8{list-style-type:none}ol.lst-kix_xgq4y4xln1s-0{list-style-type:none}ol.lst-kix_xgq4y4xln1s-3{list-style-type:none}ol.lst-kix_xgq4y4xln1s-2{list-style-type:none}.lst-kix_rjzoughkzvzw-0>li:before{content:"\0025cf  "}.lst-kix_b7uuq29jz54a-1>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-1}ol.lst-kix_seg2qxi99oen-2.start{counter-reset:lst-ctn-kix_seg2qxi99oen-2 0}ol.lst-kix_uf4umlhhckq2-8.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-8 0}.lst-kix_4h5ayc5t6q0q-8>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-3>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-3,decimal) ". "}.lst-kix_gv17x2lsey8i-7>li:before{content:"\0025cb  "}.lst-kix_qgxhqyjzp80f-1>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-1}.lst-kix_s1e4p75lcpk8-7>li:before{content:"\0025cb  "}.lst-kix_2qvefga6tw9t-2>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-2,lower-roman) ". "}.lst-kix_c9w8l0v8vj60-2>li:before{content:"-  "}ol.lst-kix_stodkckubncd-4.start{counter-reset:lst-ctn-kix_stodkckubncd-4 0}.lst-kix_mzqsrs9zicmn-1>li:before{content:"\0025cb  "}ol.lst-kix_bz3wxvkk86wr-8.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-8 0}ol.lst-kix_q7k3qhhwoyo7-1.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-1 0}.lst-kix_ujrictqeu2kx-2>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-2}.lst-kix_4h5ayc5t6q0q-2>li:before{content:"\0025a0  "}ol.lst-kix_uf4umlhhckq2-6.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-6 0}.lst-kix_m0nrdnud90zq-3>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-3,decimal) ". "}ol.lst-kix_bz3wxvkk86wr-5.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-5 0}ol.lst-kix_b7uuq29jz54a-0.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-0 0}ol.lst-kix_vkx5887x6ome-5.start{counter-reset:lst-ctn-kix_vkx5887x6ome-5 0}ul.lst-kix_r1qxtw4k9pgo-1{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-0{list-style-type:none}ol.lst-kix_b0ja666m9l9x-8.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-8 0}.lst-kix_puq7slv7ersb-5>li{counter-increment:lst-ctn-kix_puq7slv7ersb-5}.lst-kix_c9w8l0v8vj60-8>li:before{content:"-  "}.lst-kix_yfnaf4f33kdr-4>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-4}.lst-kix_yhp6v7of3e00-3>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-3}.lst-kix_76cwqgc9ntcg-4>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-4,lower-latin) ". "}.lst-kix_d9wep1z810b6-6>li{counter-increment:lst-ctn-kix_d9wep1z810b6-6}.lst-kix_bh4xapke1dje-1>li:before{content:"\0025cb  "}ol.lst-kix_stodkckubncd-8.start{counter-reset:lst-ctn-kix_stodkckubncd-8 0}ul.lst-kix_u7vldufjcii4-0{list-style-type:none}ul.lst-kix_u7vldufjcii4-1{list-style-type:none}.lst-kix_r1qxtw4k9pgo-0>li:before{content:"-  "}ul.lst-kix_u7vldufjcii4-2{list-style-type:none}.lst-kix_8hc53kjy1j5y-6>li:before{content:"-  "}.lst-kix_9kz8bq8q3b2i-4>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-4}.lst-kix_qgxhqyjzp80f-7>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-7}ul.lst-kix_u7vldufjcii4-7{list-style-type:none}ol.lst-kix_vkx5887x6ome-3.start{counter-reset:lst-ctn-kix_vkx5887x6ome-3 0}ul.lst-kix_u7vldufjcii4-8{list-style-type:none}ul.lst-kix_u7vldufjcii4-3{list-style-type:none}ul.lst-kix_u7vldufjcii4-4{list-style-type:none}ul.lst-kix_u7vldufjcii4-5{list-style-type:none}.lst-kix_8hc53kjy1j5y-3>li:before{content:"-  "}ul.lst-kix_u7vldufjcii4-6{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-1.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-1 0}ol.lst-kix_seg2qxi99oen-1.start{counter-reset:lst-ctn-kix_seg2qxi99oen-1 0}.lst-kix_m0nrdnud90zq-0>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-0,decimal) ". "}ul.lst-kix_km6c63ta0u1m-8{list-style-type:none}ul.lst-kix_km6c63ta0u1m-7{list-style-type:none}.lst-kix_efg97u94j8hb-3>li:before{content:"-  "}ol.lst-kix_vkx5887x6ome-2.start{counter-reset:lst-ctn-kix_vkx5887x6ome-2 0}.lst-kix_uf4umlhhckq2-2>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-2,lower-roman) ". "}.lst-kix_b7uuq29jz54a-4>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-4}ol.lst-kix_uf4umlhhckq2-3.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-3 0}.lst-kix_ks1i5lssvjkg-3>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-3}ol.lst-kix_bz3wxvkk86wr-2.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-2 0}.lst-kix_vkx5887x6ome-5>li{counter-increment:lst-ctn-kix_vkx5887x6ome-5}.lst-kix_vkx5887x6ome-8>li{counter-increment:lst-ctn-kix_vkx5887x6ome-8}.lst-kix_ks1i5lssvjkg-0>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-0}.lst-kix_73zznxkq85l2-7>li{counter-increment:lst-ctn-kix_73zznxkq85l2-7}ol.lst-kix_uf4umlhhckq2-4.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-4 0}.lst-kix_stodkckubncd-0>li{counter-increment:lst-ctn-kix_stodkckubncd-0}.lst-kix_9kz8bq8q3b2i-3>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-3,decimal) ". "}.lst-kix_m09drfn41lbc-2>li:before{content:"\0025a0  "}ol.lst-kix_bz3wxvkk86wr-0.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-0 0}ol.lst-kix_seg2qxi99oen-8.start{counter-reset:lst-ctn-kix_seg2qxi99oen-8 0}.lst-kix_76cwqgc9ntcg-7>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-7,lower-latin) ". "}.lst-kix_76cwqgc9ntcg-6>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-6}ol.lst-kix_seg2qxi99oen-5.start{counter-reset:lst-ctn-kix_seg2qxi99oen-5 0}.lst-kix_69woh12i7ucg-8>li{counter-increment:lst-ctn-kix_69woh12i7ucg-8}.lst-kix_qaijc6nbpdk4-7>li:before{content:"-  "}.lst-kix_a6itagplhb2w-8>li:before{content:"\0025a0  "}.lst-kix_q7k3qhhwoyo7-4>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-4}.lst-kix_s078hly7oqfy-3>li:before{content:"-  "}ol.lst-kix_uf4umlhhckq2-2.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-2 0}.lst-kix_qgxhqyjzp80f-0>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-0,decimal) ". "}.lst-kix_4h5ayc5t6q0q-5>li:before{content:"\0025a0  "}.lst-kix_yhp6v7of3e00-0>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-0,decimal) ". "}ol.lst-kix_stodkckubncd-7.start{counter-reset:lst-ctn-kix_stodkckubncd-7 0}.lst-kix_vkx5887x6ome-8>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-8,lower-roman) ". "}.lst-kix_efg97u94j8hb-0>li:before{content:"-  "}.lst-kix_u7vldufjcii4-5>li:before{content:"\0025a0  "}.lst-kix_h8i9ymdmzkx8-0>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-0}ul.lst-kix_km6c63ta0u1m-4{list-style-type:none}.lst-kix_5f9t9fms2d21-6>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-6}ul.lst-kix_km6c63ta0u1m-3{list-style-type:none}ul.lst-kix_km6c63ta0u1m-6{list-style-type:none}ul.lst-kix_km6c63ta0u1m-5{list-style-type:none}.lst-kix_bz3wxvkk86wr-7>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-7}ul.lst-kix_km6c63ta0u1m-0{list-style-type:none}ul.lst-kix_km6c63ta0u1m-2{list-style-type:none}.lst-kix_m0nrdnud90zq-2>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-2}ul.lst-kix_km6c63ta0u1m-1{list-style-type:none}.lst-kix_9kz8bq8q3b2i-1>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-1}ol.lst-kix_uf4umlhhckq2-0.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-0 0}ol.lst-kix_seg2qxi99oen-7.start{counter-reset:lst-ctn-kix_seg2qxi99oen-7 0}.lst-kix_c9w8l0v8vj60-5>li:before{content:"-  "}.lst-kix_puq7slv7ersb-2>li{counter-increment:lst-ctn-kix_puq7slv7ersb-2}.lst-kix_puq7slv7ersb-0>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-0,decimal) ". "}ol.lst-kix_jrq3pc6b7fs5-7{list-style-type:none}.lst-kix_yfnaf4f33kdr-7>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-7}ol.lst-kix_jrq3pc6b7fs5-8{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-5{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-6{list-style-type:none}.lst-kix_ujrictqeu2kx-0>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-0,decimal) ". "}ol.lst-kix_jrq3pc6b7fs5-3{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-4{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-1{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-2{list-style-type:none}.lst-kix_yhp6v7of3e00-6>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-6}ol.lst-kix_jrq3pc6b7fs5-0{list-style-type:none}ol.lst-kix_seg2qxi99oen-6.start{counter-reset:lst-ctn-kix_seg2qxi99oen-6 0}ol{margin:0;padding:0}table td,table th{padding:0}.c58{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:60.8pt;border-top-color:#000000;border-bottom-style:solid}.c75{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:73.5pt;border-top-color:#000000;border-bottom-style:solid}.c39{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:98.2pt;border-top-color:#000000;border-bottom-style:solid}.c41{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:106.5pt;border-top-color:#000000;border-bottom-style:solid}.c26{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:65.2pt;border-top-color:#000000;border-bottom-style:solid}.c42{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:79.5pt;border-top-color:#000000;border-bottom-style:solid}.c59{margin-left:0pt;padding-top:18pt;list-style-position:inside;text-indent:45pt;padding-bottom:6pt;line-height:1.1500022727272727;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c17{-webkit-text-decoration-skip:none;color:#1155cc;text-decoration:underline;vertical-align:baseline;text-decoration-skip-ink:none;font-size:11pt;font-family:"Arial";font-style:normal}.c47{-webkit-text-decoration-skip:none;color:#000000;text-decoration:underline;vertical-align:baseline;text-decoration-skip-ink:none;font-size:18pt;font-family:"Arial";font-style:normal}.c0{margin-left:108pt;padding-top:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c5{background-color:#ffffff;padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c6{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c18{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:10pt;font-family:"Arial";font-style:normal}.c7{background-color:#ffffff;padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c52{margin-left:36pt;padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c23{margin-left:18pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c61{padding-top:20pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c48{color:#000000;text-decoration:none;vertical-align:super;font-size:11pt;font-family:"Arial";font-style:normal}.c36{padding-top:10pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c34{color:#ff0000;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c38{color:#000000;text-decoration:none;vertical-align:baseline;font-size:7pt;font-family:"Arial";font-style:normal}.c43{color:#000000;text-decoration:none;vertical-align:baseline;font-size:16pt;font-family:"Arial";font-style:normal}.c49{color:#000000;text-decoration:none;vertical-align:baseline;font-size:20pt;font-family:"Arial";font-style:normal}.c20{color:#000000;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c19{padding-top:18pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;text-align:left}.c65{padding-top:18pt;padding-bottom:6pt;line-height:1.1500022727272727;page-break-after:avoid;text-align:left}.c35{padding-top:18pt;padding-bottom:6pt;line-height:1.0;page-break-after:avoid;text-align:left}.c29{color:#000000;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial"}.c77{text-decoration:none;vertical-align:baseline;font-size:12pt;font-family:"Calibri";font-style:normal}.c88{color:#3c4043;text-decoration:none;vertical-align:baseline;font-family:"Roboto";font-style:normal}.c95{padding-top:20pt;padding-bottom:6pt;line-height:1.1500022727272727;page-break-after:avoid;text-align:left}.c84{text-decoration:none;vertical-align:baseline;font-family:"Calibri";font-style:normal}.c56{padding-top:0pt;padding-bottom:0pt;line-height:1.07;text-align:left}.c76{padding-top:0pt;padding-bottom:0pt;line-height:1.15;text-align:right}.c93{padding-top:10pt;padding-bottom:4pt;line-height:1.0;text-align:left}.c60{text-decoration:none;vertical-align:baseline;font-family:"Arial";font-style:normal}.c1{padding-top:0pt;padding-bottom:0pt;line-height:1.0;text-align:left}.c46{padding-top:0pt;padding-bottom:0pt;line-height:1.1500022727272727;text-align:left}.c91{margin-left:-15.8pt;border-spacing:0;border-collapse:collapse;margin-right:auto}.c8{margin-left:144pt;padding-left:0pt;orphans:2;widows:2}.c12{margin-left:180pt;padding-left:0pt;orphans:2;widows:2}.c15{margin-left:36pt;padding-left:0pt;orphans:2;widows:2}.c81{vertical-align:baseline;font-size:12pt;font-family:"Calibri";font-style:normal}.c57{margin-left:216pt;padding-left:0pt;orphans:2;widows:2}.c13{margin-left:72pt;padding-left:0pt;orphans:2;widows:2}.c80{text-decoration:none;vertical-align:baseline;font-size:8pt;font-family:"Arial"}.c82{padding-top:4pt;padding-bottom:0pt;line-height:1.0;text-align:left}.c73{text-decoration:none;vertical-align:baseline;font-size:16pt;font-family:"Arial"}.c40{-webkit-text-decoration-skip:none;color:#1155cc;text-decoration:underline;text-decoration-skip-ink:none}.c10{margin-left:117pt;padding-left:-9pt;orphans:2;widows:2}.c21{margin-left:108pt;padding-left:0pt;orphans:2;widows:2}.c9{padding-top:0pt;padding-bottom:0pt;line-height:1.15;text-align:left}.c54{text-decoration-skip-ink:none;-webkit-text-decoration-skip:none;text-decoration:underline}.c67{vertical-align:baseline;font-family:"Arial";font-style:normal}.c45{margin-left:72pt;orphans:2;widows:2}.c87{text-decoration:none;vertical-align:baseline;font-family:"Arial"}.c25{orphans:2;widows:2;height:11pt}.c79{font-size:7pt;font-family:"Times New Roman"}.c14{padding:0;margin:0}.c69{margin-left:225pt;padding-left:-9pt}.c86{padding-left:0pt;page-break-after:avoid}.c53{margin-left:117pt;padding-left:-9pt}.c33{border:1px solid black;margin:5px}.c44{font-size:14pt;color:#ff0000}.c70{margin-left:144pt;padding-left:0pt}.c2{background-color:#ffffff;font-style:italic}.c68{orphans:2;widows:2}.c3{color:inherit;text-decoration:inherit}.c85{max-width:468pt;padding:72pt 72pt 72pt 72pt}.c24{margin-left:108pt;padding-left:0pt}.c83{margin-left:72pt;padding-left:0pt}.c97{color:#333333}.c28{vertical-align:sub}.c72{color:#1155cc}.c62{color:#ff0000}.c4{font-style:italic}.c92{color:#0000ff}.c96{color:#222222}.c32{font-size:10.5pt}.c11{font-weight:700}.c90{height:20pt}.c16{background-color:#ffffff}.c63{font-size:11pt}.c64{vertical-align:super}.c22{font-weight:400}.c66{color:#000000}.c71{margin-left:144pt}.c89{font-size:7pt}.c94{height:59.2pt}.c30{height:11pt}.c51{margin-left:180pt}.c55{font-size:18pt}.c74{margin-left:36pt}.c50{font-size:14pt}.c27{font-size:10pt}.c78{margin-left:108pt}.c37{background-color:#ffff00}.c31{height:0pt}.title{padding-top:0pt;color:#000000;font-size:26pt;padding-bottom:3pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.subtitle{padding-top:0pt;color:#666666;font-size:15pt;padding-bottom:16pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}li{color:#000000;font-size:11pt;font-family:"Arial"}p{margin:0;color:#000000;font-size:11pt;font-family:"Arial"}h1{padding-top:20pt;color:#000000;font-size:20pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h2{padding-top:18pt;color:#000000;font-size:16pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h3{padding-top:16pt;color:#434343;font-size:14pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h4{padding-top:14pt;color:#666666;font-size:12pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h5{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h6{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;font-style:italic;orphans:2;widows:2;text-align:left}</style></head><body class="c16 c85"><div><p class="c76 c68"><span class="c6">Version 3.19.20</span></p></div><p class="c1 c25"><span class="c29 c4 c22"></span></p><p class="c7 c30"><span class="c47 c11"></span></p><p class="c7"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 468.50px; height: 93.85px;"><img alt="" src="images/image6.jpg" style="width: 468.50px; height: 93.85px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c7"><span class="c60 c11 c66 c55">Brigham and Women&rsquo;s Hospital</span></p><p class="c7"><span class="c11 c55">COVID-19 Critical Care Clinical Guidelines </span></p><p class="c7 c30"><span class="c11 c47"></span></p><p class="c7"><span class="c60 c22 c66 c55">Updated: 3/19/2020</span></p><p class="c5 c30"><span class="c60 c11 c66 c55"></span></p><p class="c7"><span class="c60 c44 c11">This document is a work in progress. We have much to learn. </span></p><p class="c7"><span class="c44 c11 c60">This is updated daily with evolving information; do not print.</span></p><p class="c7 c30"><span class="c60 c11 c66 c50"></span></p><p class="c7"><span class="c11 c44">Please send suggestions:</span><span class="c11 c50">&nbsp;</span><span class="c40 c50"><a class="c3" href="mailto:BWHCOVIDGuidelines@gmail.com">BWHCOVIDGuidelines@gmail.com</a></span><span class="c60 c11 c66 c50">&nbsp;</span></p><p class="c5 c30"><span class="c47 c11"></span></p><p class="c9 c68"><span class="c11 c27">Disclaimer: </span><span class="c27">This document is intended as a resource for clinicians caring for critically-ill COVID-19 patients, based on available evidence and recommendations of governing bodies. The recommendations do not replace clinical judgment or the need for individualized patient care plans. While we attempt to keep this document up-to-date, the literature on COVID-19 is rapidly evolving, and we suggest that practitioners search for the most up-to-date literature on any specific topic. These guidelines will also rapidly evolve as they are implemented into clinical practice and we receive feedback from practitioners. Finally, these guidelines were developed based on practice patterns and infrastructure at Brigham and Women&rsquo;s Hospital in Boston, MA; local factors should be taken into account if utilized at other hospitals.</span></p><h1 class="c61" id="h.7amkd6138bxo"><span class="c49 c22">COVID-19 one page Quick Guides:</span></h1><p class="c9 c68"><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.dropbox.com/s/th0vxif5x3hoejs/INITIAL%2520WORKUP-%2520covid%2520quick%2520guide.pdf?dl%3D0&amp;sa=D&amp;ust=1584714690122000">COVID-19 Initial work-up QUICK GUIDE</a></span></p><p class="c9 c68"><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.dropbox.com/s/1na1vj0kq7dt0ys/RESP%2520FAILURE-%2520covid%2520quick%2520guide.pdf?dl%3D0&amp;sa=D&amp;ust=1584714690122000">COVID-19 ARDS management QUICK GUIDE</a></span></p><p class="c9 c68"><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.dropbox.com/s/9ff4h4a8wea35oq/ICU%2520CARE-%2520covid%2520quick%2520guide.pdf?dl%3D0&amp;sa=D&amp;ust=1584714690122000">COVID-19 ICU care QUICK GUIDE</a></span></p><p class="c5"><span class="c54 c11 c66 c81">&nbsp;</span></p><hr style="page-break-before:always;display:none;"><p class="c5 c30"><span class="c47 c11"></span></p><p class="c7"><span class="c47 c11">Table of Contents</span></p><p class="c5 c30"><span class="c54 c67 c11 c66 c50"></span></p><p class="c68 c82"><span class="c40 c11"><a class="c3" href="#h.7amkd6138bxo">COVID-19 one page Quick Guides:</a></span><span class="c40 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c40 c11"><a class="c3" href="#h.7amkd6138bxo">1</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.3mwu0obb6xmi">Chapter 1: Non-ICU Management, Triage, Transfers</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.3mwu0obb6xmi">3</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.a8294aye0lbq">Clinical Course of COVID-19</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.a8294aye0lbq">3</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.ymvixg917k3e">Non-ICU Management Principles</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.ymvixg917k3e">4</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.tsr53lmedjah">Triage to ICU</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.tsr53lmedjah">6</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.32yrxx2cn5j">Transfer Process</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.32yrxx2cn5j">6</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.hu2czim2nti8">Chapter 2: Respiratory Support for COVID-19 Patients</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.hu2czim2nti8">7</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.5z5wj4l0ghah">Respiratory Failure and ARDS</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.5z5wj4l0ghah">7</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.z178d8l3t5u1">Management of Hypoxemia</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.z178d8l3t5u1">7</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.welz4k559gib">Initial Mechanical Ventilation</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.welz4k559gib">9</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.mcb6j64zp5u6">PEEP and Mechanics</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.mcb6j64zp5u6">10</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.nhqe52dtgmrn">Targeting Sedation for Ventilator Synchrony</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.nhqe52dtgmrn">11</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.f3ug6fi0aj01">General Management of Ventilated ARDS Patients</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.f3ug6fi0aj01">12</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.qrh9t96165ug">Managing Ventilation</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.qrh9t96165ug">13</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.4wvmhdtgo9di">Managing Oxygenation</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.4wvmhdtgo9di">13</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.wgrateeto9z4">Proning and Pulmonary Vasodilators</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.wgrateeto9z4">15</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.24j39tc7pjup">ECMO consultation</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.24j39tc7pjup">16</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.kx686gedgtzg">Chapter 3: COVID-19 Therapies and Clinical Trials</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.kx686gedgtzg">17</a></span></p><p class="c23"><span class="c4">Note: The anti-viral and anti-inflammatory section below written by our critical care group is meant to provide a summary of the literature. This section does not represent the views or recommendations of the BWH Div. of Infectious Disease. </span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.szvkuh7mguyn">Clinical trials</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.szvkuh7mguyn">17</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.8vhrbtln428m">Antibiotic stewardship</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.8vhrbtln428m">17</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.eudti5z0ojjo">Metered-dose inhalers (MDIs) vs. nebulizers</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.eudti5z0ojjo">18</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.8pktimpr5u6o">Airway Clearance</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.8pktimpr5u6o">18</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.ym3ao1e1uli3">Inhaled Pulmonary Vasodilators</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.ym3ao1e1uli3">19</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.x05c129ivxrw">Systemic Corticosteroids</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.x05c129ivxrw">20</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.m6l0vgre9d0s">Anti-IL6 Agents (Tocilizumab, Siltuximab)</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.m6l0vgre9d0s">20</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.wr1agkjgho7b">Hydroxychloroquine and Chloroquine</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.wr1agkjgho7b">21</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.uebugzw0ifj">Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.uebugzw0ifj">23</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.msot2gdaj2bg">Non-steroidal anti-inflammatory drugs (NSAIDs)</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.msot2gdaj2bg">23</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.p7atxkt2b3sh">Blood Products</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.p7atxkt2b3sh">24</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.6zfga8b63w2s">Chapter 4: Cardiac Complications of COVID-19</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c11 c17"><a class="c3" href="#h.6zfga8b63w2s">25</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.sxzvrsrmkd1g">Acute Cardiac Injury</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.sxzvrsrmkd1g">25</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.es6b8f4xqski">Cardiovascular Testing</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.es6b8f4xqski">25</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.rm4wr985h2i8">Arrhythmias</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.rm4wr985h2i8">26</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.13b1uhteftcc">Acute Coronary Syndromes</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.13b1uhteftcc">27</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.txp16938ptwl">Pericarditis and Myocarditis</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.txp16938ptwl">28</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.dpe5gr1hwjp">Chapter 5: Shock: Septic, Cardiogenic, and Cytokine Storm</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.dpe5gr1hwjp">28</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.bdbn9kepy2bs">Undifferentiated Shock in COVID</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.bdbn9kepy2bs">28</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.ebuidko2u3iz">Differentiating Shock</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.ebuidko2u3iz">30</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.lydcfzsuv4hc">Septic Shock and Secondary Infections</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.lydcfzsuv4hc">31</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.ftupyxepmedz">Cardiogenic Shock</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.ftupyxepmedz">32</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.7i62kagnynf0">Cytokine Activation Syndrome</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.7i62kagnynf0">34</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.5s70bzlr4ojz">Chapter 6: Thrombotic and Coagulation Manifestations</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.5s70bzlr4ojz">35</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.9wzf9ick65rt">Thrombotic Disease</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.9wzf9ick65rt">35</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.vpg0k312hzmd">Disseminated Intravascular Coagulation (DIC)</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.vpg0k312hzmd">36</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.9jn4ulxubc3h">Chapter 7: Renal Manifestations</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.9jn4ulxubc3h">37</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.fj20lj7bpd6o">Acute Kidney Injury</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.fj20lj7bpd6o">37</a></span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.l3i6lcz3jr27">Chapter 8: Other Guidance</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.l3i6lcz3jr27">38</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.fg1hqkm6u1r8">Liver Disease</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.fg1hqkm6u1r8">38</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.aayfijcxre19">Considerations for Oncology Patients</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.aayfijcxre19">39</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.t1khoickfgoo">Goals of Care</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.t1khoickfgoo">42</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.ipfys4gecnv0">Management of Cardiac Arrest</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.ipfys4gecnv0">42</a></span></p><p class="c23"><span class="c17 c22"><a class="c3" href="#h.6ogwg6sl9a40">Ethical Considerations and Resource Allocation</a></span><span class="c17 c22">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c22"><a class="c3" href="#h.6ogwg6sl9a40">43</a></span></p><p class="c36"><span class="c40 c11">AFTERWORD</span><span class="c72 c11">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </span></p><p class="c36"><span class="c17 c11"><a class="c3" href="#h.iw1b3dijf01r">REFERENCES</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.iw1b3dijf01r">4</a></span><span class="c40 c11">5</span></p><p class="c68 c93"><span class="c17 c11"><a class="c3" href="#h.t36cynad724o">ADDENDUM: COVID ICU Bundle Checklist</a></span><span class="c17 c11">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c17 c11"><a class="c3" href="#h.t36cynad724o">4</a></span><span class="c40 c11">9</span></p><h1 class="c61" id="h.3mwu0obb6xmi"><span class="c49 c22">Chapter 1: Non-ICU Management, Triage, Transfers</span></h1><ol class="c14 lst-kix_seg2qxi99oen-0 start" start="1"><li class="c19 c15"><h2 id="h.a8294aye0lbq" style="display:inline"><span>Clinical Course of </span><span>COVID-19</span><span class="c22 c43">&nbsp;</span></h2></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c1 c13"><span class="c11">Clinical presentation: </span><span>non-specific, flu-like illness</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c9 c24"><span class="c6">Fever &nbsp;(44-98%) </span></li><li class="c9 c24"><span class="c6">Cough &nbsp;(46-82%)</span></li><li class="c9 c24"><span class="c6">SOB &nbsp;(20-64%)</span></li><li class="c9 c24"><span class="c6">URI &nbsp;(5-25%)</span></li><li class="c9 c24"><span class="c6 c16">GI sx &nbsp;(10%; usually before respiratory sx)</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="2"><li class="c9 c83"><span class="c20 c11 c16">Transmission:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c9 c24"><span class="c6 c16">Large droplets and fomites</span></li><li class="c9 c24"><span class="c6 c16">Incubation period: typi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cally 2-7d, up to 14d</span></li><li class="c9 c24"><span class="c16">Symptomatic and asymptomatic patients can transmit the virus</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="3"><li class="c1 c13"><span class="c11">Course for admitted patients</span><span class="c6">: </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c1 c21"><span class="c6">~ 80% don&rsquo;t require critical care</span></li><li class="c1 c21"><span>~ 10-20% develop bacterial </span><span>superinfection</span><span>&nbsp;</span></li><li class="c1 c21"><span>~ 30% develop </span><span>ARDS</span></li><li class="c1 c21"><span class="c6">~ 5% develop renal injury requiring renal replacement therapy </span></li><li class="c1 c21"><span class="c6">Transaminemia is common; fulminant hepatitis not yet reported</span></li><li class="c1 c21"><span>Rep</span><span>orts of cardiomyopathy in critically ill patients; some progress to cardiogenic shock late in course</span></li><li class="c1 c21"><span>The data on rates of viral co-infection is </span><span>incomplete</span><sup><a href="#cmnt1" id="cmnt_ref1">[a]</a></sup><span class="c6">. </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="4"><li class="c1 c13"><span class="c20 c11">Reasons for ICU admission:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c1 c21"><span class="c6">Hypoxemic respiratory failure is the most common indication for ICU.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c1 c8"><span class="c6">Reports of rapid progression to intubation within 12-24h</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="2"><li class="c1 c21"><span class="c6">Few patients present with shock, can develop late in course</span></li><li class="c1 c21"><span class="c6">Median time from symptom onset to ICU transfer is ~10 days</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="5"><li class="c1 c13"><span class="c20 c11">Poor prognostic indicators:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c1 c21"><span class="c6">Demographics: Age &gt; 65, male</span></li><li class="c1 c21"><span class="c6">Comorbidities: cardiovascular disease (including HTN), pulmonary disease, diabetes, malignancy, immunosuppression</span></li><li class="c1 c21"><span>Lab findings: severe lymphopenia, elevated TnT, elevated Cr, elevated LDH, elevated CRP, elevated D-dimer</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="6"><li class="c13 c9"><span class="c20 c11">Cause of death:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c0"><span>&nbsp;Cause of death in r</span><span>etrospective study from Wuhan of 68 patients who died of COVID (Ruan et al, </span><span class="c4">Intensive Care Med</span><span class="c6">, 2020):</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c8 c9"><span class="c6">53% (n=36) respiratory failure</span></li><li class="c8 c9"><span class="c6">7% (n=5) myocardial damage/ heart failure </span></li><li class="c8 c9"><span>33% (n=22) concomitant respiratory &amp; heart failure </span></li><li class="c8 c9"><span class="c6">7% (n=5) unknown causes </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="2"><li class="c0"><span class="c6">Mortality rate appears to correlate closely with age and availability of medical resources</span></li></ol><p class="c9 c25"><span class="c6"></span></p><ol class="c14 lst-kix_seg2qxi99oen-0" start="2"><li class="c35 c15"><h2 id="h.ymvixg917k3e" style="display:inline"><span>Non-ICU Management Principles</span></h2></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Diagnostic studies: </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c0"><span class="c6">Labs </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c8 c9"><span class="c6">On admission: CBC with differential, BMP, LFTs, LDH, CRP, D-dimer, Troponin / CPK, PTT / INR, Procalcitonin</span></li><li class="c8 c9"><span class="c6">Daily: CBC with differential, BMP</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-4 start" start="1"><li class="c12 c9"><span class="c6">For stable floor patients, consider every other day</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3" start="3"><li class="c8 c9"><span class="c6">Every other day: LFTs, LDH, CRP, D-dimer, Troponin / CPK (if in ICU), Triglycerides (if on propofol) </span></li><li class="c8 c9"><span class="c6">If clinical worsening: LFTs, LDH, CRP, D-dimer, Troponin, CPK, PTT / INR, Procalcitonin, Ferritin, Fibrinogen</span></li><li class="c8 c9"><span class="c6">Expert opinion does not recommend routine pro-BNP. </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="2"><li class="c0"><span class="c6">Chest imaging: Portable CXR is sufficient in most cases, and the utility of daily CXR should be evaluated on a case-by-case basis.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c1 c8"><span class="c6">Chest imaging variable; bilateral patchy opacities most common</span></li><li class="c1 c8"><span class="c6">Chest CT often will not change treatment and should only be obtained only if necessary due to risks and time associated with transport and decontamination of equipment. </span></li><li class="c1 c8"><span class="c6">Point of Care Ultrasound (POCUS) of the lungs can be used in lieu of Chest Xray by experienced providers </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="3"><li class="c0"><span class="c6">Baseline EKG </span></li><li class="c0"><span class="c6">Obtain additional studies only if necessary</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c8 c9"><span class="c6">No routine TTEs (for cardiac studies, see &nbsp;&ldquo;Cardiac Complications of COVID&rdquo; chapter).</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="2"><li class="c13 c9"><span class="c20 c11">Medical management:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c0"><span class="c6">Management is supportive</span></li><li class="c0"><span class="c6">Fluid management should be conservative due to risk of hypoxia/CHF</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c8 c9"><span class="c6">Do not use maintenance fluids</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="3"><li class="c0"><span class="c6">Antiviral and immune-modulating therapies are investigational (see &ldquo;COVID Therapies and Clinical Trials&rdquo;)</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="3"><li class="c13 c9"><span class="c20 c11">Early Advance Care Planning:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c0"><span class="c6">In conscious patients, review or sign Health Care Proxy form </span></li><li class="c0"><span class="c6">Discuss and document goals of care on admission</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c8 c9"><span class="c6">Educate patient and family on disease course </span></li><li class="c1 c8"><span class="c6">Focus on desired quality of life and tolerance for ICU measures</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-4 start" start="1"><li class="c1 c12"><span>Avoid implying availability of ICU measures if unknown (refer to local ethics guidance)</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="4"><li class="c13 c9"><span class="c11">Avoid increasing risk of transmission: </span><span class="c6">Generally avoid transport if possible.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c0"><span class="c6">Non-Invasive Positive Pressure Ventilation (NIPPV: BiPAP, CPAP), High Flow Nasal Cannula (HFNC), Humidified Venturi Face Masks, Nebulizers increase aerosolization. </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c8 c9"><span class="c6">Any aerosol-generating intervention must be performed under Strict (Airborne) Isolation Precautions </span></li><li class="c8 c9"><span>In current policy, patients with severe OSA may continue nocturnal CPAP / BiPAP</span><span>&nbsp;but </span><span class="c54">must use a BWH</span><span>&nbsp;NIPPV </span><span class="c54">mask</span><span>&nbsp;and </span><span class="c54">machine</span><span class="c6">, not their home mask or nasal pillows which have elevated aerosol risk. BWH machines have dual limb (with HEPA filter); in contrast, home machine have a single limb so have an anti-asphyxiation (pop-off) valve that increases aerosol risk. </span></li><li class="c8 c9"><span>Use m</span><span class="c6">etered dose inhalers instead of nebulizers.</span></li><li class="c8 c9"><span class="c6">If patient already on BiPAP / CPAP / HFNC becomes COVID-suspected, transition to non-rebreather followed by intubation.</span></li><li class="c8 c9"><span class="c6">NIPPV* is not used for ARDS; early intubation is preferred. </span></li></ol><p class="c9 c68 c71"><span>*Can be considered on case-by-case basis for highly reversible indications (</span><span class="c4">e.g.</span><span>, </span><span class="c6">flash pulmonary edema with rapid resolution). </span></p><ol class="c14 lst-kix_seg2qxi99oen-3" start="6"><li class="c8 c9"><span class="c6">Similar to many U.S. medical centers, our current default is to avoid HFNC in DNI patients and to use NRB, although exceptions can be considered on a case-by-case basis. </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-0" start="3"><li class="c35 c15"><h2 id="h.tsr53lmedjah" style="display:inline"><span class="c43 c22">Triage to ICU</span></h2></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c1 c13"><span class="c11">Consult the ICU triage team EARLY for:</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c1 c21"><span class="c6">Provider concern</span></li><li class="c1 c21"><span>Respiratory distress</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c1 c8"><span class="c6">Need O2 &gt; 6 LPM to maintain SpO2 &gt; 92 or PaO2 &gt; 65.</span></li><li class="c1 c8"><span class="c6">Rapid escalation of oxygen requirement.</span></li><li class="c1 c8"><span class="c6">Significant work of breathing.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="3"><li class="c1 c21"><span>Hemodynamic instability after initial </span><span>conservative</span><span class="c6">&nbsp;fluid resuscitation </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c1 c8"><span class="c6">SBP &lt; 90, Mean arterial pressure &lt; 65, or Heart rate &gt; 120.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="4"><li class="c1 c21"><span class="c6">Acidosis</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c1 c8"><span class="c6">ABG with pH &lt; 7.3 or PCO2 &gt; 50 or above patient&rsquo;s baseline.</span></li><li class="c1 c8"><span class="c6">Lactate &gt; 2.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2" start="5"><li class="c1 c21"><span class="c6">Need for intensive nursing care or frequent laboratory draws requiring arterial line.</span></li><li class="c1 c21"><span class="c6">Severe comorbid illness / high risk for deterioration.</span></li></ol><p class="c1 c25 c78"><span class="c6"></span></p><ol class="c14 lst-kix_seg2qxi99oen-0" start="4"><li class="c35 c15"><h2 id="h.32yrxx2cn5j" style="display:inline"><span class="c43 c22">Transfer Process </span></h2></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Additional details in Strict Isolation Procedures Manual.</span></li><li class="c1 c13"><span class="c11">Floor / ED to ICU:</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c1 c21"><span class="c6">ICU RN brings ICU bed to the floor for transfer (to avoid bed transfer in COVID precautions room and subsequent bed cleaning).</span></li><li class="c1 c21"><span class="c6">Patient wears surgical mask, with an extra clean gown and sheet on top. &nbsp; </span></li><li class="c1 c21"><span class="c6">Providers wear standard PPE during transport.</span></li><li class="c1 c21"><span class="c6">Security facilitates the shortest and fastest transfer route, walks 6 ft away from patient and providers, not required to wear PPE</span></li><li class="c1 c21"><span>Necessary tests (</span><span class="c4">e.g.</span><span class="c6">&nbsp;CT), should be obtained during transfer if possible.</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="3"><li class="c1 c13"><span class="c20 c11">ICU to floor: </span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c1 c21"><span class="c6">RN wears standard PPE</span></li><li class="c1 c21"><span class="c6">Patient travels in wheelchair or stretcher</span></li><li class="c1 c21"><span class="c6">Security facilitates the shortest and fastest transfer route, walks 6 ft away from patient and providers, not required to wear PPE</span></li></ol><ol class="c14 lst-kix_seg2qxi99oen-1" start="4"><li class="c1 c13"><span class="c11">Floor to discharge: s</span><span class="c11">ee separate documentation of discharge criteria/ planning</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_5f9t9fms2d21-2 start" start="1"><li class="c1 c21"><span class="c6">RN wears standard PPE</span></li><li class="c1 c21"><span class="c6">Patient travels in wheelchair </span></li><li class="c1 c21"><span class="c6">Security facilitates the shortest and fastest transfer route, walks 6 ft away from patient and providers, not required to wear PPE</span></li><li class="c1 c21"><span class="c6">Patient is escorted directly into vehicle; contact care management if patient does not have access to a personal vehicle</span></li></ol><h1 class="c61" id="h.hu2czim2nti8"><span class="c49 c22">Chapter 2: Respiratory Support for COVID-19 Patients</span></h1><ol class="c14 lst-kix_uf4umlhhckq2-0 start" start="1"><li class="c19 c15"><h2 id="h.5z5wj4l0ghah" style="display:inline"><span class="c43 c22">Respiratory Failure and ARDS </span></h2></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Pathophysiology: </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c0"><span>Histology shows </span><span class="c16">bilateral diffuse alveolar damage with cellular fibromyxoid exudates, desquamation of pneumocytes, pulmonary edema, and hyaline membrane formation (Xu et al., </span><span class="c2">Lancet Respir Med</span><span class="c16">, </span><span class="c16">2020)</span></li><li class="c0"><span>Some evidence of direct viral injury to lung tissue, rather than purely hyperinflammatory process</span><span class="c16">&nbsp;(Xu et al., </span><span class="c2">Lancet Respir Med,</span><span class="c16">&nbsp;2020)</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-1" start="2"><li class="c13 c9"><span class="c20 c11">Time course:</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c0"><span class="c6">Anecdotal reports that progression of hypoxemic respiratory failure occurs rapidly (within ~12-24 hours)</span></li><li class="c0"><span class="c6">From onset of symptoms, median time to: </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c8 c9"><span>D</span><span>evelopment of ARDS:</span><span>&nbsp;</span><span class="c16">8-12 days (Wang et al., </span><span class="c2">JAMA</span><span class="c16">, 2020; Zhou et al., </span><span class="c2">Lancet</span><span class="c16">, 2020; Huang et al., </span><span class="c2">Lancet</span><span class="c6 c16">, 2020)</span></li><li class="c8 c9"><span>M</span><span>echanical ventilation:</span><span>&nbsp;10.5-14.5 days (</span><span class="c16">Huang et al., </span><span class="c2">Lancet</span><span class="c16">, 2020; Zhou et al., </span><span class="c2">Lancet</span><span class="c6 c16">, 2020)</span></li></ol><p class="c9 c25 c71"><span class="c6 c16"></span></p><ol class="c14 lst-kix_uf4umlhhckq2-0" start="2"><li class="c19 c15"><h2 id="h.z178d8l3t5u1" style="display:inline"><span class="c43 c22">Management of Hypoxemia</span></h2></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Supplemental Oxygen:</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c1 c21"><span>Humidified n</span><span class="c6">asal cannula (NC) 1 to 6 LPM for target SpO2 92-96%</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-1" start="2"><li class="c13 c9"><span class="c20 c11">Escalation: </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c0"><span>If a patient requires &gt; 6 LPM NC, initiate </span><span>dry</span><span class="c6">&nbsp;Venturi mask (non-humidified to reduce aerosolization risk) </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c8 c9"><span class="c6">Start Venturi mask at 9 LPM and FiO2 28%</span></li><li class="c8 c9"><span class="c6">Up-titrate FiO2 to goal SpO2 of 92-96% (not exceeding FiO2 35%)</span></li><li class="c8 c9"><span class="c6">If FiO2 &gt; 35% then increase flow to 12 LPM</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2" start="2"><li class="c0"><span class="c6">Notify ICU triage pager</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-1" start="3"><li class="c1 c13"><span class="c11">Avoid </span><span class="c11">high-flow nasal cannula (HFNC) </span><span class="c11">and non-invasive positive pressure ventilation (NIPPV; </span><span class="c11">i.e.</span><span class="c20 c11">&nbsp;CPAP/BiPAP) for ARDS.</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c1 c21"><span>Patients on nocturnal NIPPV at home should continue their nocturnal NIPPV. However, patient must use BWH NIPPV </span><span class="c54">mask</span><span>&nbsp;and </span><span class="c54">machine</span><span class="c6">&nbsp;(not home mask/nasal pillow or machine due to increased aerosol risk with home pillows/mask/machine) under strict airborne precautions. &nbsp; </span></li><li class="c1 c21"><span class="c6">If a patient already on HFNC or NIPPV becomes a COVID-19 PUI, transition to non-rebreather if safe</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c1 c8"><span class="c6">Ideally, the patient should be off an aerosol generating device like &nbsp;HFNC or NIPPV for 45 minutes prior to intubation, but it is definitely not a requirement. &nbsp;</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2" start="3"><li class="c1 c21"><span>If a patient is </span><span>DNR/DNI</span><span>&nbsp;or </span><span>otherwise</span><span class="c6">&nbsp;is not eligible for intubation: </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c1 c8"><span class="c20 c11">Current policy is to default to avoiding HFNC or NIPPV in DNI / DNR patients. However, neither HFNC nor NIPPV is prohibited and case-by-case exceptions could apply. </span></li><li class="c1 c8"><span>T</span><span class="c6">his is an evolving area without definitive evidence or uniform policy that underwent multi-disciplinary discussion. </span></li><li class="c1 c8"><span class="c6">Considerations include: </span></li></ol><ul class="c14 lst-kix_cmax3c5l3b9l-0 start"><li class="c1 c12"><span class="c6">Safety of staff (particularly Resp. Therapy and nursing);</span></li><li class="c1 c12"><span>Paucity of data on the increased aerosol risk;</span><span>&nbsp;</span></li><li class="c1 c12"><span>WHO interim guidelines (published 2020 Mar 13) on COVID-19 are more liberal about the usage of HFNC and NIPPV, stating that systems with &ldquo;good interface fitting [i.e., good seal, no air leak]</span><span class="c6 c16">&nbsp;do not create widespread dispersion of exhaled air and therefore should be associated with low risk of airborne transmission.&rdquo; </span></li><li class="c1 c12"><span class="c6">Difficulty in assessing how many patients that fail Non-Rebreathing mask would survive if given HFNC. </span></li><li class="c1 c12"><span class="c6">Pro-active treatment of air hunger through other means.</span></li><li class="c1 c12"><span class="c6">HFNC has been utilized in lieu of ventilation of both full code and DNI / DNR patients in the setting of limited resources. </span></li></ul><p class="c1 c68 c71"><span class="c29 c2 c22">If HFNC or NIPPV used</span></p><ol class="c14 lst-kix_uf4umlhhckq2-4 start" start="1"><li class="c1 c12"><span>For HFNC, have patient wear a surgical mask if possible. and </span><span class="c6">try to limit flow rate to &lt; 30 L/min</span></li><li class="c1 c12"><span class="c6">For BiPAP, use an in-line viral filter.</span></li><li class="c1 c12"><span class="c6">Ensure masks/devices fit well and there is no air leak, as leaks propel potentially infected air significant distances (see below)</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2" start="4"><li class="c1 c21"><span class="c4">Rationale</span><span class="c6">: General consensus suggests that HFNC and NIPPV increase the risk of viral transmission. Given the rapid progression of disease, we do not expect many patients can be salvaged/avoid intubation using HFNC/NIPPV, but this is unknown</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c1 c8"><span>A systematic review on SARS found that NIPPV was associated with increased risk of viral transmission to healthcare workers (n=2 studies), but HFNC was not (n=1) (Tran et al., </span><span class="c4">PLoS One</span><span>,</span><span class="c6">&nbsp;2012)</span></li><li class="c1 c8"><span>Other studies with very limited power exist, such as a post-hoc analysis that found no secondary infections in medical staff from patients with influenza H1N1 treated with HFNC but was limited to only n=20 (Rello </span><span class="c4">et al.</span><span>, </span><span class="c4">J Crit Care. </span><span>2012</span><sup><a href="#cmnt2" id="cmnt_ref2">[b]</a></sup><span>); </span><span class="c4">&nbsp;</span><span>&nbsp;</span></li><li class="c1 c8"><span class="c16">Exhaled air distances are minimally increased with CPAP pressures up to 20 cm H2O and HFNC up to 60 LPM; device/interface leaks cause significant lateral air travel (Hui et al., </span><span class="c2">Eur Respir Ji,</span><span class="c16">&nbsp;2019)</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-1" start="4"><li class="c13 c9"><span class="c20 c11">Early intubation: </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c0"><span>If FiO2 requirements are rising rapidly, we recommend </span><span class="c6">early consultation with anesthesia for possible intubation</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c8 c9"><span>Case reports from China suggest high failure rates for non-invasive ventilation, including high-flow nasal oxygen (Zuo et al., </span><span class="c4">Chin Med Sci J</span><span>, 2020)</span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2" start="2"><li class="c0"><span class="c6">Once FiO2=60% and SpO2 &lt; 92%, call for intubation if patient is a candidate for mechanical ventilation </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c1 c8"><span>There is a </span><span>COVID Airway Code Team</span><span class="c6">&nbsp;with specific protocols for avoiding aerosolization.</span></li><li class="c1 c8"><span>Many centers suggest Rapid Sequence Intubation when fully paralyzed, without ambu-bag (which generates aerosols) and highly experienced operators (</span><span class="c4">e.g.</span><span class="c6">, anesthesia attending). </span></li></ol><ol class="c14 lst-kix_uf4umlhhckq2-2" start="3"><li class="c0"><span>Other indications for intubation (tachypnea, work of breathing) apply</span><span class="c6">&nbsp;</span></li></ol><p class="c9 c68 c78"><span>&nbsp;</span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0 start" start="3"><li class="c19 c15"><h2 id="h.welz4k559gib" style="display:inline"><span class="c43 c22">Initial Mechanical Ventilation</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Intubations outside of ICU:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>S</span><span class="c6">hould be attended by the Resource RT, who can facilitate early and appropriate ventilator settings with non-intensivists</span></li><li class="c0"><span class="c6">Use &ldquo;Mechanical Ventilation with Sedation&rdquo; orderset </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c20 c11">Initiate Volume Control (AC/VC) mode </span></li><li class="c13 c9"><span class="c11">Initial tidal volume (Vt):</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Vt = 6 ml/kg (based on ideal body weight [IBW] from ARDSnet table -see table)</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">IBW men (kg)= 50 + 2.3 (height in inches &ndash; 60)</span></li><li class="c8 c9"><span class="c6">IBW women (kg)= 45.5 + 2.3 (height in inches &ndash; 60)</span></li></ol><p class="c9 c45"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 487.00px; height: 346.50px;"><img alt="" src="images/image4.png" style="width: 487.00px; height: 353.00px; margin-left: 0.00px; margin-top: -6.50px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c13 c9"><span class="c20 c11">Initial respiratory rate 16-24, higher if acidosis present</span></li><li class="c13 c9"><span class="c20 c11">Initial PEEP based on BMI:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">BMI &lt; 35: PEEP 10</span></li><li class="c0"><span class="c6">BMI 35 to 50: PEEP 12</span></li><li class="c0"><span class="c6">BMI &gt; 50: PEEP 15</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="6"><li class="c13 c9"><span class="c20 c11">Initial FiO2: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>100% immediately post-intubation, then rapidly wean to SpO2 92-96% (</span><span>Barrot et al., </span><span class="c4">N Engl J Med</span><span>,</span><span class="c4">&nbsp;</span><span>2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="7"><li class="c13 c9"><span class="c11">Obtain STAT portable CXR to confirm endotracheal tube location:</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Order and page radiology at time of intubation </span></li><li class="c0"><span class="c6">Prioritize CXR and vent titration over procedures (such as central venous catheter placement) if possible. </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="8"><li class="c13 c9"><span class="c11">Within 30 minutes of intubation, obtain an ABG</span><span class="c20 c11">&nbsp;(preferred) or a VBG and adjust ventilation and oxygenation as needed</span></li></ol><p class="c9 c45 c30"><span class="c6"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="4"><li class="c19 c15"><h2 id="h.mcb6j64zp5u6" style="display:inline"><span class="c43 c22">PEEP and Mechanics</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c20 c11">If patients supported by Hamilton G5 Ventilator (most common), perform the following within 10 minutes of intubation:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>Determine best PEEP following intubation </span><span>while paralyzed</span><span class="c6">&nbsp;using Pressure-Volume (PV) tool</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span>This is a departure from use of Best PEEP Trials.</span><span class="c6">&nbsp;PV tool is the preferred method due to widespread familiarity with RT staff, institutional experience, and minimizing provider exposure</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c11">If patients not supported by Hamilton G5 Ventilator, perform the following within 10 minutes of intubation</span><span class="c6">:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>Initiate PEEP at BMI settings above and titrate PEEP according to ARDSnet Lower PEEP table. Currently, after discussion, both MGH and BWH recommend the lower PEEP table as a back-up if PEEP cannot be individualized (</span><span class="c4">e.g.</span><span class="c6">, experienced respiratory therapists or intensivists unavailable). The lower (rather than higher) PEEP table was selected primarily to avoid doing initial harm patients with poor lung compliance.</span></li></ol><p class="c52"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 530.00px; height: 135.00px;"><img alt="" src="images/image3.png" style="width: 530.00px; height: 135.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c13 c9"><span class="c11">After best PEEP determined, obtain</span><span>&nbsp;</span><span class="c11">respiratory mechanics</span><span class="c6">:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>Plateau pressure (with goal &lt; 30, management below)</span></li><li class="c0"><span class="c6">Static compliance</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c13 c9"><span class="c20 c11">Obtain arterial blood gas: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>G</span><span>oal pH 7.25 to 7.45 </span></li><li class="c0"><span class="c6">Calculate P/F ratio from initial post-intubation ABG</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="5"><li class="c13 c9"><span class="c20 c11">Routine esophageal balloon use is not recommended</span></li></ol><p class="c9 c25"><span class="c6"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="5"><li class="c15 c19"><h2 id="h.nhqe52dtgmrn" style="display:inline"><span class="c43 c22">Targeting Sedation for Ventilator Synchrony</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c11">Initially target </span><span class="c11">RASS -2 to -3 (see table)</span><span class="c11">:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Maintain deep sedation immediately post-intubation while paralyzed (assume 60 minutes for Rocuronium, 10 minutes for succinylcholine)</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c54">Preferred initial sedation regimen</span><span>:</span><span class="c32 c16 c22 c88">&nbsp;</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c12 c9"><span>Fentanyl/Hydromorphone (boluses +/- infusion) + Propofol: target analgosedation and optimize analgesia first while decreasing sedative requirements</span></li><li class="c12 c9"><span class="c6">Measure triglycerides every third day on propofol or earlier if other reasons for hypertriglyceridemia</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3" start="2"><li class="c8 c9"><span class="c54">Adjunct agent:</span><span class="c6">&nbsp;Midazolam</span></li><li class="c8 c9"><span class="c54 c63 c22 c66 c67">Use dexmedetomidine only when nearing extubation</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c11">Target ventilator synchrony: </span><span>Ventilator-induced lung injury (VALI) is common in patients who are not synchronous with the ventilator and can cause significant lasting damage</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Once at target RASS after paralytics have worn off, assess patient synchrony with the ventilator (e.g. signs of breath-stacking, double triggering, other ventilator alarms)</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span>Titrate sedatives/analgesics to ventilator synchrony allowing for deeper RASS</span></li><li class="c8 c9"><span>If patient remains dyssynchronous despite deep sedation (RASS -5), initiate continuous paralytics </span><span>(ensure BIS 40 to 60 prior to initiating and during paralysis)</span></li></ol><p class="c52"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 301.00px; height: 323.38px;"><img alt="" src="images/image5.png" style="width: 301.00px; height: 323.38px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c9 c45 c30"><span class="c6"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="6"><li class="c19 c15"><h2 id="h.f3ug6fi0aj01" style="display:inline"><span class="c43 c22">General Management of Ventilated ARDS Patients</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Consider whether patient requires daily CXR: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">CXR clearly indicated for: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Clinical change </span></li><li class="c8 c9"><span class="c6">Concern for displaced ET tube:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c12 c9"><span class="c6">Sudden increase in peak inspiratory pressure or resistance</span></li><li class="c12 c9"><span class="c6">Decreased, unilateral breath sounds (usually on the right)</span></li><li class="c12 c9"><span class="c6">RN or RT concern for change in depth of ET tube at teeth </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c20 c11">COVID-19 ICU Bundle:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>Ventilated patients should all have a daily ICU &ldquo;Bundle&rdquo; of best practices. See Addendum 1 for a proposed </span><span>&ldquo;</span><span class="c6">COVID-19 ICU Bundle&rdquo;</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c13 c9"><span class="c20 c11">Ventilator consults:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">If you need additional assistance managing ventilator choices, you can request a pulmonary phone/in-person consult (pager 11957) </span></li></ol><p class="c9 c25"><span class="c6"></span></p><p class="c9 c25"><span class="c6"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="7"><li class="c19 c15"><h2 id="h.qrh9t96165ug" style="display:inline"><span class="c43 c22">Managing Ventilation</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c11">Follow ARDSnet ventilation where possible:</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Tidal volumes should be 4-6 cc/kg using IBW (see table above) to minimize volumes (and thus ventilator injury) </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c20 c11">Minute ventilation (respiratory rate x tidal volume) typically drives pH and PC02:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Titrate ventilatory parameters to pH, not PCO2 </span></li><li class="c0"><span class="c6">To achieve low tidal volumes, we tolerate hypercapnia (functionally no limitation unless clinical sequelae) and acidemia (pH &gt; 7.2)</span></li><li class="c0"><span class="c6">Because tidal volumes are low, the respiratory rate often has to be high to accommodate; typical RR is 20-35 breaths/minute</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c13 c9"><span class="c20 c11">pH goal is normally 7.25-7.45:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">If pH &gt; 7.45, decrease respiratory rate</span></li><li class="c0"><span class="c6">If pH 7.15-7.30, then increase respiratory rate until pH &gt; 7.30, or PaCO2 &lt; 25 (maximum RR= 35 breaths/minute)</span></li><li class="c0"><span class="c6">If pH &lt; 7.15, then increase respiratory rate to 35 breaths/minute</span></li><li class="c0"><span class="c6">If pH still &lt; 7.15, then perform the following:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Tidal volume may be increased by 1 mL/kg until pH &gt; 7.15 (until plateau pressure reaches 30 cm H2O or tidal volume reaches 8 cc/kg)</span></li><li class="c8 c9"><span class="c6">Deep sedation advancing to RASS -5 if needed</span></li><li class="c8 c9"><span class="c6">If no improvement, initiate continuous paralysis</span></li><li class="c8 c9"><span class="c6">If still no improvement, initiate prone ventilation (may improve V/Q matching and better ventilation)</span></li></ol><p class="c9 c25 c71"><span class="c6"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="8"><li class="c19 c15"><h2 id="h.4wvmhdtgo9di" style="display:inline"><span class="c43 c22">Managing Oxygenation</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Minimizing oxygen toxicity: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">PEEP and Fi02 drive oxygenation </span></li><li class="c0"><span>The goal is to deliver a partial pressure of oxygen to perfuse tissues (PaO2 &gt; 75, Sp02 &gt;92%) while limiting lung injury from high distending pressures (Ppl &lt; 30) and hyperoxia (</span><span>FiO2 &lt; 95, SpO2 &lt; 96%)</span><span class="c6">.</span></li><li class="c0"><span>Lower limit goals for PaO2 / SpO2 are widely debated (and discuss in </span><span class="c4">Rationale</span><span>);</span><span class="c6">&nbsp;PaO2 &gt; 65 and SpO2 &gt;89% is also commonly used at BWH. </span></li></ol><p class="c9 c25 c78"><span class="c6"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c20 c11">PEEP management:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Initial PEEP should be set as explained in section 4 above. </span></li><li class="c0"><span class="c6">If patient is hypoxic on Vt = 6 ml/kg and ideal PEEP from PV tool (or PEEP determination from ARDSnet table for non-Hamilton G5 ventilators), perform the following:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span>Deep sedation,</span><span class="c11">&nbsp;</span><span class="c6">advancing to RASS -5 if needed; if no improvement then:</span></li><li class="c8 c9"><span>Initiate continuous paralysis</span><span class="c11">&nbsp;</span><span class="c6">(cisatracurium bolus 0.2mg/kg followed by infusion at 0-5 mcg/kg/min titrated to patient-ventilator synchrony); if no improvement then:</span></li><li class="c8 c9"><span>Initiate prone</span><span class="c11">&nbsp;</span><span>ventilation (see below); high consideration for use </span><span>early</span><span class="c6">&nbsp;in severe ARDS (&lt;36 hours from ARDS onset, start discussion of proning when P:F &lt; 150, prone within 12 hours of FiO2 &gt; 75%)</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c13 c9"><span class="c20 c11">Checking plateau pressure:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Check plateau pressure with every change in tidal volume, PEEP, or clinical deterioration (worsening oxygenation) but not as part of routine practice</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">If plateau pressure is &gt; 30 cm H20, then decrease tidal volume by 1 ml/kg (minimum 4 mL/kg)</span></li><li class="c8 c9"><span class="c6">If plateau pressure is &lt; 25 H20 and tidal volume &lt; 6 mL/kg, then increase tidal volume by 1 mL/kg until plateau pressure is &gt; 25 cm H2O or tidal volume = 6 mL/kg</span></li><li class="c8 c9"><span class="c6">If plateau pressure is &lt; 30 cm H20 and patient is breath stacking or dys-synchronous, then increase tidal volume in mL/kg increments to 7 mL/kg or 8 mL/kg so long as plateau pressure is &lt; 30 cm H20</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c13 c9"><span class="c20 c11">Adjusting Fi02:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Adjust Fi02 after optimizing PEEP &nbsp;</span></li><li class="c0"><span class="c6">Goal FiO2 &lt; 75%; if FiO2 &gt; 75%; patient requires ventilator optimization. If you need assistance, pulmonary consultation is available (pager 11957)</span></li><li class="c0"><span class="c6">It is reasonable to put a desaturating patient temporarily on 100% Fi02, but remember to wean oxygen as rapidly as possible</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="5"><li class="c13 c9"><span class="c4 c11">Rationale</span><span class="c6">: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c4">Avoiding hyperoxia: </span><span>Extensive mammalian animal data demonstrates that hyperoxic injury occurs at an FiO2 &ge; 75% (at sea level) with the rate of injury increasing as FiO2 exceeds that threshold. In multiple mammalian models, an FiO2 of 100% for 48 to 72 hours is associated with nearly 100% mortality rate. In lung injury models, the time to death is markedly attenuated. In an effort to reduce the potential for hyperoxic injury, the threshold of FiO2 &ge; 75% triggers progressive intervention throughout this protocol: increased sedation, paralysis, proning and ECMO consultation. For a review of hyperoxic acute lung injury, see Kallet and Matthay, </span><span class="c4">Respir Care</span><span>, 2013.</span><span class="c6">&nbsp;</span></li><li class="c0"><span class="c4">Setting the lower oxygen limits: </span><span>There is debate on the proper PaO2 goal, and our rationale relies on evidence for lack of benefit from conservative PaO2 goals in clinical trials (</span><span class="c4">i.e.</span><span>, PaO2 &gt; 55) and past association between lower PaO2 and cognitive impairment, although the evidence is certainly not definitive (mean PaO2 71 [IQR 67-80] for cognitively impaired survivors versus mean PaO2 86 [IQR, 70-98] in non-impaired survivors of ARDS (Mikkelsen </span><span class="c4">et al</span><span>., </span><span class="c4">Am J Respir Crit Care Med</span><span>. </span><span>2012</span><sup><a href="#cmnt3" id="cmnt_ref3">[c]</a></sup><span>). In the LOCO</span><span class="c28">2</span><span>&nbsp;multi-center, randomized clinical trial, patients with ARDS were randomized to their PaO2 55-70, SpO2 88-92%; or PaO2 90-105, SpO2 &gt;95%); the trial was stopped after enrollment of 205 patients due to futility and safety concerns (44% mortality in conservative oxygen group versus 30%; (Barrot </span><span class="c4">et al.</span><span>, </span><span class="c4">New Eng J Med</span><span>, </span><span>2020</span><sup><a href="#cmnt4" id="cmnt_ref4">[d]</a></sup><span>).</span></li></ol><p class="c9 c25"><span class="c62 c63 c22 c84"></span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="9"><li class="c19 c15"><h2 id="h.wgrateeto9z4" style="display:inline"><span class="c43 c22">Proning and Pulmonary Vasodilators</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Prone early:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>We recommend </span><span>early</span><span>&nbsp;proning in severe ARDS without vasodilator trial (a depature from our typical practice for ARDS not due to COVID-19): &lt;36 hours from ARDS onset, start discussion of prone when P:F &lt; 150, prone within 12 hours of FiO2 &gt; 75% (</span><span>Gu&eacute;rin, </span><span class="c4">N Engl J Med</span><span>, </span><span>2013)</span><span>.</span><span class="c97">&nbsp;</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c20 c11">Eligibility criteria for proning:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Eligibility may vary depending on resources and staffing. Currently we recommend: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Age &lt; 75</span></li><li class="c8 c9"><span>No high grade shock (either single agent norepinephrine </span><span>20 mcg/min or norepinephrine &lt; 15 mcg/min</span><span class="c6">&nbsp;and vasopressin)</span></li><li class="c8 c9"><span class="c6">Not on CRRT or at risk of impending renal failure (due to difficulties in maintaining dialysis access while proned)</span></li><li class="c8 c9"><span>The o</span><span class="c6">nly absolute contraindications to proned ventilation are spinal cord injury and open chest; BMI and patient size are not contraindications</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c13 c9"><span class="c20 c11">To initiate prone ventilation outside of MICU and 11C:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">Discuss with the PCCM Consultation team assigned to that unit</span></li><li class="c0"><span class="c6">ICU charge nurse to contact MICU charge nurse for nursing assistance</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c13 c9"><span class="c20 c11">Managing a proned patient: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>Proning protocol is available at the MICU sharepoint</span></li><li class="c0"><span class="c6">Maintain deep sedation with target RASS -4 to -5 while proned</span></li><li class="c0"><span class="c6">1 hour post-initiation of prone ventilation:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Adjust oxygen parameters: re-assess lung mechanics (plateau pressure and P-V tool to determine optimal PEEP) and adjust PEEP and titrate FiO2 as in &ldquo;Managing Ventilation&rdquo; (section 7)</span></li><li class="c8 c9"><span class="c6">Assess tidal volume and adjust ventilation parameters as in section 6</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c12 c9"><span>If Vt &lt; 6 ml/kg, may increase to maximum limit o</span><span>f 8 ml/kg while Ppl &lt; 30</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2" start="4"><li class="c0"><span class="c6">If patient demonstrates improvement on proning then recommend:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Discontinuing of continuous neuromuscular blockade and re-assess ventilator dyssynchrony; re-institute if dyssynchronous</span></li><li class="c8 c9"><span class="c6">Return to supine ventilation when following criteria are met:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c12 c9"><span class="c6">Ppl &lt; 25</span></li><li class="c12 c9"><span class="c6">FiO2 &lt; 50</span></li><li class="c12 c9"><span class="c6">pH &gt; 7.3</span></li><li class="c12 c9"><span class="c6">P:F &gt; 200</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2" start="5"><li class="c0"><span class="c6">Repositioning and skin care while proned: </span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Currently we recommend continuing proning as per the MICU proning protocol. This may change in the future depending on availability of PPE and staffing.</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="5"><li class="c13 c9"><span class="c20 c11">Escalation if still hypoxic:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span class="c6">If hypoxia (PaO2 &lt; 55 with FiO2 &gt; 75) persists after proning; then initiate continuous inhaled epoprostenol (see &ldquo;COVID-19 Therapies and Clinical Trials&rdquo; section)</span></li><li class="c0"><span class="c6">If FiO2 &gt; 75% despite above, recommend consultation with ECMO team (see below)</span></li></ol><p class="c9 c45"><span class="c6">&nbsp;</span></p><ol class="c14 lst-kix_qgxhqyjzp80f-0" start="10"><li class="c19 c15"><h2 id="h.24j39tc7pjup" style="display:inline"><span class="c43 c22">ECMO consultation</span></h2></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Refractory Hypoxemia:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>If despite PEEP optimization, paralysis, prone ventilation, optimizing volume status, pulmonary vasodilators (when available) the patient meets the following criteria, then consider ECMO consult (</span><span>pager 35010</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c12 c9"><span class="c6">Ppl &gt; 30</span></li><li class="c12 c9"><span class="c6">FiO2 &gt; 75%</span></li><li class="c12 c9"><span class="c6">P:F &lt; 80</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c13 c9"><span class="c20 c11">Candidacy:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c0"><span>Final ECMO guidelines for COVID-19 patients remain </span><span>under development</span><sup><a href="#cmnt5" id="cmnt_ref5">[e]</a></sup><span>. Examples of common considerations include:</span></li></ol><ol class="c14 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c8 c9"><span class="c6">Patient age &lt; 65</span></li><li class="c8 c9"><span class="c6">Mechanical ventilation duration &lt; 7 days</span></li><li class="c8 c9"><span class="c6">BMI &lt; 35 and patient body weight &lt; 150 kg</span></li><li class="c8 c9"><span class="c6">CrCl &gt; 30</span></li><li class="c8 c9"><span class="c6">No multiorgan failure or high grade shock (can be on single pressor; norepinephrine &lt; 15 mcg/min)</span></li><li class="c8 c9"><span class="c6">No active solid or liquid malignancy</span></li><li class="c8 c9"><span class="c6">Absolute neutrophil count &gt; 500</span></li><li class="c8 c9"><span class="c6">Platelets &gt; 50,000</span></li><li class="c8 c9"><span class="c6">Able to tolerate anticoagulation on initiation (no active hemorrhage)</span></li><li class="c8 c9"><span class="c6">No evidence of irreversible neurological injury</span></li><li class="c8 c9"><span class="c6">Able to perform ADLs at baseline prior to illness</span></li></ol><p class="c9 c25 c78"><span class="c6"></span></p><h1 class="c61" id="h.kx686gedgtzg"><span class="c49 c22">Chapter 3: COVID-19 Therapies and Clinical Trials</span></h1><p class="c9 c68"><span class="c62">Note: </span><span class="c4">The anti-viral and anti-inflammatory section below written by our critical care group is meant to provide a summary of the literature. This section does not represent the views or recommendations of the BWH Div. of Infectious Disease. The separate BWH Infectious Disease guidelines and ID consultation service take precedence over the information from the literature below. </span></p><ol class="c14 lst-kix_73zznxkq85l2-0 start" start="1"><li class="c35 c15"><h2 id="h.szvkuh7mguyn" style="display:inline"><span class="c43 c22">Clinical trials </span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Consult Infectious Disease for:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span>P</span><span class="c6">atients with +COVID-19 PCR; and clinical history and any chest imaging suspicious for COVID-19 </span></li><li class="c1 c10"><span class="c6">Re-consult if the patient develops ARDS (mechanically ventilated with P/F ratio &lt; 300) or shock/cytokine syndrome </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c20 c11">Current trials:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">ID teams are enrolling for clinical trials of Remdesivir and possibly other antiviral agents</span></li><li class="c1 c10"><span class="c6">ID and the PETAL network are coordinating to enroll for clinical trials of host-response modifying therapies (see &nbsp;&ldquo;Systemic Corticosteroids&rdquo; and &ldquo;Anti-IL6 agents&rdquo; subsections of this chapter)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span class="c20 c11">Monitor for drug-drug interactions:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Patients may arrive at the ICU already enrolled in a COVID19 clinical trial. &nbsp;Verify that ICU treatment regimen does not add harmful drug interactions with study agents </span></li></ol><p class="c1 c25"><span class="c6"></span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="2"><li class="c35 c15"><h2 id="h.8vhrbtln428m" style="display:inline"><span class="c43 c22">Antibiotic stewardship</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Antibiotic choice:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Antibiotics should reflect IDSA guidelines, presumed source, and MDRO risk. For a presumed pulmonary source: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Without risk factors for MRSA or Pseudomonas (i.e. living in community, no prior MDROs): </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span>Ceftriaxone +</span><span class="c4">&nbsp;</span><span class="c6">Azithromycin &nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="2"><li class="c1 c8"><span class="c6">With risk factors for MRSA or Pseudomonas (i.e. chronic hospitalization, prior MDR infections): </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span>Vancomycin </span><span>+</span><span class="c4">&nbsp;</span><span class="c6">Cefepime, and consider Ciprofloxacin if high concern for Pseudomonas</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="3"><li class="c1 c8"><span>See special dispensations for oncology patients in chapter 7</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c20 c11">Formulation:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Give oral antibiotics (Azithromycin, Levofloxacin, Ciprofloxacin) when possible to reduce volume load, unless concerns for poor oral absorption</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span class="c20 c11">Coinfection:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">If concurrent influenza give Oseltamivir</span></li><li class="c1 c10"><span class="c6">Given lymphopenia consider Pneumocystis and treat accordingly</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="4"><li class="c1 c13"><span class="c20 c11">Discontinuation:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Antibiotics should be discontinued as soon as possible (within 48h) if:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Clinical status is not deteriorating, cultures do not reveal pathogens at 48h, and procalcitonin and WBC are relatively stable from 0 to 48h</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">Clinical judgement should prevail over any specific lab value</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="5"><li class="c1 c13"><span class="c4 c11">Rationale</span><span class="c11">: </span><span>Clinical reports indicate that rates of bacterial superinfection of COVID19 are low (10-20%), but when present increase mortality risk. Anecdotal reports suggest less MRSA superinfection than with influenza. Unnecessary antibiotics carry risks of fluid overload and drug-resistance, as well as the possibility that antibiotics may become a limited resource. (Zhou et al., </span><span class="c4">Lancet</span><span>,</span><span>&nbsp;2020; Yang et al., </span><span class="c4">Lancet</span><span>,</span><span>&nbsp;2020; Lippi and Plebani, </span><span class="c4">Clinica Chimica Acta</span><span>,</span><span class="c4">&nbsp;</span><span>2020</span><span>; WHO, </span><span class="c4">COVID-19 Guidelines</span><span>, 2020)</span></li></ol><p class="c1 c68"><span class="c20 c11">&nbsp;</span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="3"><li class="c35 c15"><h2 id="h.eudti5z0ojjo" style="display:inline"><span>M</span><span>etered-dose inhalers (MDIs)</span><span>&nbsp;vs. </span><span>nebulizers</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c11">N</span><span class="c20 c11">on-intubated patients: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">For COVID-19 Confirmed or PUI, use MDI (inhalers), not nebulizers, due to the increased aerosol risk. </span></li><li class="c1 c10"><span class="c6">Because MDI supply is limited, only prescribe when needed. &nbsp;</span></li><li class="c1 c10"><span>For non-COVID-19 Confirmed or PUI patient, use nebulizers even if on droplet precautions (</span><span class="c4">e.g.,</span><span class="c6">&nbsp;influenza) because MDI supply is limited. </span></li><li class="c1 c10"><span>After a patient is COVID-neg (and no longer on COVID precautions per infection control): After the patient&rsquo;s current MDI runs out, switch to neb. </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c11">Intubated patients</span><span class="c11">:</span><span class="c20 c11">&nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span>The ventilator circuit is a closed system so nebulizers can be used when required (</span><span class="c4">e.g., </span><span>DuoNeb standing and albuterol PRN). </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span class="c11">Rationale</span><span class="c11">:</span><span>&nbsp;Nebulization may aerosolize viral particles and contribute to disease transmission. &nbsp;COVID-19 clinical reports do not indicate wheeze as a common symptom, and not all patients require bronchodilators (Zhou et al, </span><span class="c4">Lancet</span><span>,</span><span>&nbsp;2020; Yang et al, </span><span class="c4">Lancet</span><span>,</span><span>&nbsp;2020; Guan et al, </span><span class="c4">N Engl J Med</span><span>,</span><span class="c4">&nbsp;</span><span>2020; WHO, </span><span class="c4">COVID-19 Guidelines</span><span class="c6">, 2020)</span></li></ol><p class="c1 c25"><span class="c20 c11"></span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="4"><li class="c35 c15"><h2 id="h.8pktimpr5u6o" style="display:inline"><span class="c43 c22">Airway Clearance &nbsp;</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Management principles:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Reports from Wuhan and Italy indicate that some patients develop very thick secretions causing dangerous mucus plugging. However, nebulizers and airway clearance techniques may aerosolize secretions</span></li><li class="c1 c10"><span>Airway clearance should be used only in </span><span>selected ventilated patients</span><span class="c4 c11">&nbsp;</span><span>(closed circuit)</span><span class="c4">&nbsp;</span><span>with extremely thick secretions to avoid mucus plugging that would require bronchoscopy</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c11">For t</span><span class="c20 c11">hinning secretions:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span>A</span><span>necdotal reports suggest Dornase alfa may be particularly effective in thinning secretions in COVID19</span><span>&nbsp;</span><span>patients</span><span>.</span><span>&nbsp;</span><span>However, data for Dornase alfa in non-CF patients is poor</span><span>. For now we recommend:</span><sup><a href="#cmnt6" id="cmnt_ref6">[f]</a></sup></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span>Consideration of </span><span class="c6">Dornase alfa 2.5mg nebulizer once daily </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">Can cause bronchoconstriction and mucosal bleeding </span></li><li class="c1 c12"><span class="c6">Pre-treat with albuterol 2.5mg, just prior to delivery</span></li><li class="c1 c12"><span>Avoid in setting of bloody secretions </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="2"><li class="c1 c8"><span>Alternative: Nebulized </span><span class="c6">hypertonic (3-7%) saline once daily</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">Side effects can include bronchoconstriction</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c69 c68"><span class="c6">Start with 3% to assess response and bronchoconstriction</span></li><li class="c1 c69 c68"><span>Pre-treat with albuterol 2.5mg just prior to delivery</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="3"><li class="c1 c8"><span>Avoid N-acetylcysteine due to frequent dosing requirements </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span class="c11">Airway clearance: &nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span>Continue</span><span>&nbsp;chest PT vests if patient uses at home (</span><span class="c4">e.g.</span><span>&nbsp;CF patients) with appropriate isolation precautions</span><span class="c6">. Bronchiectasis patients may be considered on a case-by-case basis </span></li><li class="c1 c10"><span>Avoid oscillating positive expiratory pressure devices (Aerobika or Acapella) and cough assist (MIE) </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-0" start="5"><li class="c35 c15"><h2 id="h.ym3ao1e1uli3" style="display:inline"><span class="c43 c22">Inhaled Pulmonary Vasodilators</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Indications for use:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Inhaled vasodilators should not be routinely used except in two circumstances</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">As a rescue strategy in already prone ventilated patients (see &ldquo;Respiratory Support for COVID-19 Patients&rdquo; section). </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span>There is no evidence of survival benefit of inhaled vasodilators in ARDS, and there are risks of viral aerosolization when connecting the device &nbsp;(</span><span>Fuller et al., </span><span class="c4">Chest</span><span>, 2015; Gebistorf et al., </span><span class="c4">Cochrane Database Syst Rev</span><span>,</span><span class="c4">&nbsp;</span><span>2016; Afshari et al, </span><span class="c4">Cochrane Database Syst Rev</span><span>, 2017</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="2"><li class="c1 c8"><span>To reduce RV afterload in hemodynamically significant RV failure in consultation with cardiology</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c20 c11">Instructions for use:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">If inhaled vasodilators are used, they should reevaluated at 4 hours &nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c54 c16">Inhaled Epoprostenol:</span><span class="c54 c67 c62 c16 c63 c22">&nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c16">S</span><span class="c6 c16">tart continuous nebulization at 0.05mcg/kg/min based on IBW &nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c69 c68"><span class="c16">If no improvement in P/F ratio in 2 hours, wean off by decreasing 0.01mcg/kg/min every </span><span class="c16">hour</span><span class="c6 c16">&nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="2"><li class="c1 c8"><span class="c54 c67 c63 c22 c66">Inhaled Nitric Oxide (iNO):</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span>Strong consideration in refractory ARDS that does not respond to inhaled epoprostenol. </span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c68 c69"><span>Limited </span><span>in vitro</span><span>&nbsp;data notes that iNO at high doses inhibits replication of SARS-CoV, but this has not been studied </span><span>in vivo</span><span>. (</span><span>Akerstrom et al., </span><span class="c4">J Virol</span><span>,</span><span class="c4">&nbsp;</span><span>2005</span><span>;</span><span>&nbsp;</span><span>Gebistorf et al., </span><span class="c4">Cochrane Database Syst Rev</span><span>,</span><span class="c4">&nbsp;</span><span>2016</span><span class="c6">)</span></li><li class="c1 c69 c68"><span>iNO may be included in future trial protocols</span><span class="c6">, such as early initiation in milder disease (non-intubated). </span></li></ol><p class="c1 c25 c51"><span class="c6"></span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="6"><li class="c35 c15"><h2 id="h.x05c129ivxrw" style="display:inline"><span>S</span><span class="c43 c22">ystemic Corticosteroids</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c11">Data on </span><span class="c11">corticosteroids for COVID-19: </span><span class="c29 c4 c11">&nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Most studies show negative effects of corticosteroids on similar viruses</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span>There is no clinical evidence of net benefit from steroids in SARS-CoV, MERS-CoV or influenza infection, and observational data show increased mortality, more secondary infections, impaired viral clearance and more adverse effects in survivors (e.g. psychosis, diabetes, avascular necrosis). (Lee et al.,</span><span class="c4">&nbsp;J Clin Virol</span><span>,</span><span class="c4">&nbsp;</span><span>2004; Stockman et al., </span><span class="c4">PLoS Med</span><span>, 2006; Arabi</span><span>&nbsp;et al., </span><span class="c4">Am J Respir Crit Care Med</span><span>, 201</span><span>8; WHO, </span><span class="c4">COVID-19 Guidelines</span><span>, 2020; Wu et al., </span><span class="c4">JAMA Int Med</span><span>,</span><span class="c4">&nbsp;</span><span class="c6">2020) </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2" start="2"><li class="c1 c10"><span>However, a new retrospective cohort (201 patients, 84 [42%] of whom developed ARDS) demonstrated that among patients with ARDS, methylprednisolone decreased risk of death (HR, 0.38; 95% CI, 0.20-0.72)</span><span>&nbsp;(Wu et al., </span><span class="c4">JAMA Int Med</span><span>,</span><span class="c4">&nbsp;</span><span class="c6">2020)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c11">Recommendation</span><span class="c6">:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c20 c11">We recommend against using steroids for COVID-19 except as part of a clinical trial</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">This is in line with WHO Guidelines as of 3/13/2020</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span>&nbsp;</span><span class="c20 c11">Use corticosteroids if required for other indications:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">&nbsp;Use the lowest dose for the shortest duration:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Asthma or COPD exacerbation</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">40mg prednisone PO or 30mg methylprednisolone IV, once daily x 3-5 days</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="2"><li class="c1 c8"><span class="c6">Shock with history of chronic steroid use &gt; 10mg prednisone daily:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">50mg hydrocortisone IV Q6H until improvement in shock </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3" start="3"><li class="c1 c8"><span class="c6">Multipressor shock without history of chronic steroid use</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">50mg hydrocortisone IV Q6H until improvement in shock </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-0" start="7"><li class="c35 c15"><h2 id="h.m6l0vgre9d0s" style="display:inline"><span class="c43 c22">Anti-IL6 Agents (Tocilizumab, Siltuximab) &nbsp;</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">IL-6 activates T cells and macrophages, among other cell types (see &ldquo;Cytokine Activation Syndrome&rdquo;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span>IL-6 inhibitors are approved for cytokine activation syndrome complications related to Chimeric Antigen Receptor T cell (CAR-T) therapy (Brudno &amp; Kochenderfer, </span><span class="c4">Blood Rev</span><span>,</span><span class="c4">&nbsp;</span><span>2019; </span><span>Rubin et al, </span><span class="c4">Brain</span><span>,</span><span class="c4">&nbsp;</span><span>20</span><span class="c6">19)</span></li><li class="c1 c8"><span class="c6">&nbsp;IL-6 levels are reported to correlate with severe COVID-19 </span></li><li class="c1 c8"><span class="c6">While patients have peripheral lymphopenia, BAL fluid is often lymphocytic, suggesting that IL-6 inhibition and prevention of T cell activation may be protective</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c11">Recommendation:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">We do not recommend routine use at this time </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">There are anecdotal reports of benefit of tocilizumab in COVID19 patients but no rigorous studies are available (Anecdotal reports from Italy; Chinese National Health Commission Clinical Guideline, March 3, 2020.)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2" start="2"><li class="c1 c10"><span>For severe </span><span class="c6">cytokine activation syndrome cases (see Chapter 7, &ldquo;Other Guidance&rdquo;):</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span>Consult</span><span>&nbsp;Infectious Disease team for enrollment in a clinical trial based on CRP and IL-6 levels.</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c69 c68"><span>Exercise caution if </span><span class="c6">secondary infection is clinically suspected - including sepsis, pneumocystis or bacterial pneumonia </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span class="c11">Dosing regimens</span><span class="c11">: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span class="c6">Tocilizumab 4-8mg/kg (suggested dose 400mg) IV x1 (anti-IL6R mAb)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Dose can be repeated 12h later if inadequate response to first dose. &nbsp;Total dose should be no more than 800mg. Tocilizumab should not be administered more than twice. </span></li><li class="c1 c8"><span class="c6">Common adverse effects include: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">Transaminitis (AST, ALT) &gt; 22%</span></li><li class="c1 c12"><span class="c6">Infusion reaction 4-20%</span></li><li class="c1 c12"><span class="c6">Hypercholesterolemia 20%</span></li><li class="c1 c12"><span class="c6">Upper respiratory tract infection 7%</span></li><li class="c1 c12"><span class="c6">Neutropenia 2-7%</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2" start="2"><li class="c1 c10"><span class="c6">Alternative: Siltuximab 11mg/kg IV x1 (anti-IL6 mAb)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Common adverse effects include: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c1 c12"><span class="c6">Edema &gt;26%</span></li><li class="c1 c12"><span class="c6">Upper respiratory infection &gt;26%</span></li><li class="c1 c12"><span class="c6">Pruritis / skin rash 28%</span></li><li class="c1 c12"><span class="c6">Hyperuricemia 11%</span></li><li class="c1 c12"><span class="c6">Lower respiratory tract infection 8%</span></li><li class="c1 c12"><span class="c6">Thrombocytopenia 8%</span></li><li class="c1 c12"><span class="c6">Hypotension 4% </span></li></ol><p class="c1 c25"><span class="c6"></span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="8"><li class="c35 c15"><h2 id="h.wr1agkjgho7b" style="display:inline"><span class="c43 c22">Hydroxychloroquine and Chloroquine</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c9"><span class="c20 c11 c16">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c5 c53"><span class="c16">Hydroxychloroquine is an anti-malarial 4-aminoquinoline shown to have in vitro (but not yet in-vivo) activity against diverse RNA viruses including SARS-CoV-1 (Touret et al, </span><span class="c2">Antivir Res</span><span class="c6 c16">, 2020). </span></li><li class="c5 c53"><span class="c16">It is thought to act through multiple mechanisms. (Devaux et al, </span><span class="c2">Int J Antimicrob Agent</span><span class="c6 c16">, 2020)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c5 c70"><span class="c11 c16">Inhibition of viral entry.</span><span class="c16">&nbsp;HQ inhibits synthesis of sialic acids and interferes with protein glycosylation, which may disrupt interactions necessary for viral attachment and entry. (Vincent et al, </span><span class="c2">Virol J</span><span class="c16">, 2005). (Olofsson et al, </span><span class="c2">Lancet Infect Dis,</span><span class="c6 c16">&nbsp;2005).</span></li><li class="c5 c70"><span class="c11 c16">Inhibition of viral release into the host cell.</span><span class="c16">&nbsp;HQ blocks endosomal acidification, which activates endosomal proteases. These proteases are required to initiate coronavirus/endosome fusion that releases viral particles into the cell. (Yang ZY et al, </span><span class="c2">J Virol </span><span class="c6 c16">2004)</span></li><li class="c5 c70"><span class="c11 c16">Reduction of viral infectivity.</span><span class="c16">&nbsp;HQ has been shown to inhibit protein glycosylation and proteolytic maturation of viral proteins. Studies on other RNA viruses have shown a resulting accumulation of non-infective viral particles, or an inability of viral particles to bud out of the host cell (Savarino et al, </span><span class="c2">J AIDS</span><span class="c16">, 1996; Klumperman et al, </span><span class="c2">J Virol</span><span class="c6 c16">, 1994)</span></li><li class="c5 c70"><span class="c11 c16">Immune modulation.</span><span class="c16">&nbsp;HQ reduces toll-like receptor and cGAS-STING signaling. It has been shown to reduce release of a number of pro-inflammatory cytokines from several immune cell types (Schrezenmeier and Dorner, </span><span class="c2">Nat Rev Rheum</span><span class="c16">, 2020)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c9"><span class="c11 c16">Data:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c10 c9"><span class="c16">An </span><span class="c16">expert consensus group out of China </span><span class="c16">suggests that Chloroquine </span><span class="c16">improved lung imaging and shortened disease course. (Zhonghua et al., </span><span class="c2">CMAPH</span><span class="c16">, 2020). Chloroquine will be included in the next treatment guidelines from the National Health Commission, but the specific data on which this is based is not available yet. (Gao et al., </span><span class="c2">Biosci Trends</span><span class="c16">, 2020)</span></li><li class="c10 c9"><span class="c16">Hydroxychloroquine was found to be more potent than chloroquine in inhibiting SARS-CoV-2 in vitro (Yao et al., </span><span class="c2">Clin Infect Dis</span><span class="c16">, 2020)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="3"><li class="c13 c9"><span class="c20 c11 c16">Recommendation:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c10 c9"><span class="c16">Strong consideration of h</span><span class="c6 c16">ydroxychloroquine in patients who require supplemental oxygen who are not candidates for other clinical trials.</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="4"><li class="c13 c9"><span class="c11 c16">Dosing </span><span class="c16">(from the literature)</span><span class="c20 c11 c16">:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c10 c9"><span class="c6 c16">Hydroxychloroquine: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c8 c9"><span class="c16">400mg PO BID on the first day, </span><span class="c16">followed by 200mg </span><span class="c6 c16">q12 (q8h &nbsp;if concerns for absorption) for 5-10 days</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2" start="2"><li class="c10 c9"><span class="c6 c16">Chloroquine (not available at BWH):</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c8 c9"><span class="c6 c16">Second line agent (increased toxicity compared to Hydroxychloroquine)</span></li><li class="c8 c9"><span class="c6 c16">500mg Chloroquine phosphate 500mg PO bid for 10 days</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c12 c9"><span class="c6 c16">Common adverse reactions include: </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c9 c69 c68"><span class="c6 c16">Prolonged QT interval and risk of Torsade de pointes</span></li><li class="c9 c69 c68"><span class="c6 c16">Cardiomyopathy</span></li><li class="c9 c69 c68"><span class="c6 c16">Bone marrow suppression</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-4" start="2"><li class="c12 c9"><span class="c6 c16">Contraindicated in epilepsy and porphyria</span></li></ol><p class="c9 c25 c51"><span class="c6 c16"></span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="9"><li class="c15 c65"><h2 id="h.uebugzw0ifj" style="display:inline"><span>Angiotensin Converting Enzyme Inhibitors (ACE-I) and </span><span class="c43 c22">Angiotensin II Receptor Blockers (ARB)</span></h2></li></ol><ol class="c14 lst-kix_69woh12i7ucg-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-2 start" start="1"><li class="c0"><span class="c16">The role of ACE-I/ARBs in the treatment or pathogenesis of renal failure in COVID-19 confirmed patients is paradoxical and inadequately understood at this time</span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c8 c9"><span>COVID-19 enters the same cell entry receptor as SARS-CoV: angiotensin converting enzyme II (ACE2) (</span><span>Zhou et al.</span><span class="c4">, Nature, 2020</span><span class="c6">). COVID-19 is thought to have 10-20x higher affinity to ACE2 than SARS </span></li><li class="c8 c9"><span class="c6">In addition to the kidneys, ACE2 is expressed in the heart, lungs, and vasculature. &nbsp;This has led to the hypothesis that ACE-I and ARBs, which increase the levels of ACE2, might worsen myocarditis or ACS </span></li><li class="c8 c9"><span>However, </span><span class="c16">ACE2 has been shown to have a </span><span class="c16">protective</span><span class="c16">&nbsp;effect against virus-induced lung injury by increasing </span><span class="c16">angiotensin</span><sup><a href="#cmnt7" id="cmnt_ref7">[g]</a></sup></li></ol><ol class="c14 lst-kix_69woh12i7ucg-1" start="2"><li class="c13 c9"><span class="c32 c11 c16">Recommendation:</span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-2 start" start="1"><li class="c0"><span class="c16 c32">For </span><span class="c32 c16">outpatients</span><span class="c60 c32 c16 c22 c66">: </span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c8 c9"><span class="c32 c16">We recommend </span><span class="c32 c16">against discontinuing</span><span class="c60 c32 c16 c22 c66">&nbsp;outpatient ACE-I/ARBs </span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-4 start" start="1"><li class="c12 c9"><span class="c32 c16">The American College of Cardiology, American Heart Association and Heart Failure Society of America joint statement recommends </span><span class="c32 c16">against</span><span class="c32 c16">&nbsp;discontinuing ACE-I and ARBs in patients with COVID-19 (</span><span class="c32 c16">Bozkurt et al.,</span><span class="c2 c32">&nbsp;HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19, </span><span class="c32 c16">2020</span><span class="c60 c32 c16 c22 c66">) </span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-2" start="2"><li class="c0"><span class="c32 c16">For </span><span class="c32 c16">inpatients</span><span class="c60 c32 c16 c22 c66">:</span></li></ol><ol class="c14 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c8 c9"><span class="c32 c16">We recommend strong consideration of </span><span class="c32 c16">discontinuing</span><span class="c60 c32 c16 c22 c66">&nbsp;and avoiding ACE-I/ARBs in inpatients given the risk of kidney injury in severe illness (see Chapter 7, &ldquo;Other Guidance&rdquo;)</span></li></ol><p class="c9 c25 c71"><span class="c60 c32 c16 c22 c96"></span></p><ol class="c14 lst-kix_73zznxkq85l2-0" start="10"><li class="c19 c15"><h2 id="h.msot2gdaj2bg" style="display:inline"><span>Non-steroidal anti-inflammatory drugs (NSAIDs)</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c10 c9"><span class="c6">SARS-CoV-2 binds to cells via ACE2. ACE2 is upregulated by ibuprofen in animal models, and this might contribute (see &ldquo;Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)&rdquo; section)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c9"><span class="c20 c11">Recommendation:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c10 c9"><span class="c6">Use Acetaminophen instead of NSAIDs wherever possible</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c8 c9"><span>WHO recommends avoiding NSAIDs as of 3/18/20. There is a paucity of evidence, though WHO suggests this is best practice </span><span>based on case reports of sudden deaths in France.</span><span>&nbsp;To date, there are no published human studies to support this hypothesis.(WHO, </span><span class="c4">COVID-19 Guidelines</span><span>, 2020; Fang et al., </span><span class="c4">Lancet Respir Med</span><span>,</span><span class="c4">&nbsp;</span><span>2020; Day, </span><span class="c4">BMJ</span><span class="c6">, 2020)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2" start="2"><li class="c10 c9"><span class="c6">Risk/benefit should be considered in select circumstances (e.g. pericarditis)</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-0" start="11"><li class="c35 c15"><h2 id="h.p7atxkt2b3sh" style="display:inline"><span>B</span><span>lood Products</span><span class="c43 c22">&nbsp;</span></h2></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Recommendation:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c1 c10"><span>R</span><span class="c6">estrictive transfusion strategy (Hct &gt; 21, Hgb &gt; 7) is recommended unless the patient is actively bleeding or there is concern for acute coronary syndrome </span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Parsimony is encouraged given limited supplies (blood drives are limited by social distancing)</span></li><li class="c1 c8"><span>Acute coronary </span><span>syndrome</span><span class="c6">: Hgb &gt; 10</span></li><li class="c1 c8"><span class="c6">Oncology patients: if possible, reduce threshold to Hgb &gt;7</span></li><li class="c1 c8"><span>All others: Hgb &gt; 7</span></li><li class="c1 c8"><span>Massive transfusion protocol, as a very limited resource, will need to be activated only by the ICU attending</span><span>&nbsp;</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-2" start="2"><li class="c1 c10"><span class="c6">Other blood products:</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c1 c8"><span class="c6">Treat bleeding not numbers</span></li><li class="c1 c8"><span class="c6">FFP or 4 factor-PCC (lower volume) for active bleeding in setting of known or suspected coagulation abnormalities</span></li><li class="c1 c8"><span class="c6">Warfarin reversal: use 4 factor-PCC given longer effect and lower volume</span></li><li class="c1 c8"><span class="c6">Platelets: goal &gt; 30K unless actively bleeding</span></li></ol><ol class="c14 lst-kix_73zznxkq85l2-1" start="2"><li class="c1 c13"><span class="c4 c11">Rationale</span><span>: Volume overload is of particular concern in patients with COVID-19 so transfusions may be harmful. Randomized controlled trials of ICU patients have shown that a conservative transfusion strategy (Hgb 7) is associated with less pulmonary edema, fewer cardiac events, fewer transfusions (likely fewer transfusion reactions) and no evidence of harm compared to a liberal transfusion strategy. (Hebert et al, </span><span class="c4">N Engl J Med</span><span>,</span><span class="c4">&nbsp;</span><span>1999; Holst et al, </span><span class="c4">N Engl J Med</span><span>, 2014; Gajic et al, </span><span class="c4">Crit Care Med</span><span>, 2006).</span></li></ol><p class="c1 c25"><span class="c6"></span></p><h1 class="c61 c16" id="h.6zfga8b63w2s"><span class="c49 c22">Chapter 4: Cardiac Complications of COVID-19</span></h1><ol class="c14 lst-kix_yfnaf4f33kdr-0 start" start="1"><li class="c19 c15"><h2 id="h.sxzvrsrmkd1g" style="display:inline"><span class="c43 c22">Acute Cardiac Injury</span></h2></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Definition:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span>Defined as troponin &gt; 99</span><span class="c64">th</span><span class="c6">&nbsp;percentile, or abnormal EKG or echocardiographic findings</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c13 c9"><span class="c11">Incidence</span><span class="c6">:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span>Incidence of 7-22% in hospitalized patients with COVID-19 in China (Ruan et al., </span><span class="c4">Intensive Care Med</span><span>,</span><span>&nbsp;2020; Wang et al., </span><span class="c4">JAMA</span><span>, 2020; Chen et al., </span><span class="c4">Lancet</span><span>,</span><span class="c6">&nbsp;2020) &nbsp;</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c13 c9"><span class="c20 c11">Prognostic implications: </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span>ACI is higher in non-survivors (59%, n=32) than survivors (1%, n=1) (Zhou, </span><span class="c4">Lancet</span><span class="c6">, 2020)</span></li><li class="c0"><span class="c6">ACI is higher in ICU patients (22%, n=22) compared to non-ICU patients (2%, n=2) (Wang, JAMA, 2020)</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="4"><li class="c13 c9"><span class="c20 c11">Time course:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Troponin rise and acute cardiac injury tend to be late manifestations </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span>Troponin increased rapidly from ~14 days from illne</span><span>ss onset, after the onset of respiratory failure. (Zhou et al., </span><span class="c4">Lancet</span><span>,</span><span>&nbsp;2020) </span><sup><a href="#cmnt8" id="cmnt_ref8">[h]</a></sup><sup><a href="#cmnt9" id="cmnt_ref9">[i]</a></sup></li><li class="c8 c9"><span>Among non-survivors, a steady rise in troponin I levels was observed throughout the disease course from day 4 of illness through day 22 (Zhou et al., </span><span class="c4">Lancet</span><span>, 2020)</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="5"><li class="c13 c9"><span class="c20 c11">Mechanism:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span>The mechanism is unknown, though several have been proposed, based on very limited data outside of case reports (Zeng et al., </span><span class="c4">Preprints</span><span class="c6">, 2020)</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span>Possible direct toxicity through viral invasion into cardiac myocytes (i.e. myocarditis), though direct myocardial viral infiltration does not seem to have been found in specimens obtained at biopsy (American College of Cardiology, &nbsp;</span><span class="c4">Cardiologist&rsquo;s Insights From Treating COVID-19 Patients in China</span><span class="c6">, 2020)</span></li><li class="c12 c9"><span class="c6">Acute coronary syndrome and demand ischemia</span></li><li class="c12 c9"><span class="c6">Stress Cardiomyopathy (i.e. Takotsubo&rsquo;s) </span></li></ol><p class="c9 c25 c51"><span class="c6"></span></p><ol class="c14 lst-kix_yfnaf4f33kdr-0" start="2"><li class="c19 c15"><h2 id="h.es6b8f4xqski" style="display:inline"><span class="c43 c22">Cardiovascular Testing </span></h2></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Troponin: </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">ICU patients: Check hsTrop daily and SCvO2 daily</span></li><li class="c0"><span class="c6">Inpatients: Check hsTrop every other day </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">If hsTrop &gt; 200 ng/L or CvO2 &lt; 60%</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span class="c6">Obtain 12-lead ECG</span></li><li class="c12 c9"><span class="c6">Perform point-of-care US (POCUS) if you are trained to do so </span></li><li class="c12 c9"><span class="c6">If no new ECG or echocardiographic abnormalities, continue to monitor daily hsTrop and CvO2</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c13 c9"><span class="c20 c11">Telemetry: </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Telemetry should be used for all critically-ill patients</span></li><li class="c0"><span>In floor patients, telemetry should be used only in patients who meet </span><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000527%23T7&amp;sa=D&amp;ust=1584714690188000">AHA </a></span><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000527%23T7&amp;sa=D&amp;ust=1584714690188000">criteria</a></span><sup><a href="#cmnt10" id="cmnt_ref10">[j]</a></sup><span class="c6">. It should not be used routinely for every COVID-19 admission</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c13 c9"><span class="c20 c11">ECGs: </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Daily ECGs are reasonable for individuals with severe COVID-19</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">When possible, print ECGs from the in-room monitor to minimize contamination of equipment</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="4"><li class="c13 c9"><span class="c20 c11">TTE:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Do not order routine TTEs on COVID-19 patients</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Cardiology consult or a trained provider should perform POCUS if:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span class="c6">Troponin elevation or decline in SCV02/ MV02</span></li><li class="c12 c9"><span class="c6">Shock</span></li><li class="c12 c9"><span>New</span><span class="c6">&nbsp;heart failure (not pre-existing heart failure) </span></li><li class="c12 c9"><span>New persistent</span><span class="c4">&nbsp;</span><span class="c6">arrhythmia</span></li><li class="c12 c9"><span class="c6">Significant ECG changes</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c0"><span class="c6">If abnormalities are identified (e.g. new reduction in LV EF&lt;50%), a formal TTE should be obtained and cardiology consulted</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Where possible order limited TTEs instead of full TTEs to conserve resources</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="5"><li class="c13 c9"><span class="c20 c11">Stress Testing: </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Stress testing is likely not indicated in individuals with active COVID. </span></li><li class="c0"><span class="c6">Any question of possible stress testing should be directed to cardiology</span></li></ol><p class="c9 c25 c78"><span class="c6"></span></p><ol class="c14 lst-kix_yfnaf4f33kdr-0" start="3"><li class="c19 c15"><h2 id="h.rm4wr985h2i8" style="display:inline"><span class="c43 c22">Arrhythmias</span></h2></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c13 c9"><span class="c11 c79">&nbsp;</span><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span>C</span><span>ase series report the occurrence of unspecified arrhythmias in 17% of hospitalized patients with COVID-19 (n=23 of 138), with higher rate in ICU patients (44%, n=16) compared to non-ICU patients (7%, n=7) (Zhou et al., </span><span class="c4">Lancet</span><span class="c6">, 2020).</span></li><li class="c0"><span class="c6">There are anecdotal reports of VT and VF as a late manifestation of COVID-19. No specific published findings were identified </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c13 c9"><span class="c20 c11">Workup:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Telemetry, 12-lead EKG, Cardiac troponin, NT-proBNP, TFT</span></li><li class="c8 c9"><span class="c6">SCVO2 if central line present (goal SCVO2 &gt; 60%)</span></li><li class="c8 c9"><span class="c6">POCUS to assess LV and RV function</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span class="c6">Obtain formal TTE if abnormalities of any of the above</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c13 c9"><span class="c20 c11">Treatment:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Atrial fibrillation/atrial flutter </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Beta blockade if no evidence of heart failure or shock</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span>If significant heart failure or borderline BPs, use amiodarone. </span><span class="c6">There is no known increased concern for amiodarone lung toxicity</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3" start="2"><li class="c8 c9"><span class="c6">&nbsp;If unstable, synchronized DCCV with 100-200 Joules</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c0"><span>Ventricular tachycardia</span><span>&nbsp;or </span><span>VT</span><sup><a href="#cmnt11" id="cmnt_ref11">[k]</a></sup><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Unstable/pulseless: initiate ACLS</span></li><li class="c8 c9"><span class="c6">Stable:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span class="c6">Cardiology consult (may represent evolving myocardial involvement)</span></li><li class="c12 c9"><span class="c6">Amiodarone 150mg IV x 1 or lidocaine 100mg IV x 1 </span></li></ol><p class="c9 c25 c51"><span class="c6"></span></p><ol class="c14 lst-kix_yfnaf4f33kdr-0" start="4"><li class="c19 c15"><h2 id="h.13b1uhteftcc" style="display:inline"><span class="c43 c22">Acute Coronary Syndromes</span></h2></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">There is no current available data on the incidence of ACS in COVID. However, we presume that due to the presence of ACE2 receptors on the endothelium, and the known increased risk of ACS in influenza that there is likely an increased incidence of ACS among COVID-19 patients.</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span>The incidence of ACS is about 6 times as high within seven days of an influenza diagnosis than during control interval - incidence ratio 6.05 (95% CI, 3.86 to 9.50). </span><span>(Kwong et al., </span><span class="c4">NEJM</span><span>, 2018)</span><sup><a href="#cmnt12" id="cmnt_ref12">[l]</a></sup><sup><a href="#cmnt13" id="cmnt_ref13">[m]</a></sup></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c13 c9"><span class="c20 c11">Workup:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Elevated troponin/ECG changes alone may not be able to discriminate between:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Coronary thrombosis </span></li><li class="c8 c9"><span class="c6">Demand-related ischemia </span></li><li class="c8 c9"><span class="c6">Myocarditis</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c0"><span class="c6">Determination of ACS will rely on all evidence available: </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Symptoms (if able to communicate)</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span class="c6">New dyspnea, chest pain, anginal equivalents</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3" start="2"><li class="c8 c9"><span>Regional</span><span class="c6">&nbsp;ECG changes</span></li><li class="c8 c9"><span>Rate of change</span><span class="c6">&nbsp;of Troponin changes (i.e. acute rise suggests ACS)</span></li><li class="c8 c9"><span class="c6">Echo findings (e.g. new RWMA)</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2" start="3"><li class="c0"><span class="c6">When in doubt, request a cardiology consult</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c13 c9"><span class="c20 c11">Management:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Medical management of ACS should be coordinated with cardiology</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">Treat with full dose aspirin, clopidogrel (if not bleeding), heparin, oxygen (if hypoxemic), statin, nitrates (if hypertensive), and opioids (if persistent pain during medical management)</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c12 c9"><span class="c6">Beta blockers should be used with caution given possible concomitant myocarditis/decompensated heart failure</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c0"><span class="c6">As of the time of this writing, the cath lab will take COVID-19 patients, even if ventilated </span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c8 c9"><span class="c6">If resources become constrained and door-to-balloon time is no longer adequate, cardiology may decide to use lytic medications for COVID-19 STEMI patients in lieu of PCI</span></li></ol><p class="c9 c25 c78"><span class="c6"></span></p><ol class="c14 lst-kix_yfnaf4f33kdr-0" start="5"><li class="c19 c15"><h2 id="h.txp16938ptwl" style="display:inline"><span class="c43 c22">Pericarditis and Myocarditis</span></h2></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span>Myocarditis and pericarditis may be potential manifestations of COVID-19 and source of Acute Cardiac Injury, based on case reports/case series (Ruan et al., </span><span class="c4">Intensive Care Med</span><span>,</span><span>&nbsp;2020; Zeng et al., </span><span class="c4">Preprints</span><span>, 2020; Hu et al., </span><span class="c4">Eur Heart J</span><span class="c6">, 2020) </span></li><li class="c0"><span class="c6">However, there is currently little evidence of proven pericarditis or myocarditis, either by biopsy or cMRI</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c13 c9"><span class="c20 c11">Diagnosis:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Likely no role for endomyocardial biopsy</span></li><li class="c0"><span class="c6">cMRI should be discussed on a case-by-case basis with a cardiology consult team</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c13 c9"><span class="c20 c11">Management:</span></li></ol><ol class="c14 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c0"><span class="c6">Supportive for heart failure and direct viral treatments </span></li><li class="c0"><span>The use of anti-inflammatory medications such as Colchicine and Ibuprofen should also be discussed with the cardiology consult team as this is evolving </span></li></ol><h1 class="c61" id="h.dpe5gr1hwjp"><span>Chapter 5: Shock: Septic, Cardiogenic, and Cytokine Storm</span></h1><ol class="c14 lst-kix_q7k3qhhwoyo7-0 start" start="1"><li class="c19 c15"><h2 id="h.bdbn9kepy2bs" style="display:inline"><span class="c43 c22">Undifferentiated Shock in COVID</span></h2></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Definition:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>Acute onset of new and sustained hypotension (MAP &lt; 65 or SBP &lt; 90) with signs of hypoperfusion requiring IVF or vasopressors to maintain adequate blood pressure</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="2"><li class="c13 c9"><span class="c20 c11">Time course:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>Patients rarely present in shock on admission</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Natural history seems to favor the development of shock after multiple days of critical illness. </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="3"><li class="c13 c9"><span class="c20 c11">Etiology:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">The range of reasons for shock is wide and more variable than for most patients and includes: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Cardiogenic shock</span></li><li class="c8 c9"><span class="c6">Secondary bacterial infection</span></li><li class="c8 c9"><span class="c6">Cytokine storm </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="4"><li class="c13 c9"><span class="c11">Workup for new </span><span class="c11">undifferentiated shock:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">Assess for severity of end organ damage:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">UOP, &nbsp;Mental status, Lactate, BUN/creatinine, electrolytes, LFTs</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="2"><li class="c0"><span class="c6">Obtain a FULL infectious workup, which includes all of the following:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span>Labs: </span><span>CBC with differential. </span><span>Note that most COVID patients are lymphopenic (83%). &nbsp;However, new leukocytosis can occur and left-shift can be used as a part of clinical picture</span><span>&nbsp;(Guan et al, </span><span class="c4">N Engl J Med</span><span>, 2020). </span><span>Two sets of blood cultures, LFTs (for cholangitis/acalculous cholecystitis), urinalysis (with reflex to culture), sputum culture (if safely obtained via inline suctioning, do not perform bronchoscopy or sputum induction), procalcitonin at 0 and 48h (</span><span>do not withhold early antibiotics on the basis of procalcitonin</span><span class="c4">), </span><span>urine Strep and legionella antigens</span></li><li class="c8 c9"><span class="c6">Portable CXR (avoid CT unless absolutely necessary)</span></li><li class="c8 c9"><span class="c6">Full skin exam</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c0"><span class="c6">Assess for cardiogenic shock</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Assess extremities: warm or cool on exam</span></li><li class="c8 c9"><span class="c6">Assess patient volume status: JVP, CVP, edema, CXR</span></li><li class="c8 c9"><span>Assess pulse pressure: If &lt; 25% of the SBP, correlates highly with a reduction in cardiac index to less than 2.2 with a sensitivity of 91% and a specificity of 83% (Stevenson and Perloff, </span><span class="c4">JAMA</span><span>,</span><span class="c6">&nbsp;1989)</span></li><li class="c8 c9"><span class="c6">Perform POCUS if trained to do so</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">For TTE protocols see Chapter 4, &ldquo;Cardiac Complications of COVID-19&rdquo; </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="5"><li class="c8 c9"><span class="c6">Labs: Obtain an SCV02 or MV02 if the patient has central access, troponin x2, NT proBNP, A1c, lipid profile, TSH</span></li><li class="c8 c9"><span class="c6">EKG (and telemetry)</span></li><li class="c8 c9"><span class="c6">Calculate estimated Fick Cardiac Output</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span>CO (Cardiac Output), L/min = VO</span><span class="c28">2</span><span>/ [(SaO</span><span class="c28">2</span><span>&nbsp;- SvO</span><span class="c28">2</span><span class="c6">) x Hb x 13.4)],</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-5 start" start="1"><li class="c57 c9"><span>where VO</span><span class="c28">2</span><span>&nbsp;= 125 mL O</span><span class="c28">2</span><span>/min x </span><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa&amp;sa=D&amp;ust=1584714690198000">BSA,</a></span><span>&nbsp;where </span><span>BSA = [(Height, cm x Weight, kg)/ 3,600 ]</span><span class="c64">&frac12;</span><span>; i</span><span>n patients aged &ge;70, use 110 mL O</span><span class="c28">2 </span><span>x BSA for VO</span><span class="c28">2</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="4"><li class="c0"><span class="c6">Assess for other causes of shock:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Vasoplegia: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">Run medication list for recent cardiosuppressive medications, vasodilatory agents, antihypertensives </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="2"><li class="c8 c9"><span class="c6">Adrenal insufficiency:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">Unless high pretest probability of adrenal insufficiency, we recommend against routine cortisone stimulation testing</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="3"><li class="c8 c9"><span class="c6">Obstruction:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">PE (given the elevated risk of thrombosis)</span></li><li class="c12 c9"><span class="c6">Tamponade (given elevated risk of pericarditis)</span></li><li class="c12 c9"><span class="c6">Obstruction from PEEP</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="4"><li class="c8 c9"><span>C</span><span>ytokine storm</span><span class="c62">&nbsp;</span><span class="c6">(see &ldquo;Cytokine Storm&rdquo; section below)</span></li><li class="c8 c9"><span class="c6">Allergic reactions to recent medications</span></li><li class="c8 c9"><span class="c6">Neurogenic shock is uncommon in this context</span></li><li class="c8 c9"><span class="c6">Hypovolemia:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">Bleeding</span></li><li class="c12 c9"><span class="c6">Insensible losses from fever</span></li><li class="c12 c9"><span class="c6">Diarrhea/vomiting</span></li></ol><p class="c9 c25 c51"><span class="c6"></span></p><ol class="c14 lst-kix_q7k3qhhwoyo7-0" start="2"><li class="c19 c15"><h2 id="h.ebuidko2u3iz" style="display:inline"><span>Differentiating Shock</span></h2></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c54 c4 c92"><a class="c3" href="https://www.google.com/url?q=https://www.khanacademy.org/science/health-and-medicine/circulatory-system-diseases/shock/v/differentiating-shock&amp;sa=D&amp;ust=1584714690200000">This video is a helpful tutorial</a></span><span class="c29 c4 c22">&nbsp;</span></li></ol><p class="c9 c25"><span class="c29 c4 c11"></span></p><p class="c9 c25"><span class="c29 c4 c11"></span></p><a id="t.8182c59cf796328da7c39a1e2186d9101289c6b4"></a><a id="t.0"></a><table class="c91"><tbody><tr class="c31"><td class="c41" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Type of Shock</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Cardiac Output</span></p></td><td class="c58" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">SVR</span></p></td><td class="c42" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">CVP/ Wedge</span></p></td><td class="c75" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">SCv02, MVO2</span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c1"><span class="c4 c11">Other features</span></p></td></tr><tr class="c31"><td class="c41" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Cardiogenic</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c58" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c42" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c75" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c1 c30"><span class="c4 c11 c66 c80"></span></p></td></tr><tr class="c94"><td class="c41" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Distributive (sepsis,cytokine, anaphylaxis)</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c58" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c42" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c75" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c1 c30"><span class="c29 c4 c11"></span></p></td></tr><tr class="c31"><td class="c41" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Obstructive</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c58" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c42" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c75" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c1 c30"><span class="c29 c4 c11"></span></p></td></tr><tr class="c31"><td class="c41" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Hypovolemic</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c58" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="images/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c42" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c75" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c1 c30"><span class="c29 c4 c11"></span></p></td></tr><tr class="c31"><td class="c41" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Neurogenic</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c58" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c42" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span class="c29 c4 c11">/normal</span></p></td><td class="c75" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="images/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c1"><span class="c29 c4 c11">Decreased HR</span></p></td></tr></tbody></table><p class="c9 c25"><span class="c6"></span></p><p class="c9 c25"><span class="c29 c4 c11"></span></p><ol class="c14 lst-kix_q7k3qhhwoyo7-0" start="3"><li class="c19 c15"><h2 id="h.lydcfzsuv4hc" style="display:inline"><span>S</span><span class="c43 c22">eptic Shock and Secondary Infections </span></h2></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">The reported rates of sepsis and septic shock are not reported consistently in currently available case series</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Secondary bacterial infections are reported:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span>20% of non-survivors (Zhou et al, </span><span class="c4">Lancet</span><span class="c6">, 2020)</span></li><li class="c12 c9"><span>16% of non-survivors (Ruan et al, </span><span class="c4">Intensive Care Med</span><span class="c6">, 2020)</span></li><li class="c12 c9"><span>12-19% In H1N1 epidemic (MacIntyre, </span><span class="c4">BMC Infect Dis</span><span class="c6">, 2018) </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="2"><li class="c0"><span class="c6">Concurrent Pneumocystis pneumonia has been reported in at least one case (possibly due to lymphopenia)</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="2"><li class="c13 c9"><span class="c20 c11">Antibiosis:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>Early empiric antibiotics should be initiated within 1 hour (see Chapter 3, &ldquo;COVID-19 Therapies and Clinical Trials,&rdquo; &ldquo;Antibiotic Stewardship&rdquo; section)</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="3"><li class="c13 c9"><span class="c20 c11">Conservative Fluid Management:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">Goal MAP &gt; 65mmHg</span></li><li class="c0"><span>Start Norepinephrine while determining the etiology of undifferentiated shock</span></li><li class="c0"><span class="c6">We do not recommend conventional 30cc/kg resuscitation</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Give 250-500cc IVF and assess in 15-30 minutes for:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">Increase &gt; 2 in CVP</span></li><li class="c12 c9"><span class="c6">Increase in MAP or decrease in pressor requirement</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-5 start" start="1"><li class="c9 c57"><span class="c6">Use isotonic crystalloids; Lactated Ringer&rsquo;s solution is preferred where possible. Avoid hypotonic fluids, starches, or colloids</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="2"><li class="c1 c8"><span class="c6">Repeat 250-500cc IVF boluses; Use dynamic measures of fluid responsiveness</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span>Pulse Pressure Variation: can be calculated in mechanically </span><span class="c6">ventilated patients without arrhythmia; PPV &gt;12% is sensitive and specific for volume responsiveness</span></li><li class="c12 c9"><span class="c6">Straight Leg Raise: raise legs to 45&deg; w/ supine torso for at least one minute. A change in pulse pressure of &gt; 12% has sensitivity of 60% &amp; specificity of 85% for fluid responsiveness in mechanically ventilated patients; less accurate if spontaneously breathing</span></li><li class="c12 c9"><span class="c6">Ultrasound evaluation of IVC collapsibility should only be undertaken by trained personnel to avoid contamination of ultrasound</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="3"><li class="c1 c8"><span>For further guidance, </span><span>Conservative Fluid Management protocols are available from from </span><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1584714690211000">FACCT</a></span><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1584714690211000">&nbsp;Lite trial </a></span><span>(Grissom et al,</span><span class="c4">&nbsp;Crit Care Med</span><span>, 2015)</span></li><li class="c8 c9"><span class="c4">Rationale</span><span>: COVID-19 clinical reports indicate the majority of patients present with respiratory failure without shock. ARDS is mediated in part by pulmonary capillary leak, and randomized controlled trials of ARDS indicate that a conservative fluid strategy is protective in this setting. (</span><span>Grissom et al,</span><span class="c4">&nbsp;Crit Care Med</span><span>, 2015</span><span>; Famous et al., </span><span class="c4">Am J Respir Crit Care Med,</span><span>&nbsp;2017; Silversides et al., </span><span class="c4">Int Care Med,</span><span>&nbsp;2017; WHO, </span><span class="c4">COVID-19 Guidelines</span><span class="c6">, 2020)</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="4"><li class="c1 c13"><span class="c20 c11">Pressor management</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c1 c21"><span>Unless new evidence emerges, standard choices for distributive shock (</span><span class="c4">i.e.</span><span class="c6">, norepinephrine then vasopressin) are recommended, with high vigilance for the development of cardiogenic shock, addressed in the next section.</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="5"><li class="c1 c13"><span class="c20 c11">Corticosteroids</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c1 c21"><span class="c6">See Chapter 3, &ldquo;COVID-19 Therapies and Clinical Trials,&rdquo; section on &ldquo;Systemic Corticosteroids&rdquo;</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c1 c8"><span>Stress dose hydrocortisone should still be considered in patients on &gt; 2 pressors</span><span class="c4">&nbsp;</span></li></ol><p class="c9 c25 c78"><span class="c6"></span></p><ol class="c14 lst-kix_q7k3qhhwoyo7-0" start="4"><li class="c19 c15"><h2 id="h.ftupyxepmedz" style="display:inline"><span>&nbsp;Cardiogenic Shock</span></h2></li></ol><p class="c56 c25"><span class="c6"></span></p><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="6"><li class="c13 c9"><span class="c20 c11">Incidence: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">Heart failure or cardiogenic shock was observed in 23% (n=44 of 191) of hospitalized patients in one case series</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span>Higher rates in non-survivors (52%, n=28) compared to survivors (12%, n=16) (Zhou et al., </span><span class="c4">Lancet</span><span class="c6">, 2020). &nbsp;</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="2"><li class="c0"><span class="c6">Heart failure or myocardial damage contributed to death in 39% (n=29) of deaths in a series of 68 patients in Wuhan</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span>Most (n=22 of 29) had concomitant respiratory failure (Ruan et al., &nbsp;</span><span class="c4">Intensive Care Med</span><span>, 2020)</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c0"><span class="c6">Anecdotally, our U.S. colleagues have not seen such high rates of heart failure</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="7"><li class="c56 c13"><span class="c20 c11">Diagnosis:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c56 c21"><span class="c6">Significant concern for cardiogenic shock if any of the following are present with evidence of hypoperfusion (e.g. elevated lactate):</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c56 c8"><span class="c6">Elevated NT-ProBNP or</span></li><li class="c56 c8"><span class="c6">CvO2 &lt; 60% (PvO2 &lt; 35 mm Hg) or</span></li><li class="c56 c8"><span class="c6">Echo w depressed LV and/or RV function</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="8"><li class="c13 c9"><span class="c20 c11">Time course:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>C</span><span>ardiogenic shock may present late in the course of illness even after improvement of respiratory symptoms, and manifest as a precipitous clinical deterioration in the setting of an acute decline in LVEF (see section on &ldquo;Acute Cardiac Injury&rdquo;) </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="9"><li class="c13 c9"><span class="c20 c11">Etiology:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">See section on &ldquo;Acute Cardiac Injury; mechanism is unknown, potentially direct viral toxicity, ACS, or stress cardiomyopathy</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="10"><li class="c13 c9"><span class="c20 c11">Workup:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">Rule out ACS and complete the initial work up as described in Chapter 4</span></li><li class="c0"><span>Ongoing monitoring: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span>Labs</span><span class="c6">: Trend troponins to peak, SCvO2 (obtained by upper body CVC) or MvO2 q8-12h or with clinical change, Lactate q4-6h, &nbsp;LFTs daily (for hepatic congestion)</span></li><li class="c8 c9"><span class="c6">Daily EKGs or prn with clinical deterioration</span></li><li class="c8 c9"><span class="c6">Trend troponin to peak</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c0"><span class="c6">All cardiogenic shock cases require cardiovascular consult</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">PA Catheters may be placed bedside by experienced providers, with preference for use only in mixed shock or complex cases with cardiology guidance</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="11"><li class="c13 c9"><span class="c20 c11">Medical management:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">Close collaboration with the cardiovascular consultation service is recommended</span></li><li class="c0"><span class="c6">Goals: MAPs 65-75, CVP 6-14, PCWP 12-18, PAD 20-25, SVR 800-1000, SCvO2 &gt; 60%, CI &gt; 2.2</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Note: Achieving MAP goal is first priority, then optimize other parameters</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c0"><span class="c6">How to achieve goals:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c8 c9"><span class="c6">Continue titration of norepinephrine gtt for goal MAP 65-75</span></li><li class="c8 c9"><span class="c6">Initiate diuretic therapy for CVP &gt; 14, PCWP &gt;18, PAD &gt; 25</span></li><li class="c8 c9"><span class="c6">Initiate inotropic support: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c12 c9"><span class="c6">Dobutamine gtt for SCvO2 &lt; 60%, CI &lt; 2.2 and MAP &gt; 65. &nbsp;Start at 2mcg/kg/min. Up-titrate by 1-2mcg/kg/min every 30-60 minutes for goal parameters. Alternative strategies should be considered once dose exceeds 5mcg/kg/min. &nbsp;Maximum dose is 10mcg/kg/min</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="4"><li class="c56 c8"><span>Ensure negative inotropes such as beta blockers, calcium channel blockers and antihypertensives are discontinued</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="12"><li class="c13 c9"><span class="c20 c11">Candidacy for Mechanical Support</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>The benefit of Mechanical Support in COVID-19 is not yet clear. In one study of patients with severe COVID-19, five (83%) of six patients receiving ECMO died (Yang et al., </span><span class="c4">Lancet, </span><span class="c6">2020). There is concern that the further decrease of lymphocytes from ECMO could contribute to higher mortality. However, this is a very small study and more information is needed</span></li><li class="c21 c56"><span>Patients who experi</span><span>ence the following should prompt an immediate call to the cardiovascular medicine consult service for consideration of mechanical support:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c56 c8"><span class="c6">Dobutamine gtt at 5mcg/kg/min (or unable to tolerate dobutamine due to tachyarrhythmias) and SCVO2 &lt; 60% or CI &lt; 2.2</span></li><li class="c56 c8"><span>Lactate &gt; 4 after medical therapy </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c0"><span class="c6">The criteria for ECMO and other mechanical cardiovascular support varies among centers and are difficult to develop under typical circumstances. The unclear trajectory of the COVID-19 pandemic makes these evaluations even more difficult. Please refer to the separate BWH ECMO and Cardiovascular Medicine guidelines which are in development. </span></li></ol><p class="c9 c25 c78"><span class="c6"></span></p><p class="c9 c68 c78"><span>The following does not reflect the recommendation of the BWH ECMO and Cardiovascular services. However, for the purposes of general education, a </span><span class="c62">hypothetical</span><span>&nbsp;set of</span><span class="c54">&nbsp;inclusion criteria</span><span class="c6">&nbsp;for ECMO or MCS could cover: </span></p><ol class="c14 lst-kix_q7k3qhhwoyo7-3" start="3"><li class="c12 c9"><span class="c6">Younger age </span></li><li class="c12 c9"><span class="c6">Expected life expectancy &gt;6 months pre-hospitalization</span></li><li class="c12 c9"><span class="c6">No evidence of solid or liquid malignancy</span></li><li class="c12 c9"><span class="c6">Able to tolerate anticoagulation</span></li><li class="c12 c9"><span class="c6">Platelets &gt;50,000</span></li><li class="c12 c9"><span class="c6">Absence of severe peripheral arterial disease</span></li><li class="c12 c9"><span class="c6">No evidence of irreversible neurological injury</span></li><li class="c12 c9"><span class="c6">Able to perform ADLs at baseline prior to illness</span></li><li class="c12 c9"><span>Cannot have profound respiratory failure (defined as requiring prone ventilation at time of consult for MCS or having PaO2:FiO2 ratio &lt; 150)</span><span>&nbsp;(for MCS other than </span><span>ECMO</span><span>)</span></li></ol><p class="c9 c25 c51"><span class="c6"></span></p><ol class="c14 lst-kix_q7k3qhhwoyo7-0" start="5"><li class="c19 c15"><h2 id="h.7i62kagnynf0" style="display:inline"><span class="c43 c22">&nbsp;Cytokine Activation Syndrome</span></h2></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>A subgroup of patients with severe COVID-19 may have cytokine storm syndrome and secondary HLH (</span><span>Mehta et al.</span><span class="c4">, Lancet, </span><span>2020</span><span>). Patients who had cytokine storm developed rapid progression to ARDS, shock, and multiorgan failure (</span><span>Chen et al.</span><span class="c4">, Lancet, </span><span>2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="2"><li class="c13 c9"><span class="c20 c11">Pathophysiology: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span>Neutrophil activation likely contributes to the pathogenesis of cytokine storm and ARDS (Wu</span><span class="c4">, JAMA Intern Med, </span><span>2020).</span><span class="c64">&nbsp;</span><span class="c6">Wu et al. found that COVID-19 confirmed patients with ARDS have higher neutrophil counts, average 7.04 (95% CI: 3.98 to 10.12) vs. those without ARDS, average 3.06 (2.03 to 5.56) </span></li><li class="c0"><span>Similar patterns of cytokine storm and ARDS have been seen with SARS, MERS (Kim et al.</span><span class="c4">, J Korean Med Sci, </span><span class="c6">2016)</span></li><li class="c0"><span>Other studies have suggested that increased proinflammatory cytokines in the serum are associated with pulmonary injury in SARS, MERS, and COVID-19 (Wong et al.</span><span class="c4">, Clin Exp Immunol, </span><span class="c6">2004) </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="3"><li class="c46 c13"><span class="c20 c11">Workup:</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c46 c21"><span>Suspect if clinical deterioration with shock and multiorgan failure</span></li><li class="c46 c21"><span>CBC with diff, PT/INR, PTT, fibrinogen, d-dimer, ferritin, liver function test, triglycerides, c-reactive protein (CRP) (</span><span>Ruan</span><span class="c4">, Intensive Care Med, </span><span>2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c46 c8"><span>CRP seems to correlate with disease severity and prognosis of COVID-19 (</span><span>Ruan</span><span class="c4">, Intensive Care Med, </span><span>2020</span><span class="c4">; </span><span>Young</span><span class="c4">, JAMA, </span><span>2020</span><span>)</span></li><li class="c46 c8"><span>An </span><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://www.mdcalc.com/hscore-reactive-hemophagocytic-syndrome&amp;sa=D&amp;ust=1584714690218000">Hscore</a></span><span>&nbsp;may be helpful in estimating the probability of secondary HLH in these patients</span><span class="c48 c22">&nbsp;</span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-1" start="4"><li class="c13 c9"><span class="c20 c11">Management: </span></li></ol><ol class="c14 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c0"><span class="c6">If high suspicion, discuss with ID about the use of IVIG, steroids, cytokine blockade--particularly IL-6 pathway and perhaps IL-1 (see Chapter 3, &ldquo;COVID-19 Therapies and Clinical Trials,&rdquo; section on &ldquo;Anti-IL6 Agents&rdquo;). While steroids have been implicated with worse lung injury and outcomes, they may be beneficial in the hyperinflammatory state</span></li></ol><p class="c9 c25"><span class="c6"></span></p><h1 class="c61" id="h.5s70bzlr4ojz"><span>Chapter 6: Thrombotic and Coagulation Manifestations</span></h1><ol class="c14 lst-kix_h8i9ymdmzkx8-0 start" start="1"><li class="c19 c15"><h2 id="h.9wzf9ick65rt" style="display:inline"><span class="c43 c22">Thrombotic Disease</span></h2></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>Unclear incidence, though case reports suggest there may be increased venous thromboembolism (VTE) in COVID-19 patients </span><span>(</span><span>Xie et al., </span><span class="c4">Radiol: Cardiothoracic Imaging,</span><span>&nbsp;2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="2"><li class="c13 c9"><span class="c20 c11">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>The mechanism for VTE are unknown and likely multifactorial:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span class="c6">Systemic inflammatory response as seen in sepsis</span></li><li class="c8 c9"><span class="c6">Stasis/critical illness</span></li><li class="c8 c9"><span class="c6">Possibly direct endothelial damage from viral injury/ ACE2 binding</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2" start="2"><li class="c0"><span>Colleagues from Wuhan have reported finding microthrombi in pulmonary vasculature on autopsy, (Luo W et al, </span><span class="c4">Preprints</span><span class="c6">&nbsp;2020) which could contribute to local V/Q mismatch or hydrostatic changes causing edema. However these mechanisms remain entirely hypothetical</span></li><li class="c0"><span>One theory: SARS-CoV requires coagulation F</span><span>actor Xa for viral replication. &nbsp;Factor Xa cleaves and activates protein S which is pro-thrombotic. &nbsp;By extension, it is hypothesized that anticoagulation or anti-platelets might inhibit SARS-CoV-2 replication. There is a small case series suggesting dipyrimadole may be useful, though anti-coagulation and anti-platelet agents requires further investigation prior to being used therapeutically </span><span>(Liu et al., </span><span class="c4">medRxiv,</span><span class="c6">&nbsp;2020)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="3"><li class="c13 c9"><span class="c20 c11">Management:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>Initiate p</span><span class="c6">rophylactic anticoagulation therapy for all COVID-19 patients unless otherwise contraindicated</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span class="c6">If CrCl &gt; 30: Lovenox 40 mg SC daily</span></li><li class="c8 c9"><span class="c6">If CrCl &lt; 30 or AKI: Heparin 5000 units SC tid</span></li><li class="c8 c9"><span class="c6">Hold if Platelets &lt;30,000 or bleeding, start TEDs and SCDs</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2" start="2"><li class="c0"><span>If the patient is on direct oral anticoagulants (DOACs) or Warfarin for Afib or VTE, switch </span><span>to full dose</span><span class="c6">&nbsp;anticoagulation (LMWH or UFH, as indicated based on renal function or clinical scenario)</span></li><li class="c0"><span class="c6">While therapeutic anticoagulation has been used empirically in some severe COVID-19 patients in Wuhan given the microthrombi in pulmonary vasculature (see above), our interpretation of the data is that the risks outweigh the benefits at this time, unless documented DVT or PE</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="4"><li class="c13 c9"><span class="c20 c11">Prognosis:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>Higher D-dimer and FDP levels track with multi-organ dysfunction syndrome and poorer prognosis. </span><span>(Wang et al, </span><span class="c4">JAMA </span><span>2020, Zhou et al, </span><span class="c4">Lancet</span><span class="c6">&nbsp;2020)</span></li></ol><p class="c9 c25"><span class="c6"></span></p><ol class="c14 lst-kix_h8i9ymdmzkx8-0" start="2"><li class="c19 c15"><h2 id="h.vpg0k312hzmd" style="display:inline"><span class="c43 c22">Disseminated Intravascular Coagulation (DIC)</span></h2></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1 start" start="1"><li class="c13 c9"><span class="c20 c11">Incidence/pathophysiology:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>Limited data: 16 of 183 hospitalized patients in Wuhan had DIC (</span><span>Tang et al., </span><span class="c4">J Thromb Haemost,</span><span>&nbsp;2020</span><sup><a href="#cmnt14" id="cmnt_ref14">[n]</a></sup><sup><a href="#cmnt15" id="cmnt_ref15">[o]</a></sup><span class="c6">).</span></li><li class="c0"><span>Laboratory changes in coagulation parameters and FDP track with multi-organ dysfunction (Zhou et al, </span><span class="c4">Lancet</span><span class="c6">&nbsp;2020)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="2"><li class="c13 c9"><span class="c20 c11">Time course:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>Median time to onset of DIC was 4 days into hospital admission (</span><span>Tang et al., </span><span class="c4">J Thromb Haemost,</span><span>&nbsp;2020</span><sup><a href="#cmnt16" id="cmnt_ref16">[p]</a></sup><sup><a href="#cmnt17" id="cmnt_ref17">[q]</a></sup><span>)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="3"><li class="c13 c9"><span class="c20 c11">Workup:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>I</span><span class="c6">dentify and treat underlying condition</span></li><li class="c0"><span class="c40"><a class="c3" href="https://www.google.com/url?q=https://reference.medscape.com/calculator/dic-score&amp;sa=D&amp;ust=1584714690222000">ISTH DIC score calculator</a></span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span class="c6">If score &lt; 5, no DIC; recalculate in 1-2 days</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="4"><li class="c13 c9"><span class="c20 c11">Management:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span class="c6">If bleeding, give blood products:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span class="c6">For elevated PT/PTT and bleeding, use FFP or 4F-PCC (KCentra - less volume, but must discuss dose with HAT/pharmacy)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2" start="2"><li class="c0"><span class="c6">If not bleeding, supportive care:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span>If fibrinogen &lt; 150: </span><span>FFP, cryoprecipitate or fibrinogen concentrate (RiaSTAP)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-4 start" start="1"><li class="c12 c9"><span class="c6">RiaSTAP is less volume, but dose must be discussed with HAT/pharmacy</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3" start="2"><li class="c8 c9"><span class="c6">Transfuse platelets if &lt; 30K</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2" start="3"><li class="c0"><span>Hold anticoagulation </span><sup><a href="#cmnt18" id="cmnt_ref18">[r]</a></sup><sup><a href="#cmnt19" id="cmnt_ref19">[s]</a></sup><span class="c6">for active bleeding. </span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span class="c6">Consider holding anticoagulation if patient requires blood products for supportive care, though clinician should weigh risks and benefits </span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2" start="4"><li class="c0"><span class="c6">Start anticoagulation only if:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c8 c9"><span class="c6">Overt thromboembolism or organ failure due to clot (i.e. purpura fulminans)</span></li><li class="c8 c9"><span class="c6">Therapeutic anticoagulation (e.g. UFH)</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-4 start" start="1"><li class="c12 c9"><span>There has been no mortality benefit of therapeutic anticoagulation in DIC. (Levi et al., </span><span class="c4">Blood,</span><span>&nbsp;2018)</span><sup><a href="#cmnt20" id="cmnt_ref20">[t]</a></sup><sup><a href="#cmnt21" id="cmnt_ref21">[u]</a></sup></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-1" start="5"><li class="c13 c9"><span class="c20 c11">Prognosis:</span></li></ol><ol class="c14 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c0"><span>DIC is associated with worse survival in COVID-19 patients. Out of 183 COVID-19 patients in Wuhan, 71% of non-survivors had DIC (ISTH score &ge; 5) compared to 0.6% of survivors (</span><span>Tang et al., </span><span class="c4">J Thromb Haemost,</span><span>&nbsp;2020</span><sup><a href="#cmnt22" id="cmnt_ref22">[v]</a></sup><sup><a href="#cmnt23" id="cmnt_ref23">[w]</a></sup><span class="c6">)</span></li></ol><p class="c9 c45 c30"><span class="c34 c11"></span></p><h1 class="c61" id="h.9jn4ulxubc3h"><span class="c49 c22">Chapter 7: Renal Manifestations </span></h1><ol class="c14 lst-kix_b0ja666m9l9x-0 start" start="1"><li class="c59"><h2 id="h.fj20lj7bpd6o" style="display:inline"><span class="c43 c22">Acute Kidney Injury</span></h2></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-1 start" start="1"><li class="c46 c13"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c46 c21"><span>I</span><span>ncidence of AKI in COVID-19 varies widely, but estimates range from 2.1% to 29% </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-1" start="2"><li class="c46 c13"><span class="c20 c11">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c46 c21"><span>L</span><span>ikely due to acute tubular necrosis (ATN) from several mechanisms including: </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span>Direct cellular injury by the virus via angiotensin converting enzyme II (</span><span>ACE2). COVID-19 uses ACE2 for cell entry. ACE2 is expressed in proximal renal tubules more than glomeruli (</span><span>Fan et al.</span><span class="c4">, Urology, </span><span>2020</span><span class="c6">) </span></li><li class="c8 c46"><span class="c6">Toxic ATN from cytokine storm</span></li><li class="c46 c8"><span>Shock and subsequent hypoperfusion leading to toxic/ischemic ATN (</span><span>Xianghong et al.</span><span class="c4">, Natl Med J China, </span><span>2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-1" start="3"><li class="c46 c13"><span class="c11">Workup:</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c46 c21"><span class="c6">Monitor Creatinine at least daily</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span>Studies find variable onset of AKI, from 7 days (</span><span class="c4">Cheng, Nephrology, preprint</span><span>) to 15 days after illness onset (</span><span>Zhou et al.</span><span class="c4">, Lancet, </span><span>2020</span><span>).</span><span class="c64">&nbsp;</span><span>Onset of AKI more rapid and severe in patients with underlying CKD</span><span class="c64">&nbsp;</span><span>(</span><span>Cheng</span><span class="c4">, Nephrology, </span><span>2020</span><span>)</span><span class="c64">&nbsp;</span><span class="c6">&nbsp;</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2" start="2"><li class="c46 c21"><span>If evidence of rising BUN and/or creatinine, order urinalysis</span><span class="c20 c11">&nbsp;</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span class="c6">Patients may present with proteinuria (44%), hematuria (26.9%)</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-1" start="4"><li class="c46 c13"><span class="c20 c11">Management: </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c46 c21"><span class="c6">Consult ICU nephrology early at the first sign of renal injury for all COVID-19 confirmed patients </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span>Do not wait until need for RRT (renal replacement therapy)/dialysis for consultation. </span></li><li class="c46 c8"><span class="c6">At this time, all confirmed COVID-19 patients should be covered by ICU nephrology, not general nephrology</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-4 start" start="1"><li class="c46 c12"><span class="c6">ICU</span></li><li class="c46 c12"><span class="c6">RRT Triage</span></li><li class="c46 c12"><span>Floor</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2" start="2"><li class="c46 c21"><span class="c6">Managing AKI:</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span class="c6">Minimize nephrotoxic agents</span></li><li class="c46 c8"><span>Give judicious fluids for suspected prerenal insults, but discuss with renal if any ambiguity (see Chapter 5, &ldquo;Shock&rdquo; for conservative fluid recommendations)</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-1" start="5"><li class="c46 c13"><span class="c20 c11">Renal Replacement Therapy (RRT):</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c46 c21"><span>Estimates for RRT range from </span><span>1 to 5%</span><span class="c6">&nbsp;of hospitalized patients. Among critically ill patients, need for CRRT ranges from 5 to 23% </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span>Few studies have reported outcomes of RRT. One case series reported that out of 191 patients, 10 received CRRT, and all 10 died (</span><span>Zhou et al.</span><span class="c4">, Lancet, </span><span>2020</span><span class="c6">) </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2" start="2"><li class="c46 c21"><span>Renal will be coordinating RRT continuation and initiation </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c46 c8"><span>Indications for dialysis in COVID-19 patients are the same as the indications for all patients</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2" start="3"><li class="c46 c21"><span class="c6">ICU nephrology will determine the need, timing, and modality of renal replacement on a case-by-case basis </span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-1" start="6"><li class="c46 c13"><span class="c11">Prognosis:</span></li></ol><ol class="c14 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c46 c21"><span>Increased serum creatine, BUN, AKI, proteinuria, or hematuria are each </span><span>independent risk factors for in-hospital death (</span><span>Cheng et al.</span><span class="c4">, Nephrology, </span><span>2020</span><span>)</span><span class="c6">&nbsp;</span></li><li class="c46 c21"><span>In two other studies, non-survivors had higher BUN and creatinine and higher rates of AKI (</span><span>Wang et al.</span><span class="c4">, JAMA, 2020; </span><span>Yang et al.</span><span class="c4">, Lancet Respir Med, </span><span>2020</span><span class="c6">) </span></li><li class="c46 c21"><span>Another study found that higher BUN and creatinine are associated with progression to ARDS, and higher BUN (though not creatinine) is associated with death (HR 1.06-1.20) (</span><span>Wu et al.</span><span class="c4">, JAMA Int Med, </span><span>2020</span><span>)</span></li><li class="c46 c21"><span>In comparison</span><span>, AKI was found in 6.7% of SARS patients. AKI correlated with poor prognosis and </span><span>91.7% of patients with AKI died</span><span class="c11">&nbsp;</span><span>(vs 8.8% without AKI, p &lt; 0.0001) (</span><span>Chu et al.</span><span class="c4">, Kidney Int, </span><span>2005)</span></li></ol><h1 class="c68 c95" id="h.l3i6lcz3jr27"><span>Chapter 8: Other Guidance</span></h1><ol class="c14 lst-kix_xgq4y4xln1s-0 start" start="1"><li class="c5 c74 c86"><h2 id="h.fg1hqkm6u1r8" style="display:inline"><span class="c43 c22">Liver Disease</span></h2></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c5 c83"><span class="c20 c11">Incidence:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0 c16"><span>Up to 53% of patients had abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (</span><span>Zhang et al.</span><span class="c4">, Lancet Gastroenterol Hepatol, </span><span>2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="2"><li class="c5 c83"><span class="c20 c11">Pathophysiology:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0 c16"><span class="c6">Possible mechanisms of liver injury include: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5 c70"><span class="c6">Direct viral infection of liver cells (2-10% of patients have diarrhea; COVID-19 found in stool samples)</span></li><li class="c5 c70"><span class="c6">Drug hepatotoxicity </span></li><li class="c5 c70"><span class="c6">Cytokine storm</span></li><li class="c5 c70"><span class="c6">Shock</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="3"><li class="c5 c83"><span class="c20 c11">Time course:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0 c16"><span>In general, liver injury in mild COVID-19 disease is transient and self-resolving. However,</span><span class="c4">&nbsp;</span><span class="c6">liver injury correlates with severity</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5 c70"><span>ALT &gt; 40 is associated with higher odds of in-hospital death (</span><span>Zhou et al.</span><span class="c4">, Lancet, </span><span>2020</span><span class="c6">) </span></li><li class="c5 c70"><span>AST is associated with progression to ARDS but not death; total bilirubin is associated with both progression to ARDS and death (</span><span>Wu et al.</span><span class="c4">, JAMA Intern Med, </span><span>2020</span><span class="c6">)</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="4"><li class="c5 c83"><span class="c20 c11">Monitoring: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0 c16"><span class="c6">Monitor LFTs every third day</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">If on hepatotoxic medications, monitor more frequently in conjunction with pharmacy</span></li><li class="c8 c9"><span>If starting L</span><span class="c63">opinavir/</span><span>R</span><span class="c63">itonavir and </span><span>C</span><span class="c6">hloroquine, monitor LFTs daily</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="2"><li class="c0"><span>Workup for other etiologies of liver injury with RUQUS, doppler ultrasound, hepatitis serologies, etc as clinically indicated</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="5"><li class="c13 c9"><span class="c20 c11">Management:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Consult GI/Hepatology if concern for acute liver failure (severe liver injury with elevated bilirubin, encephalopathy, and INR &gt;1.5)</span></li><li class="c0"><span class="c6">Run medication list for all possible offending agents and discontinue where possible</span></li><li class="c0"><span>N-Acetyl-Cysteine is not recommended at this time due to significant volume load. </span><span class="c63">Chinese studies refer to giving &ldquo;liver protective drugs&rdquo; in case of severe liver injury but </span><span class="c6">we recommend against this for now</span></li><li class="c0"><span>There are no current </span><span class="c63">guidelines for treatment of COVID-19 patients with underlying cirrhosis, but societies such as AASLD are working on registries of these patients</span></li></ol><p class="c9 c45 c30"><span class="c6"></span></p><ol class="c14 lst-kix_xgq4y4xln1s-0" start="2"><li class="c19 c15"><h2 id="h.aayfijcxre19" style="display:inline"><span>Considerations for Oncology Patients &nbsp;</span></h2></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c13 c9"><span class="c6">Data:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">As of 3/16/2020, there is no available published data specific to COVID19 management in oncologic or immunosuppressed patients</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="2"><li class="c13 c9"><span class="c6">Oncology Consultation/Coverage: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">For established DFCI patients, oncology consultation and guidance is provided by each patient&rsquo;s primary oncologist (or coverage). </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Contact primary oncologist via page not the general pager </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="3"><li class="c13 c9"><span class="c6">Prognosis: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Many patients have reasonable or even good prognoses with current therapies. Do not assume a prognosis, involve outpatient attending</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="4"><li class="c13 c9"><span class="c6">Meds: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Check in Epic medications tab and in &ldquo;Research: Active&rdquo; tab </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="5"><li class="c13 c9"><span class="c6">Workup: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Labs: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Weekly glucan/galactomannan in neutropenic/transplant patients.</span></li><li class="c8 c9"><span class="c6">Specific patient populations may require additional monitoring (such as CMV, EBV monitoring in transplant patients &ndash; ask outpatient team).</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="2"><li class="c0"><span class="c6">Exam: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Examine catheters (port, CVC, others) daily. </span></li><li class="c8 c9"><span class="c6">Avoid rectal exams in neutropenic patients, but examine the perirectal area if symptoms or persistent fevers. </span></li><li class="c8 c9"><span class="c6">Do not give per rectum therapies to neutropenic patients.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="6"><li class="c13 c9"><span class="c6">Pain management: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Patients with cancer-related pain may have high opiate needs at baseline. Opiates should not be stopped but type may need to be adjusted in the setting of respiratory failure, renal injury, or liver injury.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Pain / Palliative Care service can help guide dose titrations in these situations.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="7"><li class="c13 c9"><span class="c6">Goals of Care: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Involve primary team whenever possible (recognizing that in critical/emergent situations may not be possible)</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="8"><li class="c13 c9"><span class="c6">Anticoagulation:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Thrombosis prophylaxis should be initiated for all patients unless otherwise contraindicated, given that both COVID19 infection and malignancy increase thrombotic risk, particularly with solid tumors</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">See &nbsp;&ldquo;Thrombotic disease&rdquo; for guidelines on both prophylactic and therapeutic anticoagulation</span></li><li class="c8 c9"><span class="c6">Remember to hold if Platelets &lt;30,000</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="9"><li class="c13 c9"><span class="c6">Patients with Heme Malignancy and Stem Cell Transplant:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Daily exam: Findings are more subtle or absent in neutropenic and immune suppressed patients. Examine catheters daily. Avoid rectal exam</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="10"><li class="c13 c9"><span class="c6">Febrile Neutropenia:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Definition:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">ANC &lt; 500 cells/mm3 AND T &ge; 101F or T &ge; 100.5 for 1hr</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="2"><li class="c0"><span class="c6">Workup: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">blood cultures from peripheral (ideally two sets), and each lumen of central line (label clearly); UA/sed with urine culture (UA may not be as informative with neutropenia); Glucan and galactomannan (if not checked recently), sputum if able, CXR</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c12 c9"><span class="c6">Continue DAILY blood cultures while febrile</span></li><li class="c12 c9"><span class="c6">Monitor serum galactomannan and 1-3-beta glucan once weekly</span></li><li class="c12 c9"><span class="c6">Any positive glucan or galactomannan prompts ID consult.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="3"><li class="c0"><span class="c6">Initial Empiric Antibiotics:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">GNRs: Ceftazidime -OR- Cefepime </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c12 c9"><span class="c6">Alternatives (2nd line) Piperacillin-tazobactam or (3rd line) meropenem</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3" start="2"><li class="c8 c9"><span class="c6">GPCs: add Vancomycin if hemodynamically unstable, or if MRSA pneumonia or catheter-associated infection is suspected. Check dosing with pharmacy if able</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="4"><li class="c0"><span class="c6">Removal of lines:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Catheter removal should be discussed if associated infection is suspected - involve primary oncologist and/or ID team to weigh risks and benefits, given that not all lines require removal.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="5"><li class="c0"><span class="c6">Persistent Neutropenic Fever:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">If fever persists x3 days despite antibiotics </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c12 c9"><span class="c6">Micafungin 100mg IV daily </span></li><li class="c12 c9"><span class="c6">Consideration of further imaging even if patient appears stable (discuss with oncology / ID)</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="6"><li class="c0"><span class="c6">Antiinfective course:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Antiinfectives should be continued until the patient has met all of these criteria: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c12 c9"><span class="c6">(a) clinically improved and </span></li><li class="c12 c9"><span class="c6">(b) has been afebrile for 48h and </span></li><li class="c12 c9"><span class="c6">(c) has been non-neutropenic for 48h.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="11"><li class="c13 c9"><span class="c6">Transfusions: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Blood bank reivews order and will release appropriate product (i.e. irradiated, leukoreduced, etc)</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">RBC transfusion if Hgb &lt; 7 or Hct &lt; 21</span></li><li class="c8 c9"><span class="c6">Platelet transfusion if Platelets &lt; 10K. Higher transfusion goals if needed for procedures or if active bleeding:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c12 c9"><span class="c6">Plts &gt; 20K if mild bleeding (i.e. epistaxis, line oozing) or if patient has rigors</span></li><li class="c12 c9"><span class="c6">Plts &gt; 50K if more serious bleeding; may be higher for CNS bleeding or neurosurgery required</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3" start="3"><li class="c8 c9"><span class="c6">Cryoprecipitate transfusion if fibrinogen &lt; 100</span></li><li class="c8 c9"><span class="c6">FFP transfusion if procedure needed. INR of FFP = ~1.4</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="12"><li class="c13 c9"><span class="c6">Patients with Solid Tumors:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">Patients with solid tumors are at very high risk of thrombosis but at lower risk of infection than most heme malignancy patients</span></li><li class="c0"><span class="c6">Immune Checkpoint Inhibitors (ICIs) do not significantly immunosuppress patients when used alone</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">Most common are CTLA4 inhibitor (ipilimumab) and PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab and avelumab).</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2" start="3"><li class="c0"><span class="c6">Immune toxicity: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c8 c9"><span class="c6">If patient develops organ dysfunction, it may be due to immune toxicity- consult the service team of the involved organ system and inform primary oncologist</span></li><li class="c8 c9"><span class="c6">Common immune toxicities include pneumonitis / respiratory failure (may be difficult to distinguish between COVID19 disease or may be aggravated by COVID19 infection), colitis, endocrine dysfunction (thyroid, pituitary / hypothalamic, adrenal), nephritis. Less common hepatitis, meningitis, dermatitis.</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c12 c9"><span class="c6">Check TSH, ACTH, cortisol, Tspot, HIV, HBV, HCV serologies if concerned</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-3" start="3"><li class="c8 c9"><span class="c6">Immune toxicities are usually treated with high dose steroids - risks and benefits must be weighed immediately with primary oncologist and ID consult teams if immune toxicity is suspected concurrent with COVID19 infection.</span></li><li class="c8 c9"><span class="c40"><a class="c3" href="https://www.google.com/url?q=http://dfcionline.org/clinical/clinicalresources/immunotherapy-toxicity/&amp;sa=D&amp;ust=1584714690236000">BWH/DFCI iTox guidelines</a></span><span class="c6">&nbsp;can be found on the DFCI intranet</span></li></ol><p class="c9 c25"><span class="c6"></span></p><ol class="c14 lst-kix_xgq4y4xln1s-0" start="3"><li class="c19 c15"><h2 id="h.t1khoickfgoo" style="display:inline"><span class="c43 c22">Goals of Care</span></h2></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c1 c13"><span class="c11">Assess understanding and sign Health Care Proxy form on admission:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c0"><span class="c6">In conscious patients, review or sign Health Care Proxy form</span></li><li class="c1 c21"><span>Make sure families are aware that p</span><span>atients with significant comorbid illnesses or who have poor baseline functional or health status decompensate rapidly and have very high mortality due to COVID-19 (see Chapter 1, &ldquo;Non-ICU Management, Triage, Transfers&rdquo;) </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="2"><li class="c1 c13"><span class="c20 c11">Goals of Care should be documented and focus on:</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c1 c21"><span class="c6">A patient&rsquo;s desired quality of life</span></li><li class="c1 c21"><span class="c6">Tolerance for/ desire for invasive measures</span></li><li class="c1 c21"><span class="c6">Understanding of disease process </span></li></ol><p class="c1 c25 c71"><span class="c34 c22"></span></p><ol class="c14 lst-kix_xgq4y4xln1s-0" start="4"><li class="c15 c35"><h2 id="h.ipfys4gecnv0" style="display:inline"><span class="c43 c22">Management of Cardiac Arrest</span></h2></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c1 c13"><span class="c20 c11">Early goals of care conversations are imperative</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c1 c21"><span>&nbsp;The aim is to avoid unnecessary codes in patients without a reversible underlying condition</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="2"><li class="c1 c13"><span class="c20 c11">Health care workers should be protected in code situations: </span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c1 c21"><span class="c6">PPE should be worn by all healthcare workers, even if donning prolongs time the patient spends a low-flow state during cardiac arrest</span></li><li class="c1 c21"><span class="c6">Codes should be run with an automated compression device where available and minimal personnel</span></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1" start="3"><li class="c1 c13"><span class="c20 c11">Full code guidelines are forthcoming and will be included here when available</span></li></ol><p class="c1 c25"><span class="c6"></span></p><ol class="c14 lst-kix_xgq4y4xln1s-0" start="5"><li class="c35 c15"><h2 id="h.6ogwg6sl9a40" style="display:inline"><span class="c43 c22">The role of palliative care</span></h2></li></ol><p class="c9 c68 c74"><span>This section in progress</span><sup><a href="#cmnt24" id="cmnt_ref24">[x]</a></sup></p><p class="c9 c25 c74"><span class="c6"></span></p><ol class="c14 lst-kix_xgq4y4xln1s-0" start="6"><li class="c35 c15"><h2 id="h.foc01qidskrl" style="display:inline"><span class="c43 c22">Ethical Considerations and Resource Allocation</span></h2></li></ol><ol class="c14 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c13 c9"><span>This section </span><span>is</span><sup><a href="#cmnt25" id="cmnt_ref25">[y]</a></sup><span>&nbsp;in progress</span></li></ol><p class="c46 c25 c74"><span class="c38 c22"></span></p><hr style="page-break-before:always;display:none;"><p class="c46 c25"><span class="c38 c22"></span></p><p class="c46 c25"><span class="c22 c38"></span></p><p class="c46 c68 c74"><span class="c89">&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></p><p class="c5"><span class="c47 c11">Afterword</span></p><p class="c5"><span class="c6">Often, international societies convene a stellar committee of world experts to craft clinical guidelines that define the field for years.</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">This is not that kind of guideline.</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">We built the first iteration of these guidelines &ldquo;from the bottom up&rdquo; in less than a week. With the help of our readers, we expect to correct, revise, add and subtract as we learn about COVID-19 with the help of our patients.</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">The guideline making process</span></p><p class="c5"><span class="c6">Tuesday 3/10/2020: Commonwealth of Massachusetts declares a State of Emergency</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">Thursday 3/12/2020 7:05pm: Email asking for volunteers</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">Fri 3/13/20 12:30pm: First Zoom video conference call</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">Thurday 3/19/20 6:06pm: Email with covidprotocols.org link. Subject: It&rsquo;s ALIVE!</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">As we raced along, the pandemic raced even faster.</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">(signed)</span></p><p class="c5"><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">BWH intensivists, fellows, respiratory therapists and pharmacists</span></p><hr style="page-break-before:always;display:none;"><h1 class="c61 c90" id="h.fu2z89vxpri3"><span class="c22 c49"></span></h1><h1 class="c61" id="h.24n5wzicja05"><span>REFERENCES &nbsp;</span></h1><p class="c9 c25"><span class="c18 c16"></span></p><ol class="c14 lst-kix_d9wep1z810b6-0 start" start="1"><li class="c15 c9"><span class="c16 c27">Afshari A, Bastholm bille A, Allingstrup M. Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2017;7:CD007733. DOI: </span><span class="c16 c27 c40"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1002/14651858.CD007733.pub3&amp;sa=D&amp;ust=1584714690241000">10.1002/14651858.CD007733.pub3</a></span><span class="c16 c27">. </span><span class="c18 c16">&nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Akerstr&ouml;m S, Mousavi-jazi M, Klingstr&ouml;m J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(3):1966-9. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1128/JVI.79.3.1966-1969.2005&amp;sa=D&amp;ust=1584714690242000">10.1128/JVI.79.3.1966-1969.2005</a></span></li><li class="c15 c9"><span class="c16 c27">American College of Cardiology. Cardiologist&rsquo;s Insights From Treating COVID-19 Patients in China. Mar 12, 2020. &nbsp;</span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=https://www.acc.org/latest-in-cardiology/articles/2020/03/12/17/02/cardiologists-insights-from-treating-covid-19-patients-in-china&amp;sa=D&amp;ust=1584714690242000">https://www.acc.org/latest-in-cardiology/articles/2020/03/12/17/02/cardiologists-insights-from-treating-covid-19-patients-in-china</a></span><span class="c16 c27">&nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Arabi YM, Mandourah Y, Al-hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1164/rccm.201706-1172OC&amp;sa=D&amp;ust=1584714690242000">10.1164/rccm.201706-1172OC</a></span><span class="c18 c16">. &nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Mar 17, 2020. </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=https://www.acc.org/sitecore/content/Sites/ACC/Home/Latest-in-Cardiology/Articles/2020/03/17/08/59/HFSA-ACC-AHA-Statement-Addresses-Concerns-Re-Using-RAAS-Antagonists-in-COVID-19&amp;sa=D&amp;ust=1584714690243000">https://www.acc.org/sitecore/content/Sites/ACC/Home/Latest-in-Cardiology/Articles/2020/03/17/08/59/HFSA-ACC-AHA-Statement-Addresses-Concerns-Re-Using-RAAS-Antagonists-in-COVID-19</a></span><span class="c18 c16">&nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/j.blre.2018.11.002&amp;sa=D&amp;ust=1584714690243000">10.1016/j.blre.2018.11.002</a></span><span class="c16 c27">. </span></li><li class="c15 c9"><span class="c16 c27">Tsch&ouml;pe C, Cooper LT, Torre-amione G, Van linthout S. Management of Myocarditis-Related Cardiomyopathy in Adults. Circ Res. 2019;124(11):1568-1583.</span><span class="c16 c27">&nbsp;DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=https://doi.org/10.1161/CIRCRESAHA.118.313578&amp;sa=D&amp;ust=1584714690243000">10.1161/CIRCRESAHA.118.313578</a></span><span class="c16 c27">.</span></li><li class="c15 c9"><span class="c16 c27">Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/S0140-6736(20)30211-7&amp;sa=D&amp;ust=1584714690244000">10.1016/S0140-6736(20)30211-7</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Cheng Y, Luo R, Wang K, et al. Kidney Impairment Is Associated with In-Hospital Death of COVID-19 Patients. Nephrology. 2020. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1584714690244000">10.1101/2020.02.18.20023242</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 2005;67(2):698-705. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1111/j.1523-1755.2005.67130.x&amp;sa=D&amp;ust=1584714690245000">10.1111/j.1523-1755.2005.67130.x</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Day, M. COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1136/bmj.m1086&amp;sa=D&amp;ust=1584714690245000">10.1136/bmj.m1086</a></span><span class="c18 c16">&nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care. 2016;20:75. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/%252010.1186/s13054-016-1230-8&amp;sa=D&amp;ust=1584714690245000">10.1186/s13054-016-1230-8</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med. 2017;195(3):331-338. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1164/rccm.201603-0645OC&amp;sa=D&amp;ust=1584714690246000">10.1164/rccm.201603-0645OC. </a></span><span class="c18 c16">&nbsp; </span></li><li class="c15 c9"><span class="c16 c27">Fan C, Li K, Ding Y, Lu WL, Wang J. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-NCoV Infection. Urology. 2020. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&amp;sa=D&amp;ust=1584714690246000">10.1101/2020.02.12.20022418</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Fang, L, Karakiulakis G, Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020. &nbsp;DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/S2213-2600(20)30116-8&amp;sa=D&amp;ust=1584714690246000">10.1016/S2213-2600(20)30116-8</a></span><span class="c16 c27">. </span></li><li class="c15 c9"><span class="c16 c27">Fuller et al. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. Chest. 2015; 147(6): 1510-1522. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=https://dx.doi.org/10.1378/chest.14-3161&amp;sa=D&amp;ust=1584714690247000">10.1378/chest.14-3161</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm?. Crit Care Med. 2006;34(5 Suppl):S170-3. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1097/01.CCM.0000214288.88308.26&amp;sa=D&amp;ust=1584714690247000">10.1097/01.CCM.0000214288.88308.26</a></span><span class="c16 c27">. </span></li><li class="c15 c9"><span class="c16 c27">Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.5582/bst.2020.01047&amp;sa=D&amp;ust=1584714690247000">10.5582/bst.2020.01047</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016;(6):CD002787. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1002/14651858.CD002787.pub3&amp;sa=D&amp;ust=1584714690248000">10.1002/14651858.CD002787.pub3</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. Crit Care Med. 2015;43(2):288-95. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1097/CCM.0000000000000715&amp;sa=D&amp;ust=1584714690248000">10.1097/CCM.0000000000000715</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa2002032&amp;sa=D&amp;ust=1584714690248000">10.1056/NEJMoa2002032</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">Gu&eacute;rin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-68. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa1214103&amp;sa=D&amp;ust=1584714690248000">10.1056/NEJMoa1214103</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c16 c27">H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409-17. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJM199902113400601&amp;sa=D&amp;ust=1584714690249000">10.1056/NEJM199902113400601</a></span></li><li class="c15 c9"><span class="c16 c27">Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381-91. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa1406617&amp;sa=D&amp;ust=1584714690249000">10.1056/NEJMoa1406617</a></span><span class="c18 c16">. &nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1093/eurheartj/ehaa190&amp;sa=D&amp;ust=1584714690249000">10.1093/eurheartj/ehaa190</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy CPAP different masks. Eur Respir J. 2019;53(4). DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1183/13993003.02339-2018&amp;sa=D&amp;ust=1584714690250000">10.1183/13993003.02339-2018</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Kallet RH, Matthay MA. Hyperoxic acute lung injury. Respir Care. 2013;58(1):123-41. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.4187/respcare.01963&amp;sa=D&amp;ust=1584714690250000">10.4187/respcare.01963</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Kim ES, Choe PG, Park WB, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. J Korean Med Sci. 2016;31(11):1717-1725. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.3346/jkms.2016.31.11.1717&amp;sa=D&amp;ust=1584714690250000">10.3346/jkms.2016.31.11.1717</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Lee N, Allen chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304-9. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/j.jcv.2004.07.006&amp;sa=D&amp;ust=1584714690251000">10.1016/j.jcv.2004.07.006</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c18 c16">Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845-854. DOI: 10.1182/blood-2017-10-804096</span></li><li class="c15 c9"><span class="c18 c16">Lippi G and Plebani M. Procalcitonin in patients with severe coronavirus disease 2019: A meta-analysis. Clin Chim Acta. 2020;505:190-191. </span></li><li class="c15 c9"><span class="c18 c16">Liu X, Li Z, Liu S, Chen Z, Zhao Z, Huang Y, Zhang Q, Wang J, Shi Y, Xu Y, Sun J, Xian H, Fang R, Fan Bai F, Changxing Ou, Bei Xiong, Andrew M Lew, Jun Cui, Hui Huang, Jincun Zhao, Xuechuan Hong, &nbsp;H-BL. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv. 2020.</span></li><li class="c15 c9"><span class="c16 c27">Luo, W., Yu, H., Gou, J., et al. Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19). Preprints 2020, 2020020407</span></li><li class="c15 c9"><span class="c18 c16">MacIntyre CR, Chughtai AA, Barnes M et al (2018) The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis 18:637</span></li><li class="c15 c9"><span class="c18 c16">Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;0(0). doi:10.1016/S0140-6736(20)30628-0</span></li><li class="c15 c9"><span class="c18 c16">Nates et al. Crit Care Med 2016; 44:1553-1602</span></li><li class="c15 c9"><span class="c16 c27">Penn Medicine Treatment Guidelines for SARS-CoV-2 Infection. Mar 14 2020. Accessed Mar 18 2020 at: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://www.uphs.upenn.edu/antibiotics/COVID19.html&amp;sa=D&amp;ust=1584714690251000">http://www.uphs.upenn.edu/antibiotics/COVID19.html</a></span><span class="c18 c16">&nbsp;</span></li><li class="c15 c9"><span class="c18 c16">Ruan et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3. doi: 10.1007/s00134-020-05991-x. &nbsp;</span></li><li class="c15 c9"><span class="c16 c27">Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334-1348. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1093/brain/awz053&amp;sa=D&amp;ust=1584714690252000">10.1093/brain/awz053</a></span><span class="c18 c16">. </span></li><li class="c9 c15"><span class="c16 c18">Shahpori et al. Crit Care Med 2011; 39:827-832</span></li><li class="c15 c9"><span class="c16 c27">Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med. 2017;43(2):155-170. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1007/s00134-016-4573-3&amp;sa=D&amp;ust=1584714690252000">10.1007/s00134-016-4573-3</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c18 c16">Stockman et al.. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343</span></li><li class="c15 c9"><span class="c16 c27">Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261(6):884-8. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1001/jama.1989.03420060100040&amp;sa=D&amp;ust=1584714690253000">10.1001/jama.1989.03420060100040</a></span><span class="c16 c27">. </span></li><li class="c15 c9"><span class="c18 c16">Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. February 2020. doi:10.1111/jth.14768</span></li><li class="c15 c9"><span class="c18 c16">Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. PLoS One. 2012;7(4).</span></li><li class="c15 c9"><span class="c18 c16">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus&ndash;Infected Pneumonia in Wuhan, China. JAMA. February 2020. doi:10.1001/jama.2020.1585</span></li><li class="c15 c9"><span class="c16 c27">Lee N, Allen chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304-9. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/j.jcv.2004.07.006&amp;sa=D&amp;ust=1584714690253000">10.1016/j.jcv.2004.07.006</a></span><span class="c18 c16">. </span></li><li class="c15 c9"><span class="c16 c27">Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. DOI: </span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=http://dx.doi.org/10.1111/j.1365-2249.2004.02415.x&amp;sa=D&amp;ust=1584714690254000">10.1111/j.1365-2249.2004.02415.x</a></span><span class="c18 c16">.</span></li><li class="c15 c9"><span class="c18 c16">World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. WHO. 2020;(January):12. </span></li><li class="c15 c9"><span class="c18 c16">Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. March 2020. doi:10.1001/jamainternmed.2020.0994</span></li><li class="c15 c9"><span class="c18 c16">Xianghong Y, Renhua S, Dechang C. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored. Natl Med J China. 2020;100(00):E017-E017. doi:10.3760/cma.j.cn112137-20200229-00520</span></li><li class="c15 c9"><span class="c18 c16">Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiol Cardiothorac Imaging. 2020;2(2).</span></li><li class="c15 c9"><span class="c16 c27">Yang et al. COVID-19 control in China during mass population movements at New Year.</span><span class="c27">&nbsp;Lancet, Feb 2020; </span><span class="c27"><a class="c3" href="https://www.google.com/url?q=https://doi.org/10.1016/S0140-6736(20)30421-9&amp;sa=D&amp;ust=1584714690254000">https://doi.org/10.1016/S0140-6736(20)30421-9</a></span></li><li class="c15 c9"><span class="c18 c16">Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;0(0). doi:10.1016/S2213-2600(20)30079-5</span></li><li class="c15 c9"><span class="c18 c16">Yao et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, March 2020</span></li><li class="c15 c9"><span class="c18 c16">Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA, March 2020; doi:10.1001/jama.2020.3204</span></li><li class="c15 c9"><span class="c18 c16">Zeng, et al. First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights. Preprints 2020; doi: 10.20944/preprints202003.0180.v1</span></li><li class="c15 c9"><span class="c18 c16">Zeng, J., Huang, J. &amp; Pan, L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People&rsquo;s Hospital. Intensive Care Med, 2020; https://doi.org/10.1007/s00134-020-05993-9</span></li><li class="c15 c9"><span class="c18 c16">Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, March 2020; doi:10.1016/S2468-1253(20)30057-1</span></li><li class="c15 c9"><span class="c18 c16">Zheng, Y et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020; doi.org/10.1038/s41569-020-0360-5</span></li><li class="c15 c9"><span class="c18 c16">Zhonghua et al. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. CMAPH, Feb 2020;43(0):E019. doi: 10.3760/cma.j.issn.1001-0939.2020.0019.</span></li><li class="c15 c9"><span class="c18 c16">&nbsp;Zhonghua Xin Xue Guan Bing Za Zhi. &nbsp;Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. March 2020;48(0):E008. doi: 10.3760/cma.j.cn112148-20200225-00123. &nbsp;</span></li><li class="c15 c9"><span class="c18 c16">Zhou F, et al. Lancet 2020; DOI:https://doi.org/10.1016/S0140-6736(20)30566-3. Hamming I, et al. J Pathol 2004; 203(2): 631-7.</span></li><li class="c15 c9"><span class="c18 c16">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. March 2020. doi:10.1016/S0140-6736(20)30566-3</span></li><li class="c15 c9"><span class="c18 c16">Zhou &nbsp;P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7</span></li><li class="c15 c9"><span class="c16 c27">Zuo M-Z, Huang Y-G, Ma W-H, et al. Expert Recommendations for Tracheal Intubation in Critically ill Patients with Novel Coronavirus Disease 2019. Chin Med Sci J. February 2020.</span><span class="c16 c27">&nbsp;</span><span class="c40 c16 c27"><a class="c3" href="https://www.google.com/url?q=https://doi.org/10.24920/003724&amp;sa=D&amp;ust=1584714690256000">doi:10.24920/003724</a></span></li></ol><p class="c9 c25 c74"><span class="c22 c66 c77"></span></p><hr style="page-break-before:always;display:none;"><h1 class="c61 c90" id="h.t36cynad724o"><span class="c49 c22"></span></h1><h1 class="c61" id="h.9um4ryva0zlb"><span class="c49 c22">ADDENDUM: COVID ICU Bundle Checklist &nbsp;</span></h1><p class="c5"><span>Rationale: Use of a daily checklist ensures that routine quality measures are in place for each patient. &nbsp;Review Bundle Checklist at the end of each patient&rsquo;s presentation, every day. &nbsp;</span><span class="c54">Each section should be performed unless there is a contraindication or barrier to implementation</span><span class="c6">. If a contraindication is present, discuss how barriers may be overcome. </span></p><p class="c5 c30"><span class="c6"></span></p><p class="c5"><span class="c11">Ventilator</span><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">&#x1f5c6; Spontaneous Awakening Trial (SAT)</span></p><p class="c5"><span class="c6">= turn off sedation </span></p><p class="c5"><span class="c6">&#x1f5c6; Spontaneous Breathing Trial (SBT)</span></p><p class="c5"><span class="c6">= Place patient on Pressure Support 5/5</span></p><p class="c5"><span class="c6">- Perform SAT &amp; SBT concurrently if able</span></p><p class="c5"><span class="c6">- Contraindications to SAT/SBT include FiO2 &gt; 50%, PEEP &gt; 8, O2 sat &lt; 90%, pH &lt; 7.30, SBP &lt; 90 or MAP &lt; 60, paralysis, intracranial pressure &gt;15, concern for significant bleeding</span></p><p class="c5"><span class="c6">&#x1f5c6; If ARDS: goal Vt 6-8 cc/kg of ideal body weight (calculated by height), plateau pressure &lt; 30</span></p><p class="c5 c30"><span class="c6"></span></p><p class="c5"><span class="c6">&#x1f5c6; Head of bed at &gt;30 degrees </span></p><p class="c5"><span class="c6">&#x1f5c6; Oral care is ordered </span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c20 c11">Sedation / Delirium</span></p><p class="c5"><span class="c6">&#x1f5c6; Ask: Is patient delirious (CAM+)? </span></p><p class="c5"><span class="c6">&#x1f5c6; Review med list for any deliriogenic medications and discontinue/change where possible</span></p><p class="c5"><span class="c6">&#x1f5c6; Define RASS goal</span></p><p class="c5"><span class="c6">&#x1f5c6; Record QTc daily, consider changing medications if QTc &gt; 500 </span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c20 c11">Restraints</span></p><p class="c5"><span class="c6">&#x1f5c6; Ask: Are restraints needed? </span></p><p class="c5"><span class="c6">&#x1f5c6; Sign necessary restraint orders</span></p><p class="c5"><span class="c6">&#x1f5c6; Discuss barriers to removing restraint orders </span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c11">Mobility</span><span class="c6">&nbsp;</span></p><p class="c5"><span class="c6">&#x1f5c6; Consult PT for early mobility</span></p><p class="c5"><span class="c6">- Contraindications include: deep sedation, paralysis</span></p><p class="c5 c30"><span class="c6"></span></p><p class="c5"><span class="c20 c11">Pressure Ulcers</span></p><p class="c5"><span class="c6">&#x1f5c6; Ask: Are pressure ulcers present? Is a wound care consult needed? </span></p><p class="c5"><span class="c6">&#x1f5c6; Discuss whether any changes are needed to ulcer management plan</span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c20 c11">DVT prophylaxis</span></p><p class="c5"><span class="c6">&#x1f5c6; Review patient&rsquo;s current DVT prophylaxis orders and adjust if needed </span></p><p class="c5"><span class="c6">- Contraindications to LMWH DVT ppx include AKI (switch to UFH TID), clinically significant bleeding (hold pharmacologic), platelet count &lt; 30K (hold pharmacologic)</span></p><p class="c5"><span class="c6">- Add sequential compression boots if holding pharmacologic prophylaxis</span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c20 c11">GI / Nutrition </span></p><p class="c5"><span class="c6">&#x1f5c6; Famotidine 20mg IV BID in intubated patients; Pantoprazole 20-40mg IV daily if history of GERD or GI bleed</span></p><p class="c5"><span class="c6">&#x1f5c6; Review nutrition, consult nutrition if not already done. &nbsp;While awaiting nutrition input, start enteral nutrition: </span></p><p class="c5"><span class="c6">- In most patients, Osmolite 1.5 @10mL/hr, advance by 20mL Q6h to goal 50mL/hr</span></p><p class="c5"><span class="c6">- If renal failure and high K or phos: Nepro @ 10mL/hr, advance by 10mL Q6h to goal 40mL/hr</span></p><p class="c5"><span class="c6">- MVI with minerals daily </span></p><p class="c5"><span class="c6">- thiamine 100mg daily x3 days</span></p><p class="c5"><span class="c6">- folate 1mg daily x 3 days</span></p><p class="c5"><span class="c6">&#x1f5c6; Ask: Is bowel regimen adequate? Make changes if necessary. </span></p><p class="c5"><span class="c6">&#x1f5c6; Review glucose range over past 48h and insulin regimen, adjust regimen if needed. </span></p><p class="c5"><span class="c6">- Goal glucose range is 70-180</span></p><p class="c5 c30"><span class="c84 c63 c22 c66"></span></p><p class="c5"><span class="c20 c11">Tubes / Lines / Drains</span></p><p class="c5"><span class="c6">&#x1f5c6; List all tubes / lines / drains and discuss if any can be removed or should be changed</span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c20 c11">Patient / Family Communication </span></p><p class="c5"><span class="c6">&#x1f5c6; Discuss if patient has healthcare making capacity - if not, activate healthcare proxy </span></p><p class="c5"><span class="c6">&#x1f5c6; Update families by phone </span></p><p class="c5"><span class="c6">- Suggest RN update at least daily </span></p><p class="c5"><span class="c6">- MD update Q3 days, with any significant clinical change, or per family request</span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c11">Disposition</span></p><p class="c5"><span class="c6">&#x1f5c6; Discuss anticipated dispo, barriers to dispo</span></p><p class="c5 c30"><span class="c20 c11"></span></p><p class="c5"><span class="c20 c11">Code Status</span></p><p class="c5"><span class="c6">&#x1f5c6; Review current code status, discuss if goals of care are realistic with prognosis - if not, discuss with patient / family</span></p><p class="c5 c30"><span class="c6"></span></p><p class="c5"><span class="c6">Abbreviations: </span></p><p class="c5"><span class="c6">SAT = Spontaneous Awakening Trial </span></p><p class="c5"><span class="c6">SBT = Spontaneous Breathing Trial </span></p><p class="c5"><span class="c6">CAM = Confusion Assessment Method</span></p><p class="c5"><span class="c6">RASS = Richmond Agitation and Sedation Scale</span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><p class="c1 c25"><span class="c6"></span></p><div><p class="c25 c76"><span class="c6"></span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref1" id="cmnt1">[a]</a><span class="c6">Update soon, data will come out</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref2" id="cmnt2">[b]</a><span class="c6">add ref to bibliography J Crit Care. 2012 Oct;27(5):434-9.</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref3" id="cmnt3">[c]</a><span class="c6">Am J Respir Crit Care Med. 2012;185:1307&ndash;1315.</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref4" id="cmnt4">[d]</a><span class="c6">insert ref into bibliograph N Engl J Med. 2020 Mar 12;382(11):999-1008.</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref5" id="cmnt5">[e]</a><span class="c6">Link ECMO guidelines when available</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref6" id="cmnt6">[f]</a><span class="c6">need becky and kevin to decide</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref7" id="cmnt7">[g]</a><span class="c6">needs a citation</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref8" id="cmnt8">[h]</a><span class="c6">Would like to include a clip of the timecourse here... trop rise starts late? or thats when the problems manifest?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref9" id="cmnt9">[i]</a><span class="c6">Paper doesn&#39;t mention specifically if that&#39;s when the problems start, but it does say that in 23/50 (46%) non survivors had trop rises &gt;28 and whereas only 1/95 (1%) survivors had such a trop rise.</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref10" id="cmnt10">[j]</a><span class="c6">Not sure if you want to do this as a link or not?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref11" id="cmnt11">[k]</a><span class="c6">confused by this- is it supposed to be &quot;Ventricular tachycardia (VT)&quot; ?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref12" id="cmnt12">[l]</a><span class="c6">Here are the data by virus, but thought this was less important: Incidence ratios within 7 days of detection by virus: influenza B: 10.11(95% CI, 4.37-23.38); influenza A 5.17 (95% CI, 3.02 to 8.84), RSV 3.51 (95% CI, 1.11 to 11.12), and other viruses 2.77 (95% CI, 1.23 to 6.24).</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref13" id="cmnt13">[m]</a><span class="c6">Not sure this is what you meant but in case you want to keep it, here is the citation.</span></p><p class="c1 c30"><span class="c6"></span></p><p class="c1"><span class="c6">Kwong J, Schwartz K, Campitelli M, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018;378:345-53. DOI: 10.1056/NEJMoa1702090</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref14" id="cmnt14">[n]</a><span class="c6">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref15" id="cmnt15">[o]</a><span class="c6">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref16" id="cmnt16">[p]</a><span class="c6">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref17" id="cmnt17">[q]</a><span class="c6">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref18" id="cmnt18">[r]</a><span class="c6">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref19" id="cmnt19">[s]</a><span class="c6">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref20" id="cmnt20">[t]</a><span class="c6">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref21" id="cmnt21">[u]</a><span class="c6">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref22" id="cmnt22">[v]</a><span class="c6">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref23" id="cmnt23">[w]</a><span class="c6">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref24" id="cmnt24">[x]</a><span class="c6">Maybe a pall care fellow interested?</span></p></div><div class="c33"><p class="c1"><a href="#cmnt_ref25" id="cmnt25">[y]</a><span class="c6">Will is adding generic language here, not BWH specific</span></p></div></body></html>